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In Nature there are twenty proteogenic amino acid ‘building blocks’, from which proteins and 
enzymes are constructed. These proteogenic amino acids confer activity to enzymes; however 
there are many instances where the chemistries provided by these ‘building blocks’ are 
expanded upon. Nature recruits an array of cofactors, post-translational modifications and 
post-translationally generated cofactors, all which help to provide function or activity. Until 
recently the protein engineer was restricted to the use of the twenty proteogenic amino acids, 
and so access to this increased chemical diversity was highly challenging. 
In this thesis, chemical modification has been used to insert a variety of non-canonical amino 
acids (ncAAs) throughout the active site of the enzyme N-acetylneuraminic acid lyase (NAL). 
This modification method incorporates ncAAs site-specifically into a protein, via a 
dehydroalanine intermediate and conjugate addition with a thiol compound. Initial work using 
this method replaced the catalytic lysine at position 165 with the non-canonical analogue 
γ-thialysine. It was possible to obtain homogenously modified protein in high yields for 
detailed kinetic and X-ray crystallographic studies, and therefore possible to elucidate the 
catalytic and structural consequences of this modification.  
The work to replace Lys165 with a non-canonical analogue provided a starting point to expand 
the incorporation of ncAAs into NAL. A total of thirteen different non-canonical side chains 
were incorporated, individually, at thirteen different positions within the active site of NAL. 
These modified enzymes were then screened for activity with ten different substrates to 
determine the effects of ncAA incorporation. It was seen that the ncAAs were well tolerated by 
the enzyme, as active modified enzymes were produced. By incorporating ncAAs it was 
possible to alter the substrate specificity of the enzyme. The modified enzyme F190Dpc, 
containing a dihydroxypropyl cysteine side chain, was found to have an increased activity with 
an altered substrate, erythrose. This activity was higher than the wild-type enzyme with both 
the altered substrate and the wild-type substrate, and the non-canonical Dpc side chain 
outperformed any of the proteogenic amino acids when inserted at the same position in the 
protein, for the substrate erythrose. 
This research begins to explore the possibilities of what may be achieved by use of ncAAs. 
Facile incorporation of ncAAs will allow protein engineers to take inspiration from Nature and 
expand the chemistries provided by the proteogenic amino acids, hopefully to engineer novel 
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Chapter 1 Introduction 
Enzymes have evolved as highly powerful biological catalysts which allow biological reactions 
to occur within cells. These biological catalysts can significantly increase reaction rates up to 
1020-fold, whilst operating under ambient conditions (Lad et al., 2003, Stockbridge et al., 
2010). This catalytic power has been exploited for use in many industrial processes.  
Enzymes are polypeptides and so are produced by the sequential addition of amino acids. This 
process is directed by information stored as DNA in the genetic code.  The genetic code is a 
degenerate three-base code which allows biological information to be stored as DNA. It 
consists of 64 three base codons, made up from the four nucleoside bases guanine (G), 
cytosine (C), adenine (A) and thymine (T) (Figure 1.1). This genetic code programmes the 
production of proteins through the processes of transcription and translation, as each codon 
directs the insertion of one of the proteogenic amino acids. Degeneracy within the genetic 
code, whereby multiple codons will encode the same amino acid, accounts for the 64 codons 




Figure 1.1 The four nucleoside bases found in DNA and the twenty naturally occurring 
proteogenic amino acids. The proteogenic amino acids have been grouped by the 
functionality of their side chains. 
 
 
It is generally accepted that proteins are constructed from the twenty proteogenic amino 
acids. However, there are many instances where proteins are further processed after 
translation; post-translational modifications (PTMs) like acetylation, glycosylation and 
methylation further diversify the translated proteins and are all used to help regulate protein 
function within the cell (Seo and Lee, 2004). Enzymes are catalytically active proteins and so 
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are also constructed from the twenty proteogenic amino acids. The interplay of these amino 
acid side chains allow functionality by providing an environment primed for catalysis. Although 
the proteogenic amino acids provide a diverse range of side chains including aliphatic, 
aromatic, polar, positive and negatively charged side chains, they also lack certain 
functionalities. Therefore Nature has developed ways to circumvent these limitations. Many 
proteins require non-protein components for catalytic activity; metal ions, cofactors and 
prosthetic groups are all routinely recruited to enzymes and are essential for some catalysis 
(Broderick, 2001). In recent years it has also been seen that enzymes can utilise amino acids 
outside of the twenty proteogenic amino acids, and the 21st and 22nd amino acids 
selenocysteine and pyrrolysine (Chambers et al., 1986, Hao et al., 2002) were discovered in 
1986 and 2002. The side chains of the proteogenic amino acids can also be post-translationally 
modified, and these modifications can form novel cofactors which provide functionality. These 
examples show the need to diversify the side chains of the proteogenic amino acids, and that 
by including more varied chemistries novel functionalities may be achieved. 
 
 
Figure 1.2 Examples of some post-translationally generated cofactors and post-translational 
modifications (PTMs). Topaquinone and formylglycine are post-translationally generated 
cofactors and produced from modification of tyrosine and cysteine or serine. Phosphoserine 
is a common PTM formed by the phosphorylation of serine. Acetyllysine and methyllysine 
are common PTMs generated by the acetylation or methylation of lysine residues. O-linked 









This thesis will focus on the incorporation of non-canonical amino acids (ncAAs) in enzyme 
active sites, and the subsequent effects of these ncAAs on catalytic activity. ncAAs will be 
defined as any amino acid which has been incorporated into the protein in an artificial manner, 
for example by chemical modification of a proteogenic amino acid (Basle et al., 2010) or by 
engineering and repurposing of the natural translation machinery for ncAA insertion (Dumas et 
al., 2015, Liu and Schultz, 2010).  
1.1 Amino acid library extension 
In Nature the protein backbone of an enzyme is made up from a library of 20 amino acids. 
These 20 amino acids allow a diversity of structures and activities to be achieved. However by 
the use of cofactors and post-translational modifications the number and diversity of activities 
achieved by the proteome can be increased and these extensions of the amino acid library can 
be essential for a number of biological processes. 
1.1.1 21st and 22nd amino acids 
Although it is generally accepted that there are twenty proteogenic amino acids, encoded by 
the genetic code, there are instances when Nature has expanded upon these. Two examples of 
this are selenocysteine and pyrrolysine which are commonly referred to as the 21st and 22nd 
amino acids. 
Selenium is an important micronutrient, for both prokaryotes and eukaryotes, which can be 
incorporated into proteins in the form of selenocysteine (Schwarz and Foltz, 1957, Pinsent, 
1954, Lin et al., 2015). Selenocysteine is a structural analogue of the amino acid cysteine 
where the sulphur has been replaced with selenium. The discovery of selenocysteine in 
proteins began with the finding that selenium was essential for the production of an active 
formic dehydrogenase in some coliform organisms (Pinsent, 1954). Later, selenium was found 
to play an essential role in glutathione peroxidase where it was also found to be present in 
stoichiometric amounts (Flohe et al., 1973). In 1986 the gene sequences of two 
selenoproteins; glutathione peroxidase (Chambers et al., 1986) and formate dehydrogenase 
(Zinoni et al., 1986) were determined. These sequences revealed that the selenocysteine was 
encoded by an ‘in-frame’ opal stop codon TGA. This co-translational insertion of 
selenocysteine has been found in all major domains of life (Hatfield and Gladyshev, 2002, 
Varlamova et al., 2013). Clearly the TGA codon has two different functions; however this is not 
the first instance of a codon adopting dual functionality, the ATG codon functions to initiate 
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protein synthesis and to incorporate methionine at internal positions within a protein.  To 
allow the dual function of the TGA codon there are auxiliary components which direct the 
insertion of selenocysteine, these components differ between organisms and are reviewed 
here by (Varlamova et al., 2013, Hatfield and Gladyshev, 2002, Caban and Copeland, 2006, 
Driscoll and Copeland, 2003).       
Pyrrolysine is another amino acid that is co-translationally inserted in a similar way to 
selenocysteine, and is dubbed the 22nd amino acid.  Pyrrolysine was first discovered in proteins 
in 2002, from X-ray crystallographic studies where it was found in the active site of the 
methanogenic methylamine methyltransferase from Methanosarcina barkeri (Hao et al., 
2002). Pyrrolysine has been shown to be required for pathways which convert methylamines 
to methane (Mahapatra et al., 2006, Gaston et al., 2011), and is incorporated co-translationally 
into proteins at an amber stop codon, TAG.  
 
   
Figure 1.3 Structures of the 21st and 22nd amino acids selenocysteine and pyrrolysine. 
 
Incorporation of selenocysteine and pyrrolysine allow the proteins to access distinctive 
properties that would otherwise not be provided by the first twenty proteogenic amino acids. 
The inclusion of the selenium atom in the side chain of selenocysteine provides unique 
chemistry to the side chain compared to cysteine. For example selenocysteine has a lowered 
pKa, 5.4, compared to that of cysteine, 8.3 (Johansson et al., 2005). Due to the lower pKa, the 
selenol will be ionised at physiological pH whereas the thiol would be predominantly 
protonated (Kim and Gladyshev, 2005). Also the selenium produces a much more nucleophilic 
side chain than the cysteine which significantly enhances the chemical reaction rate with 
electrophiles (Arnér, 2010).   Incorporation of selenocysteine and pyrrolysine and their 
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essential roles within proteins, highlights the need to expand on the chemistries provided by 
the twenty proteogenic amino acids in natural enzymes and suggests intriguing possibilities for 
the protein engineer.  
1.1.2 Cofactors and post-translational modifications 
The genetic code provides the information necessary for biological functions and for the 
production of proteins. However when comparing the amount of information that could be 
stored by the genetic code to the proteome of a single organism, there is a discrepancy. There 
are far more proteins produced than could be encoded by the identified protein coding genes 
(Walsh et al., 2005). This discrepancy is due, in part, to the large amount of post-translational 
processing that occurs for many proteins. There are a wide variety of different 
post-translational modifications (PTMs) ranging from protein splicing to acetylation and 
glycosylation, which help to fine tune cellular events. These covalent post-translational 
modifications allow the chemistries of the twenty proteogenic amino acids to be altered and 
expanded. 
Post-translational modifications (PTM) occur on nascent proteins and are often enzyme 
catalysed events. Modifications can take place on the backbone of the protein or on an amino 
acid side chain (Walsh et al., 2005). PTMs can occur in two forms, firstly the cleavage of the 
protein backbone, and secondly the covalent addition of a chemical group usually to a 
nucleophilic side chain of an amino acid (Mann and Jensen, 2003, Walsh et al., 2005). These 
modifications produce a wide range of effects; regulation of protein localisation, enzyme 
activity and protein-protein interactions (Seo and Lee, 2004).  
Cofactors are also recruited by proteins to achieve biological functions. Cofactors are 
non-protein molecules and range from metal ions and iron-sulphur clusters to heme and 
flavins. One excellent example of an enzyme that recruits multiple different cofactors to 
achieve its biological function is the pyruvate dehydrogenase complex (PDH), one of the 
central enzymes in aerobic metabolism. The PDH links glycolysis and the tricaboxylic acid (TCA) 
cycle by converting pyruvate to acetyl-CoA (Patel and Korotchkina, 2003, Mande et al., 1996). 
The PDH is a multi-enzyme complex comprised of multiple copies of three catalytic enzymes; 
pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide 
dehydrogenase (E3) which work sequentially to catalyse the oxidative decarboxylation of 
pyruvate (Patel et al., 2014) (Figure 1.4). To achieve this function the three catalytic enzymes 
are required along with five organic cofactors; thiamine pyrophosphate (TPP), lipoamide, 
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coenzyme A(CoA), flavin adenine dinucleotide (FAD), nicotinamide adenine dinucleotide 
(NAD+) and one inorganic cofactor; Mg2+. TPP forms a covalent link to E1 and provides a highly 
nucleophilic group that can attack the carbonyl carbon of pyruvate, and cleave CO2 from the 
pyruvate. Lipoamide is covalently linked to E2 and the disulphide bond can be reduced to 
accept the acetyl group from TPP. The acetyl group is passed onto CoA, producing acetylCoA. 
E3 then uses FAD to oxidise the dihydrolipoamide reforming the disulphide bond producing 




Figure 1.4 Cofactors and mechanism of the pyruvate dehydrogenase complex (PDH). 
Structures of the cofactors used by the PDH are shown in panel A; thiamine pyrophosphate 
(TPP) coenzyme A (CoA). Flavin adenine dinucleotide (FAD), nicotinamide adenine 
dinucleotide (NAD+) and lipoamide. Panel B shown the roles of the cofactors in the PDH, TPP 
provides a nucleophile to attack the carbonyl of pyruvate cleaving off CO2 and producing 
hydroxyethyl-TPP, lipoamide becomes reduced and transfers the acetyl group to CoA 






1.1.3 Post-translationally generated cofactors 
As discussed above, many enzymes require cofactors for their function. These cofactors are 
usually biosynthesised separately to the protein and subsequently recruited to the protein. 
However more recently, there have been a large number of studies which have revealed 
enzymes which have alternative routes to producing cofactors via post-translational 
modification events (Okeley and Van Der Donk, 2000, Davidson, 2011, Yukl and Wilmot, 2012). 
These novel catalytic centres are generally produced by modification of one or a number of 
amino acid side chains and can be generated in a number of ways; some occur from 
auto-catalytic events and others require accessory enzymes.   
1.1.3.1 Pyruvoyl group 
Histidine decarboxylase was one of the first enzymes that was identified to undergo one of 
these modification events. Many amino acid decarboxylases require the cofactor 
pyridoxal-5-phosphate, derived from vitamin B6, for their function (Figure 1.5 B). However it 
was found that histidine decarboxylase of Lactobacillus 30a did not require PLP for its function 
(Riley and Snell, 1968, Vanpoelje and Snell, 1990). Instead it was found that the enzyme 
contained an amino-bound pyruvoyl group which acts in a manner analogous to PLP; forming a 
Schiff base with the histidine substrate and facilitating decarboxylation (Okeley and Van Der 
Donk, 2000). 
Histidine decarboxylase is produced as an inactive hexameric proenzyme, which undergoes an 
autocatalytic cleavage event to produce the α and β chains of the active enzyme (Figure 1.5 A). 
This cleavage event occurs between two serine residues, Ser81 and Ser82 (Vaaler et al., 1982, 
Vanpoelje and Snell, 1990). The inactive proenzyme contains no pyruvate and it has been 
shown that the pyruvoyl group is generated, post-translationally, during the autocatalytic 
cleavage event (Recsei et al., 1983). Ser82 becomes the pyruvoyl group on the amino terminus 
of the α chain, and Ser81 becomes the C-terminus of the β subunit. Several other enzymes 
have been identified which require the generation of a similar pyruvoyl group; arginine, 
aspartate and S-adenosylmethionine decarboxylases (Bale and Ealick, 2010) and D-proline and 
L-glycine reductases (Okeley and Van Der Donk, 2000), all of which use similar pathways to 
post-translationally generate the cofactor. Self-production of the pyruvoyl group means that 





Figure 1.5 Panel A shows the mechanism of backbone cleavage between Ser81 and Ser81 to 
form the pyruvoyl cofactor in histidine decarboxylase. The hydroxyl of Ser82 attacks the 
carboxyl of Ser81 producing tetrahedral intermediate that then forms an ester intermediate 
which undergoes elimination to release the C-terminal β subunit and hydrolysis of the 
dehydroalanine α subunit produces the N-terminal pyruvoyl group. Panel B shows a 
comparison of the structures of the post-translationally generated N-terminal pyruvoyl 











Type I sulfatases are a group of enzymes that catalyse the hydrolysis of sulphate esters. These 
enzymes contain a catalytically essential formylglycine (FGly) residue in their active site 
(Figure 1.6A), which is generated by post-translational modification (Bojarova and Williams, 
2008, Appel and Bertozzi, 2015). FGly contains an aldehyde  functional group which can form a 
geminal-diol by hydration, one of these hydroxyls can then act as the nucleophile for  attack of 
the sulphur atom of the substrate (Lukatela et al., 1998) (Figure 1.6B). This causes removal of 
the sulphate group and cleavage of the sulphate ester, producing a sulphated enzyme, the 
sulphate group can then be eliminated when the aldehyde is regenerated (Dierks et al., 1998, 
Appel and Bertozzi, 2015).  
The cofactor FGly is produced by oxidation of a cysteine, in prokaryotes and eukaryotes, or a 
serine, in prokaryotes, which is directed by a common peptide motif (C/S)XPXRXXXLTGR. This 
generation of FGly is performed by dedicated enzymes; formylglycine generating enzymes 
(FGEs) and anaerobic sulfatase maturing enzymes (anSMEs). FGEs are aerobic and operate 
through a redox mechanism that uses molecular oxygen (Dierks et al., 2005), whereas anSMEs 
work in an anaerobic manner and require the cofactor S-adenosylmethionine (Bojarova and 
Williams, 2008). FGly sulfatases produce very impressive rate enhancements, for example 
kcat/kuncat of up to 1026 for certain substrates (Edwards et al., 2012, Appel and Bertozzi, 2015). 
This significant rate enhancement may be attributed to the unique catalytic properties of the 




Figure 1.6 Formylglycine (FGly) structure and mechanism of action. Panel A shows the 
structures of cysteine, which is post-translationally converted into FGly, FGly and FGly-diol 
which is the hydrated diol form of FGly. Panel B shows the mechanism by which FGly cleaves 
the sulphate ester, one of the hydroxyls from the FGly-diol acts as a nucleophile to attack the 
sulphur atom, cleaving the sulphate ester bond and producing a sulphated FGly. 
 
 
1.1.3.3 Post-translationally generated quinone cofactors 
Redox active enzymes play vital roles in both prokaryotic and eukaryotic organisms. However 
due to the limited functionality provided by the proteogenic amino acids, these enzymes tend 
to require additional cofactors or metal ions to achieve their function. In recent years enzymes 
with catalytic redox-active centres derived from amino acid side chains have been discovered. 
Many of these enzymes produce quinone cofactors, which are highly versatile cofactors due to 
their strong electrophilic nature and their ability to undergo two reversible, one-electron 
reductions (Lang and Klinman, 2001, Davidson, 2011). There are four quinone cofactors which 
are derived from modification of amino acid side chains; topaquinone (TPQ), lysine 
tyrosylquinone (LTQ), cysteine tryptophanquinone (CTQ), and tryptophan tryptophylquinone 
(TTQ) (Figure 1.7). TPQ and LTQ are both produced auto-catalytically and derive from a 
tyrosine side chain, with LTQ being formed from the crosslinking of a lysine and tyrosine and 
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TPQ being formed by modification of a single tyrosine (Davidson, 2011). The side chain of a 
tyrosine residue can normally be involved in radical processes, by undergoing oxidation to the 
phenoxyl radical, as in ribonucleotide reductase. But, to be involved in a redox process, the 
tyrosine side chain is required to undergo modification to a quinone (Dubois and Klinman, 
2005). CTQ and TTQ are both derived from tryptophan by oxidation of the aromatic ring. 
Production of TTQ requires accessory proteins and it is hypothesised that CTQ may also require 
accessory proteins (Davidson, 2011). These post-translationally derived cofactors provide 
electrophilic functionalities to enzymes which are otherwise absent from the side chains of the 
standard proteogenic amino acids. 
 
 
Figure 1.7 Structures of the post-translationally generated quinone cofactors topaquinone 
(TPQ), lysine tyrosylquinone (LTQ), tryptophan tryptophylquinone (TTQ) and cysteine 
tryptophanquinone (CTQ). 
 
1.1.3.4 5-methylene-3,5-dihydroimidazol-4-one (MIO) 
Ammonia lyases and amino mutases share sequence and structural similarities. Aromatic 
amino acids undergo degradation by a different mechanism than other amino acids. 
Non-oxidative deamination of the aromatic amino acids is carried out by histidine, 
phenylalanine and tyrosine ammonia lyases (Ravikiran and Mahalakshmi, 2014).  Amino 
mutases catalyse the conversion of α-amino acids to β-amino acids and ammonia lyases 
catalyse the asymmetric addition of ammonia to a double bond (Turner, 2011). The aromatic 
amino acid lyases and amino mutases have been found to produce the electrophilic cofactor 
5-methylene-3,5-dihydroimidazol-4-one (MIO) (Figure 1.8) which allows them to carry out 
their processes (Christianson et al., 2007, Turner, 2011). Production of MIO occurs in an 
autocatalytic manner, where a conserved motif of Ala-Ser-Gly undergoes a self-catalysed 
condensation reaction to produce the electrophilic MIO cofactor (Christianson et al., 2007). 
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The heterocyclic moiety found in MIO has enhanced electrophilic properties, over that of a 
standard dehydroalanine, which aids the mechanism of amino mutases and ammonia lyases. 
 
        
Figure 1.8 Structure of the post-translationally generated cofactor 5-methylene-3,5-
dihydroimidazol-4-one (MIO). 
 
1.2 Incorporation of non-canonical amino acids 
The previous sections have highlighted the many ways in which Nature expands on the 
chemistries provided by the twenty proteogenic amino acids. Within a laboratory 
environment, advances in molecular biology and recombinant protein expression has made 
studies involving replacing or altering the proteogenic amino acids, within a protein, 
commonplace. However, access to the various modifications that Nature uses so frequently 
can be much more difficult.  
Developing methods to add more diverse building blocks into proteins should give an excellent 
platform to study their effects on protein function. Also, by providing more varied chemistries, 
this may expand the range of functions that can be achieved by proteins and enzymes. 
Methods for the modification of proteins and incorporation of non-canonical amino acids have 
advanced rapidly in recent years. These methods can be separated into two general groups, 
firstly the methods that incorporate non-canonical residues using the genetic machinery of the 
cell and secondly methods that use the distinctive properties of some amino acid side chains 







1.2.1 Auxotrophic incorporation 
In the 1950s it was discovered that selenomethionine could be used to replace methionine 
within bacterial proteins (Cowie and Cohen, 1957). This replacement of a proteogenic amino 
acid for a non-canonical amino acid (ncAA) can be achieved by the use of auxotrophic strains 
of bacteria. Amino acid auxotrophs are deficient in the machinery required to produce one of 
the proteogenic amino acids, and therefore the amino acid must be supplemented for growth. 
By supplementing the media with a non-canonical analogue of the proteogenic amino acid it is 
sometimes possible to insert the non-canonical analogue at every instance that the 
proteogenic amino acid should have been incorporated.  
This global replacement method can cause significant changes in the chemical and physical 
properties of proteins, and since all cellular proteins will be modified it provides a useful tool 
for proteomic studies (Johnson et al., 2010, Link et al., 2003). The global replacement of the 
hydrophobic amino acid leucine with fluorinated analogues has been shown to cause thermal 
stabilisation and stabilisation against chemical denaturation in an engineered leucine zipper 
(Tang and Tirrell, 2001). Replacement of proline with fluoroproline  in collagen strands 
(ProProGly)7, to produce a protein containing two thirds non-canonical residues, has been 
shown to increase the thermal stability by over  50˚C (Shoulders et al., 2010). Multiple 
different ncAAs, up to 13, have been individually, globally incorporated into a lipase enzyme. 
Incorporation of each non-canonical analogue of methionine, proline, phenylalanine, and 
tyrosine (shown in Figure 1.9) was carried out to determine the physical and chemical effects 
(Hoesl et al., 2011). These global replacements produced a variety of different effects 
including; increased enzyme activity, increased optimum temperature and increased tolerance 
to a variety of organic solvents, surfactants and denaturing agents (Acevedo-Rocha et al., 




Figure 1.9 Non-canonical amino acids used in global replacement studies of a lipase. Each 
ncAA was inserted using auxotrophic methods. Tryptophan was replaced with 1-3 using a 
tryptophan auxotroph. Methionine was replaced with 4 and 5 using a methionine 
auxotroph. Tyrosine was replaced with 6 and 7 using a tyrosine auxotroph. Phenylalanine 
was replaced with 8 and 9 using a phenylalanine auxotroph. Proline was replaced with 10-14 
using a proline auxotroph. 
 
Using auxotrophic bacterial strains provides a method to insert ncAAs without the need to 
manipulate the genetic machinery of the cell. However this approach relies on the ability of 
the aminoacyl-tRNA synthetase to accept different substrates, and subsequently load them 
onto the appropriate tRNA. In some cases the loading of the ncAA by the aminoacyl-tRNA 
synthetase can be very slow, and so to produce the modified proteins the aminoacyl-tRNA 
synthetase must be overexpressed within the cell (Kiick et al., 2000).  Another drawback of this 
method is that the amino acid analogues can prove to be toxic to the cell, which can lead to 
reduced expression of the modified protein and sometimes less than 100% incorporation of 
the ncAA (Budisa et al., 2004, Singh-Blom et al., 2014). To circumvent these cytotoxic effects, 
cell-free protein synthesis has been developed to globally incorporate analogues of the amino 
acid tryptophan (Singh-Blom et al., 2014). Using this cell-free system, which is depleted in 
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tryptophan it was possible to achieve 100% incorporation of the tryptophan analogue into 
target proteins. 
These residue specific incorporation methods are very useful for studying the effects of global 
ncAA incorporation, or for producing proteins with amino acids that can be chemically 
modified at multiple positions. However to study more localised effects of ncAA incorporation 
at one position, for example inserting an ncAA into the active site of an enzyme and 
investigating the effects on catalysis, a site-specific method of incorporation is needed.  
1.2.2 tRNA suppressor technology 
To insert a non-canonical residue site-specifically in vivo, alterations to the translational 
machinery of the cell must be made. Amino acid residues are inserted into a growing 
polypeptide chain, via tRNA, in response to the triplet code of mRNA. tRNAs are aminoacylated 
with their corresponding amino acid by a tRNA synthetase. The tRNA/tRNA synthetase pairs 
that are encoded in the cell have already evolved to load a specific amino acid onto its 
complementary tRNA; therefore to insert an ncAA a new orthogonal tRNA/tRNA synthetase 
pair must be evolved. The evolved tRNA must not cross react with the host system and must 
efficiently incorporate the ncAA in response to a codon. The evolved tRNA synthetase must 
efficiently load the ncAA onto the new tRNA and must not recognise any of the host tRNAs. 
The most commonly used codon, at which the ncAA is incorporated, in this methodology is the 
amber stop codon UAG, due to this codon being a nonsense codon the method is commonly 
referred to as nonsense suppression (Figure 1.10).  
The first instance of nonsense suppression was used to insert O-methyl-L-tyrosine into 
dihydrofolate reductase, in response to an amber stop codon UAG in E. coli (Wang et al., 
2001). To insert the ncAA an orthogonal tRNA/tRNA synthetase pair was evolved from the 
Methanococcus jannaschii (M. jannaschii) tyrosyl tRNA/tRNA synthetase pair. The machinery 
from M. jannaschii was a good target as an orthogonal pair as it already had a number of 
different elements from the tyrosyl tRNA tRNA synthetase pair found in E.coli. With further 
protein engineering, using rounds of positive and negative selection, it was possible to develop 
a tRNA/ tRNA synthetase pair that was fully orthogonal to the E. coli system, and which was 
used to insert the ncAA in response to the amber stop codon with a 99% fidelity (Wang et al., 





Figure 1.10 Schematic of nonsense suppression. The orthogonal tRNA synthetase 
aminoacylates the orthogonal tRNA with the non-canonical amino acid (ncAA) ready for use 
in translation. The anticodon loop of the orthogonal tRNA recognises the amber stop codon 
UAG and therefore inserts the ncAA into the growing peptide chain, rather than termination 










Over recent years this method has been extensively used and improved, allowing 
incorporation of over 150  different ncAAs into a variety of prokaryotic and eukaryotic systems 
(Dumas et al., 2015, Lang and Chin, 2014, Tuley et al., 2014, Young and Schultz, 2010). 
Approximately a third of the ncAAs to date are inserted using an orthogonal pair based on the 
original M. jannaschii tyrosyl tRNA/tRNA synthetase pair. However the M. jannaschii tyrosyl 
tRNA/ tRNA synthetase pair is not orthogonal in higher organisms like yeast, therefore to 
insert ncAAs  the E. coli tyrosyl tRNA/tRNA synthetase pair was used (Chin et al., 2003). Other 
commonly used orthogonal pairs are the leucine tRNA/tRNA synthetase pair from E. coli for 
use in higher organisms like yeast and the pyrrolysyl tRNA/tRNA synthetase pairs from 
Methanosarcina barkeri and Methanosarcina maze. The discovery of pyrrolysine in 2002 (as 
discussed in Section 1.1.1), found that pyrrolysine was inserted into the proteins of some 
organisms in response to a UAG codon, which would normally encode translation termination. 
It was found that pyrrolysine was loaded onto a corresponding tRNA, which recognises the 
UAG codon, as an intact amino acid by a pyrrolysyl tRNA synthetase (Blight et al., 2004). This 
gave an excellent starting point for an orthogonal pair; due to its origins in archaebacteria it 
has been found to be orthogonal in both prokaryotes and eukaryotes (Hao et al., 2011). Also 
since the pyrolysyl tRNA synthetase does not recognise one of the twenty proteogenic amino 
acids there is no need to remove its natural synthetase activity before evolving an activity for a 
new ncAA. The substrate scope of the wild-type pyrrolysyl tRNA synthetase was quite broad 
allowing the insertion of multiple different pyrrolysine analogues. However, with further 
engineering mutant pyrrolysyl tRNA synthetases have been developed to further expand the 
substrate scope, and over 80 different ncAAs can be inserted using the orthogonal pairs of 
wild-type and mutant pyrrolysyl tRNA/tRNA synthetases pairs (Dumas et al., 2015). Using 
these orthogonal pairs it has been possible to insert ncAAs which are mimics of naturally 
occurring PTMs, for example the lysine modification N-ε-acetyllysine, a common histone 
modification was incorporated into myoglobin using an evolved pyrrolysyl tRNA/tRNA 
synthetases pair (Neumann et al., 2008). 
Expanding on this technology, tRNA/tRNA synthetase pairs have been developed that will 
decode a quadruplet codon and insert an ncAA in response. Using this method it was possible 
to incorporate two different ncAAs into the same protein by using the quadruplet codon to 
encode homoglutamine and insert it using a lysyl tRNA/synthetase pair derived from 
Pyrococcus horikoshii, and the also using the amber stop codon to insert O-methyl-L-tyrosine 
using the tyrosyl tRNA/synthetase pair from M. jannaschii. However efficiency of incorporation 
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was low (Anderson et al., 2004). Low incorporation efficiency in response to the quadruplet 
codon is due to the larger quadruplet anti-codon of the tRNA being poorly accepted by the 
natural ribosome. Therefore, to increase efficiency the ribosome needs to be evolved to accept 
the quadruplet tRNA. To prevent this engineering affecting translation within the cell, a 
quadruplet decoding ribosome has been developed that works orthogonally to the cell’s 
natural machinery. This engineered ribosome has been shown to efficiently recognise and 
decode orthogonal mRNA designated by an alternative Shine-Dalgarno sequence, the 
orthogonal mRNA has also been shown not to cross interact with the wild-type ribosome 
(Neumann et al., 2010, Wang et al., 2007).   
This research shows the significant advances that have been made towards site-specific in vivo 
introduction of ncAAs. This method has provided an excellent way in which to site-specifically 
incorporate tags for modification, ways to study PTMs and incorporate biophysical and 
fluorescent probes (Davis and Chin, 2012). Due to the use of the pyrolysyl tRNA synthetase, 
and its relaxed substrate specificity, it has been possible to considerably expand the range of 
ncAAs that can be incorporated in this manner. However the core structural motifs that can be 
incorporated are mainly phenylalanine, tyrosine or lysine analogues (Wan et al., 2014, 
England, 2004, O'donoghue et al., 2013, Davis and Chin, 2012, Dumas et al., 2015). These 
methods are also reliant on the ability of a tRNA/tRNA synthetase pair to accept the desired 
ncAA. To incorporate a wide variety of different side chains into one protein, it would be 
necessary to evolve a specific tRNA/tRNA synthetase pair for each ncAA to be incorporated.  
Therefore more work towards discovery and engineering of new orthogonal pairs is needed to 
keep expanding the side chain chemistries that can be inserted. The majority of the ncAAs are 
inserted in this manner are in response to an amber stop codon, and so the natural function of 
the amber stop codon is in competition with the evolved function to insert the ncAA. This 
competition can reduce the efficiency of incorporation, resulting in low yields of modified 
protein, and can sometimes prevent incorporation entirely (O'donoghue et al., 2013, Zhang et 
al., 2013).  
1.2.3 Chemical modification of proteins  
Chemical modification of proteins provides a way to attempt to synthetically mimic the many 
varied modifications performed by Nature. Modifying proteins chemically can prove to be 
quite a challenge as proteins contain a variety of reactive groups; carboxylic acids, amines, 
amides, alcohols and thiols. Therefore the chemistry employed must be specific, usually to 
target the side chain of a specific amino acid, and the chemistry must be carried out under 
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conditions that will not irrevocably impair the protein structure or function, for example 
aqueous conditions, near neutral pH and ambient temperatures (Spicer and Davis, 2014, Basle 
et al., 2010).  
Pivotal experiments carried out in the 1960s used chemical methods to convert one amino 
acid into another.  Firstly an O-p-toluenesulfonyl-L-serine residue, on a short peptide, was 
converted into a thiol containing cysteine residue by reaction with thioacetate (Zioudrou et al., 
1965). This methodology was extended for use in proteins; the serine in the active site of 
subtilisin was treated firstly with phenylmethanesulfonyl fluoride (PMSF) and then with either 
thioacetate of thiobenzoate to produce a cysteine residue (Polgar and Bender, 1966). These 
experiments, carried out in the era before the development of site-directed mutagenesis, were 
the first examples of amino acid replacements. Although genetic manipulation has now made 
exchanging amino acids simple and commonplace, the power of this chemical modification 
method must not be underestimated.  
 
 
Figure 1.11 Conversion of active site serine to cysteine in subtilisin. Reaction with 
phenylmethanesulfonyl fluoride (PMSF) with the active site serine followed by displacement 
of the phenylmethanesulfonyl group by thioacetate followed by spontaneous hydrolysis to 
form cysteine. 
 
The most common approaches for chemical modification of proteins takes advantage of 
unique chemistries found in the side chains of amino acids. Another powerful approach to 
selective chemical modification can now be achieved by using a tRNA/tRNA synthetase pair to 
genetically incorporate an ncAA with a selectively reactive group, which can then be 
subsequently modified (Spicer and Davis, 2014, Hao et al., 2011).  Modification using the 
proteogenic amino acids utilises the chemistries of the side chains, for example; the primary 
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amine group of lysine which can act as a nucleophile, the side chain of arginine can be 
modified to a pyrimidine derivative (Oya et al., 1999), and histidine can be selectively modified 
with epoxides (Chen et al., 2003). However the most common proteogenic side chain to be 
modified is cysteine. Cysteine has a number of advantages as the target for modification; firstly 
it is one of the most uncommon of the proteogenic amino acids, which may allow more 
selective modification, and secondly its side chain is a free thiol group which is highly 
nucleophilic and not found within the side chains of the other proteogenic amino acids 
(Chalker et al., 2009).  
1.2.3.1 Chemical modification at cysteine 
Cysteine provides a unique chemical handle which can be modified in multiple different ways. 
The sulphur in the cysteine can interconvert between multiple oxidation states, which is how 
post-translational modification of cysteine plays a role cellular redox regulation (Wani et al., 
2014).  Oxidation of cysteine also allows formation of disulphides and by modification via 
disulphide formation it has been possible to study glycosylation mimics (Gamblin et al., 2004). 
The free thiol group of cysteine is the most highly nucleophilic of the proteogenic amino acid 
side chains and with control of pH, selective modification of cysteine over other nucleophilic 
side chains lysine and histidine, can be achieved (Chalker et al., 2009, Bischoff and Schlüter, 
2012).  Cysteine is one of the least commonly occurring proteogenic amino acids, and with the 
use of site-directed mutagenesis to remove other cysteine residues and to place a cysteine at a 
desired position for modification, it can provide a highly selective handle for modification. Due 
to the nucleophilic nature of cysteine it can be targeted by electrophiles for alkylation, which 
can be achieved using electrophilic maleimides and α-halocarbonyls. Alkylation of cysteine can 
also be used to produce mimics of the post-translational modifications of lysine, methyl lysine 
and acetyl lysine within proteins (Huang et al., 2010, Simon et al., 2007)(Figure 1.12). Methyl 
lysine and acetyl lysine play important roles in the epigenetic control of the cell, and access to 





Figure 1.12 Methyl lysine and acetyl lysine analogues produced from alkylating a cysteine 
residue. A-C show methyl lysine analogues A) monomethyl-γ-thialysine formed by reaction 
of cysteine and (2-cholorethyl)-methylammonium chloride, B) dimethyl-γ-thialysine formed 
by reaction of cysteine and (2-cholorethyl)-dimethylammonium chloride, C) 
trimethyl-γ-thialysine formed by reaction of cysteine and 
(2-bromoethyl)-trimethylammonium bromide (Simon et al., 2007). D is the acetyl lysine 
analogue, methylthiocarbonyl-γ-thialysine formed from reaction of cysteine with 
methylthiocarbonyl-aziridine (Huang et al., 2010). 
 
Cysteine can also act as a precursor for the production of the reactive electrophilic handle 
dehydroalanine (dha). Dha is a more selective target for modification, than any of the 
proteogenic amino acid side chains, as it is highly electrophilic, a feature which is lacking within 
the proteogenic amino acids. Synthetically dha can provide access to many different PTM 
analogues and ncAAs by a conjugate addition with a thiol; dha is electrophilic and therefore 
acts as a Michael acceptor for reactions with nucleophilic thiols. 
Dehydroalanine is found in nature in compounds known as lantibiotics, short peptides which 
undergo post-translational modification, where it is produced from the enzymatic dehydration 
of serine (Willey and Van Der Donk, 2007). These modifications to produce unsaturated 
compounds are common within lantibiotic synthesis, and dehydration of threonine can also 
occur to produce dehydrobutyrine (Willey and Van Der Donk, 2007, Xie and Van Der Donk, 
2004).  There are multiple reported methods for the synthetic production of dha in proteins, 
including, elimination of active site serines, the use of bromomaleimdes and the use of 
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nonsense suppression to insert a phenylselenocysteine residue followed by a subsequent 
reaction with hydrogen peroxide to form dha (Chalker et al., 2011, Tedaldi et al., 2009, Guo et 
al., 2008, Neet and Koshland, 1966). Another method to produce dha, uses the compound 
2,5-dibromohexan-1,6-diamide to target a cysteine residue which undergoes  double alkylation 
to produce a sulfonium salt which is them eliminated to produce dha (Chalker et al., 2011) 
(Figure 1.13). This method to produce dha has then been combined with the Michael addition 
of thiol compounds to produce analogues of lysine PTMs on synthetic histones (Chalker et al., 
2012), extended phosphorylated residues to investigate kinase activation (Rowan et al., 2013), 
and modify enzyme active site residues (Timms et al., 2013). 
 
 
Figure 1.13 Bis-alkylation-elimination mechanism for the conversion of a cysteine residue 
into a dehydroalanine residue carried out by the compound 2.5-dibromohexan-1,6-diamide 
(Chalker et al., 2011). 
 
1.3 Catalysis with non-canonical amino acids 
There are many different examples of ncAAs being used to mimic PTMs, as photo-crosslinkers, 
as biochemical and biophysical probes and labels, some of which have been mentioned 
previously and have been reviewed by (Dumas et al., 2015, Davis and Chin, 2012, Basle et al., 
2010, Hao et al., 2011). However, another interesting use of ncAAs is determining their effects 
on the activity of enzymes.  
Global replacement of amino acids with a non-canonical analogue has been shown to cause 
increases in activity. For example replacement of methionine with the non-canonical 
norleucine, increased peroxygenase activity in a cytochrome P450 monooxygenase (Cirino et 
al., 2003). Replacement of tryptophan with 5-fluorotryptophan in glutathione transferase  
produced a 4-fold increase in kcat by enhancing the product release (Parsons et al., 1998). It has 
also been reported that site-specific introduction of ncAAs can be used to alter catalysis.  
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Studies into the nitroreductase enzyme from E. coli, which has found use as a prodrug 
activator for cancer therapeutics, revealed that Phe124 was a critical residue for substrate 
binding (Jackson et al., 2006). Therefore mutagenesis to proteogenic amino acids was carried 
out with limited success in improving the activity, with lysine being identified as the best 
proteogenic amino acid. Therefore ncAAs were investigated to see if further improvements 
could be made. Eight different phenylalanine analogues were inserted at position 124 using 
nonsense suppression, with varying effects on catalysis, by inserting p-nitrophenylalanine a 
30-fold improvement over the wild-type enzyme was seen and a 2.3-fold improvement over 
the proteogenic F124K variant was seen (Jackson et al., 2006). A bacterial phosphotriesterase 
(PTE) activity has also been improved by the site-specific incorporation of ncAAs by nonsense 
suppression. This bacterial PTE was shown to hydrolyse toxic organophosphate pesticides like 
paraoxon, at rates thought to be at their evolutionary limits. From structural studies aromatic 
ring interactions between Tyr309, Phe132 and Trp131 were seen to stabilise the ring of the 
paraoxon substrate. The Tyr309 was replaced with the ncAAs 7-hydroxycoumarinyl and 
7-methylcoumarinyl, and the 7-hydroxycoumarinyl residue increased the turnover rate (kcat) by 
8-fold and 11-fold at higher pH, however it did not affect the kcat/Km (Ugwumba et al., 2011).  
 
 
Figure 1.14 Tyrosine analogues 7-hydroxycoumarinyl and 7-methylcourmarinyl inserted at 
Tyr309 in a bacterial phosphotriesterase. Replacement of tyrosine with 7-hydroxycoumarinyl 







Chemical modification has been used to alter enzyme active sites for decades, for example in 
the 1960s PMSF was found to modify the active site serine of serine proteases (Fahrney and 
Gold, 1963). In more recent years alkylation of cysteine residues has been carried out on a 
number of enzymes to investigate the effects on active site residues. The active site lysine 
(K107) of fructose-1,6-bisphosphate aldolase (FBPA) is critical for activity, conversion of this to 
a cysteine (K107C) and then subsequent reaction with bromoethylamine yielded the sulphur 
containing analogue γ-thialysine. The mutagenesis of the catalytic lysine into a cysteine residue 
reduced kcat/Km 700-fold, and subsequent modification to γ-thialysine recovered 80% of 
wild-type activity (Hopkins et al., 2002). This reduction in activity, of the modified enzyme 
compared to the wild-type enzyme, was attributed to only 80% conversion of the cysteine 
residue into γ-thialysine. Therefore the modified γ-thialysine side chain was an excellent mimic 




Figure 1.15 Reaction of aspartate aminotransferase. Aspartate amino transferase catalyses 
the transfer of the amino group from the amino acid aspartate onto the ketoacid 
α-ketoglutarate (α-KG) to produce the amino acid glutamate and oxaloacetate (OAA). 
 
Replacement of lysine with γ-thialysine has also been carried out in other enzymes. Aspartate 
aminotransferase, which catalyses the transfer of an amino group from aspartate onto 
α-ketoglutarate (α-KG) producing glutamate and oxaloacetate (OAA) (Figure 1.15),  has a 
catalytic lysine (K258) which was replaced with γ-thialysine (Gloss and Kirsch, 1995a). Again 
mutagenesis to the cysteine mutant resulted in a decrease in activity but modification to 
γ-thialysine only reconstituted 10% of wild-type activity. In this case, conversion of >95% to the 
γ-thialysine side chain was observed and so incomplete modification was not the cause of 
decreased activity. It was hypothesised that the change in pKa of the γ-thialysine, which is 1.3 
units lower than that of lysine, produces a less basic residue which is less effective at 
abstracting a proton from the Cα of the substrate (Gloss and Kirsch, 1995a). This work has 
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been further extended to insert a variety of lysine and glutamate analogues at position 258 
and their effects on activity were determined (Figure 1.16) (Gloss and Kirsch, 1995b). 
Interestingly it was seen that carboxylate containing ncAAs, increased the binding affinity for 
the amino acid substrate up to 4-fold.   
 
 
Figure 1.16 Lysine and glutamate non-canonical analogues inserted by alkylation of a 
cysteine in aspartate amino transferase (Gloss and Kirsch, 1995b).  
 
The enzyme glutathione transferase is a dimeric protein which requires an aromatic 
phenylalanine or tyrosine from one subunit, to be wedged into a hydrophobic patch of the 
other subunit for activity. The aromatic Tyr50 was seen to be essential for activity in human 
glutathione transferase with mutation to alanine or cysteine inactivating the enzyme (Hegazy 
et al., 2004). The Y50C variant was alkylated with twenty different haloalkanes to generate 
ncAAs at this position. For the majority of the modifications between 60 and 100 % conversion 
of the cysteine was achieved, and for all site-specific modification was achieved as assessed by 
mass spectrometry. Modification of Y50C with iodobutane to produce an S-butyl cysteine 
residue resulted in a 10-fold increase in kcat/Km than the wild-type (Y50) enzyme (Hegazy et al., 
2006). These modifications as well as being used to increase the activity of the enzyme have 
been used to investigate the allostery of the enzyme mechanism (Hegazy et al., 2013). From 
these examples, clearly one of the advantages of using chemical modification to insert ncAAs is 
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the ease with which multiple different non-canonical side chains can be accessed from one 
cysteine variant. 
With some of these alkylation modification experiments, to allow site-specific modification of 
one cysteine, it has been necessary to remove cysteine residues that were not to be targeted 
(Planas and Kirsch, 1991).  In other cases if the cysteine residues were buried within the 
protein they could not be modified and so did not need to be mutated (Hopkins et al., 2002). 
These alkylation experiments can be hindered by incomplete conversion to the desired ncAA, 
as can the nonsense suppression method since efficiency of incorporation is often incomplete, 
resulting in a heterogeneous sample of modified and unmodified protein. However, now with 
the facile conversion of cysteine into dha and an addition of a thiol it is possible to routinely 
produce homogenous ncAA containing protein (Chalker et al., 2011, Timms et al., 2013). To 
alkylate a cysteine residue, it is necessary to have an electrophile with which to modify, this 
can restrict the side chains that can be produced through this method without dedicated 
organic synthesis of a range of alkylation reagents. Whereas by incorporating an electrophilic 
dha, nucleophilic thiol compounds are used to generate the ncAA side chain which allows 
commercial access to more diverse side chains, as will be demonstrated in this thesis.   
1.4 Aldolases 
The aldol reaction is one of the foremost reactions in organic chemistry. During the aldol 
condensation between two carbonyl compounds a new carbon-carbon bond is formed, to 
produce a new β-hydroxyl carbonyl compound (Machajewski and Wong, 2000). This reaction is 
of great interest, as aldol structural units are found throughout nature and during the 
condensation up to two new stereocentres may be formed. The aldol reaction can be 
catalysed enzymatically by the family of enzymes known as the aldolases.  Aldolases are a type 
of lyase enzyme which can form and cleave carbon-carbon bonds, in the condensation reaction 
a aldehyde acceptor is added onto a ketone donor. The aldolase mechanism can be split into 
two different classes; the Class I aldolases form a Schiff bases between a catalytic lysine and 
the ketone donor, and Class II aldolases which use a zinc ion to stabilise the negative charge on 




Figure 1.17 Generalised Class I and Class II aldolase mechanisms. Class I and Class II aldolase 
mechanisms for the condensation of the ketone donor dihydroxyacetone phosphate (DHAP) 
highlighted in purple, with an aldehyde acceptor. The Class I mechanism shows a Schiff base 
formed between a lysine and the DHAP ketone donor, The Class II mechanism shows 
negative charge on the DHAP ketone donor intermediate being stabilised by a zinc ion 
coordinated by histidine residues.   
 
Aldolases can also be classified according to their ketone donor; dihydroxyacetone phosphate 
(DHAP)-dependent, pyruvate- or phosphoenolpyruvate-dependent, glycine-dependent and 
acetaldehyde-dependent (Sukumaran and Hanefeld, 2005) (Figure 1.18). DHAP-dependent 
aldolases catalyse the addition of DHAP onto an aldehyde acceptor substrate. One well known 
example of this type of aldolase is fructose-1,6-bisphosphate aldolase (FBPA) which plays an 
important role in glycolysis and gluconeogenesis, catalysing the reversible cleavage of 
fructose 1,6-bisphosphate into DHAP and glyceraldehyde 3-phosphate.  Pyruvate- or 
phosphoenol-pyruvate dependent aldolases catalyse the addition of pyruvate (or phosphoenol 
pyruvate) onto an aldehyde acceptor. Glycine-dependent aldolases catalyse the addition of 
glycine onto an aldehyde acceptor. There are two types of glycine dependent aldolase; 
threonine aldolases which condense glycine with acetaldehyde to form threonine, and serine 
hydroxyl methyl transferases which condense glycine with N5,N10 methylene tetrahydrofolate, 
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and both these enzymes require the cofactor PLP (Contestabile et al., 2001). 
Acetaldehyde-dependent aldolases catalyse the addition of acetaldehyde onto an aldehyde 
acceptor. There is only one known example of an acetaldehyde-dependent aldolase: 
2-deoxy-D-ribose-5-phosphate aldolase (DERA). DERA is an unusual aldolase, as both the donor 
and acceptor substrates are aldehydes and so can catalyse two sequential additions of 
acetaldehyde to the acceptor aldehyde (Dean et al., 2007). Aldolases tend to be highly specific 






Figure 1.18 Classification of aldolases by their donor substrate. All the aldolases require an 
aldehyde acceptor substrate and their respective ketone donor; dihydroxyacetone 
phosphate (DHAP), pyruvate or phosphoenol pyruvate, glycine or acetaldehyde. Reactions 
for DHAP-, pyruvate- or phosphoenol pyruvate- and glycine-dependent aldolases have been 
shown with a generalised aldehyde acceptor, the acetaldehyde-dependent aldolase is shown 
with glyceradehyde 3-phosphate as the aldehyde acceptor as this is the reaction catalysed by 
DERA the only known acetaldehyde dependent aldolase. 
 
Aldolase catalysed reactions are an attractive option for the production of biologically 
significant compounds like carbohydrates, since traditional syntheses are difficult due to the 
fact these compounds can contain multiple functional groups and tend to be water-soluble 
(Fesko and Gruber-Khadjawi, 2013). Since there is not always an enzyme available for a desired 
aldol reaction, there has been significant work towards the evolution of aldolases for 
synthetically useful reactions has been carried out, reviewed by (Windle et al., 2014, Bolt et al., 
2008, Dean et al., 2007, Baker and Seah, 2012). One excellent example of aldolase engineering 
for synthetically useful compounds was performed with DERA. DERA was found to catalyse the 
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sequential addition of two equivalents acetaldehyde to chloroacetaldehyde (CAA),which 
produced a valuable precursor for the production of statin drugs, for example Atorvastatin 
(Figure 1.19). Unfortunately the enzymatic reaction was hampered by low affinity for CAA and 
low tolerance to CAA. Therefore a directed evolution approach was used to produce a variant 
with significantly increased affinity for CAA and 10-fold higher catalytic activity in the presence 
of 500 mM CAA than the wild-type (Greenberg et al., 2004). 
 
 
Figure 1.19 DERA catalysed reaction of two equivalents of chloroacetaldehyde to 

















1.4.1 N-Acetylneuraminic acid lyase   
N-Acetylneuraminic acid lyase (NAL) catalyses the reversible aldol condensation of 
N-acetyl-D-mannosamine (ManNAc) and pyruvate to form N-acetylneuraminic acid (Neu5Ac). 
Neu5Ac is the most abundant of the sialic acids; a group of 9-carbon sugars which modulate a 
variety of biological processes and are often found at the terminal position of glycoconjugates 
(Severi et al., 2007, Ji et al., 2015). Neu5Ac also plays a role in host-pathogen interactions and 
infectivity of the influenza virus, which has led to analogues of Neu5Ac, Tamiflu® and Relenza®, 
being developed as anti-influenza drugs.    
 
 
         
Figure 1.20 Wild-type N-acetylneuraminic acid lyase (NAL) catalysed aldol reaction of 











Figure 1.21 Proposed mechanism of N-acetylneuraminic acid lyase. Lysine 165 is the catalytic 
lysine which forms a Schiff base with the pyruvate donor. The Schiff base enamine then 
attacks the aldehyde carbon of N-acetyl-D-mannosamine (ManNAc). Schiff base hydrolysis 
then releases the product N-acetylneuraminic acid (Neu5Ac). 
 
NAL is a Class I aldolase and has been shown to follow an ordered bi-uni aldol condensation 
kinetic mechanism (Groher and Hoelsch, 2012). Pyruvate binds in the active site forming a 
Schiff base with the catalytic lysine residue at position 165. The enamine Schiff base complex 
can then attack the aldehyde carbon of ManNAc to form the new carbon-carbon bond of the 





Figure 1.22 Crystal structure of the E. coli NAL (pdb code 4BWL) (Daniels et al., 2014). A 
shows the homotetramer of NAL and B shows the (α/β)8 TIM barrel fold of each NAL 
monomer. 
 
A number of studies have been carried out on NAL, with NALs from Clostridium perfringens 
and E. coli being cloned and expressed (Nees et al., 1976, Uchida et al., 1984). There have also 
been a number of X-ray crystallographic studies carried out; crystal structures of the 
Haemophilius influenza and E. coli NALs have been solved (Barbosa et al., 2000, Izard et al., 
1994). These studies have shown NAL to adopt a tetrameric (α/β)8 TIM barrel structure.  X-ray 
crystallographic studies of NAL with the substrate pyruvate bound in the active site have 
shown the presence of the Lys165-pyruvate Schiff base in the active site (Campeotto et al., 
2010, Lawrence et al., 1997). A variety of substrate analogues have also be solved in the crystal 
structures including; 4-oxo-Neu5Ac in the active site of the Haemophilius influenza NAL 
(Barbosa et al., 2000), and a dipropylamide analogue of ManNAc in the active site of the E. coli 
E192N variant NAL (Campeotto et al., 2010), also recently the X-ray crystal structure of the E. 
coli Y137A variant NAL was solved in complex with Neu5Ac (Daniels et al., 2014). These 
studies, and recent QM/MM studies have been able to highlight catalytically important 
residues within the active site of NAL (Daniels et al., 2014). The hydroxyl of Tyr137, a residue 
which is catalytically essential, has been shown to be the proton donor for the ManNAc 
aldehyde oxygen in the wild-type E. coli NAL reaction (3. in Figure 1.21) (Daniels et al., 2014, 
Barbosa et al., 2000). The residues Tyr110 and Ser47 are thought to act as a proton shuttle to 
aid Tyr137 as the proton donor, and Thr167 is involved in stabilising the transition state by 
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forming hydrogen bonds with the aldehyde oxygen of ManNAc, which becomes the C4 
hydroxyl of Neu5Ac (Daniels et al., 2014). 
 
   
Figure 1.23 Active site of the Y137A E. coli NAL variant in complex with the product Neu5Ac. 
Important active site residues have been highlighted as sticks and the alanine at position 137 
has been modelled back in as a tyrosine. Glu192 is involved in stabilising the glycerol end of 
Neu5Ac, Lys165 forms a Schiff base with the pyruvate end of Neu5Ac, Ser47 and Tyr110 
provide a proton shuttle for the proton donor Tyr137 and Thr167 hydrogen bonds to the C4 
hydroxyl and stabilises the transition state (Daniels et al., 2014). 
 
1.4.2 Protein engineering of N-acetylneuraminic acid lyase   
Since there is a significant amount of structural and mechanistic knowledge of NAL, and the 
ability to form new carbon-carbon bonds is extremely desirable, it is an excellent target for 
protein engineering studies. NAL has been shown to be highly specific for the ketone donor, 
pyruvate, with only a few reports of it utilising 3-fluoropyruvate as well (Daniels et al., 2014, 
Watts and Withers, 2004, Chokhawala et al., 2007). However NAL has been shown to be far 
more promiscuous towards a variety of aldehyde acceptor substrates, accepting various C6, C5 
and C4 monosaccharides (Gijsen et al., 1996, Fitz et al., 1995, Kim et al., 1988). NAL has been 
the focus of multiple different protein engineering studies, changing both the substrate 
specificity and the stereochemistry of the enzyme (Hsu et al., 2005, Wada et al., 2003, Williams 
et al., 2005, Williams et al., 2006, Joerger et al., 2003). 
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Rational redesign, using structural comparison, was used to switch the specificity of E. coli NAL  
from ManNAc and pyruvate to L-aspartate-β-semialdehyde and pyruvate, a reaction usually 
catalysed by the enzyme dihydrodipicolinate synthase, another class I aldolase (Blickling et al., 
1997). The variant L142R showed a 19-fold increase in activity with 
L-aspartate-β-semialdehyde over the wild-type NAL (Joerger et al., 2003). The E. coli NAL has 
been shown to be highly selective for D-sialic acid, and so directed evolution has been used to 
relax the stereochemistry of the E. coli NAL.  These experiments produced an enzyme capable 
of accepting L-sugars as well as D-sugars by the mutation V251I (Wada et al., 2003). Insertion of 
other proteogenic amino acids at this position produced variants with enhanced activities for a 
variety of different substrates (Chou et al., 2011). This work was further developed to produce 
an enzyme with high specificity towards L-sugars, both L-sialic acid and an analogue 
L-3-deoxy-manno-2-octulosonic acid (L-KDO), showing a 30-fold improvement in specificity to 
L-KDO over that of the wild-type NAL (Hsu et al., 2005). One of the most notable examples of 
altering the substrate specificity of E. coli NAL was a semi-rational redesign experiment to 
increase the activity of NAL with a dipropylamide analogue of Neu5Ac, [4R,5R,6R]‐7‐
(dipropylamino)‐4,5,6‐trihydroxy‐2,7‐dioxoheptanoic acid ([4R]‐DPAH) (Williams et al., 2005). 
Saturation libraries of residues along the aldehyde binding end of the active site; D191, E192 
and S208 were produced and screened for activity with DPAH. The best variant, E192N, 
exhibited a 640-fold switch in kcat/Km from Neu5Ac to ([4R]‐DPAH, this variant also had a kcat/Km 
for ([4R]‐DPAH that was higher than that of the wild-type E. coli NAL with Neu5Ac (Williams et 
al., 2005). The E192N variant was shown to exhibit poor stereocontrol at the C4 position in the 
aldol condensation of (2R,3S)-2,3-dihydroxy-4-oxo-N,N-dipropylbutanamide (DHOB) and 
pyruvate to form either [4R]-DPAH or [4S]-DPAH. Therefore directed evolution was used, with 
E192N as a starting point, to produce a pair of highly stereoselective variants (Williams et al., 
2006). 
NAL has been the focus of many different studies, which has provided extensive mechanistic 
and structural knowledge of this enzyme. The use of enzymes for the synthetic production of 
carbon-carbons bonds is also highly desirable due to their high specificity and ability to work 
under ambient conditions. Since NAL has already been shown to be a highly malleable enzyme 
through traditional protein engineering experiments, it may be an ideal candidate for the 




Figure 1.24 Protein engineering studies on the E. coli NAL. A shows the wild-type reaction of 
NAL, the reversible aldol condensation of N-acetyl-D-mannosamine and pyruvate to form 
N-acetylneuraminic acid or D-sialic acid (Neu5Ac). B shows the condensation of L-aspartate 
semialdehyde and pyruvate to form hydroxyl-tetrahydro-dipicolinic acid, this activity was 
developed in NAL by rational redesign to confer dihydrodipicolinate synthase activity onto 
NAL by the variant L142R (Joerger et al., 2003). C shows the condensation of L-arabinose and 
pyruvate to form L-3-deoxy-manno-2-octulosonic acid (L-KDO), this activity was developed in 
NAL by directed evolution (Hsu et al., 2005). D shows the condensation of (2R,3S)-2,3-
dihydroxy-4-oxo-N,N-dipropylbutanamide (DHOB) and pyruvate to form DPAH a 
dipropylamide analogue of Neu5Ac. This activity was developed in NAL by screening 
saturation libraries of a variety of positions in the active site (Williams et al., 2005), the best 
variant E192N was then subjected to directed evolution to produce a pair of 
stereocomplementary enzymes (Williams et al., 2006).  
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1.5 Thesis aims and objectives 
This thesis will report the use of a chemical method to site-specifically introduce ncAAs into 
the active site of the Staphylococcus aureus NAL (saNAL). Subsequent use of this approach was 
used to examine the effects of ncAA incorporation and also to alter the substrate specificity of 
the enzyme. The objectives of this work were as follows; 
 
1.5.1 To determine structural and functional effects of replacing the catalytic lysine 
at position 165 with the ncAA γ-thialysine. 
Previous work within the group had identified the cysteine free saNAL as the ideal system for 
the incorporation of ncAAs by a chemical modification method. This work had shown that by 
incorporation of a cysteine residue into saNAL by site-directed mutagenesis, it was possible to 
achieve site-specific insertion of an ncAA via a dehydroalanine intermediate at a desired 
position (Nicole Timms, PhD thesis, University of Leeds). Conversion of the catalytic lysine at 
position 165 into γ-thialysine had been previously carried out in saNAL. Therefore this 
chemical modification will be confirmed, and used to produce high yields of modified protein 
for detailed kinetic analysis to be carried out. High yield of chemically modified protein will 
also allow detailed structural analysis, using X-ray crystallographic methods, of the modified 
protein to be performed. Using this approach it will be possible to determine the structural 
and catalytic effects of replacing a catalytic proteogenic amino acid with a non-canonical 
analogue. 
 
1.5.2 Develop methods for high-throughput incorporation of ncAAs by chemical 
modification, and screening of modified variants. 
By using a chemical modification method to insert ncAAs, multiple different ncAAs will be 
individually incorporated site-specifically into the active site of saNAL, producing many 
different modified variants. These modified enzymes can then be screened for activity with a 
variety of different substrates, to investigate the effect of ncAAs on substrate chain length, 
stereochemistry and functional group substitutions. This approach will allow a significant 




1.5.3 To characterise modified enzymes with altered substrate specificities brought 
about by incorporation of a non-canonical side chain.  
Once modified ncAA-containing enzymes have been screened for altered activities, any ‘hits’ 
will be taken forward and their altered activity can be analysed. Kinetic analysis will allow the 
extent that the substrate specificity has been changed to be determined. Structural analysis 




Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Technical equipment 
 
Equipment      Manufacturer 
Centrifuges 
Avanti J-26 XP Centrifuge    Beckman Coulter, Brea, CA, USA 
GenFuge 24D Centrifuge    Progen Scientific, London, UK 
Micro Centaur       MSE, London, UK 
 
Incubators, mixers & shakers 
Gallenkamp Economy Incubator Size 1   Sanyo, Watford, UK 
ORBISAFE Orbital Incubator    Sanyo, Watford, UK 
Stuart Magnetic Stirrer SB161    CamLab, Cambridge, UK 
Stuart Orbital Incubator S150    Bibby Scientific, Stone, UK 
MS1 Minishaker      IKA®, Staufen, Germany 
Vortex Genie 2      Scientific Industries, New York, USA 
 
Gel electrophoresis equipment 
Vari-Gel midi system     CamLab, Cambridge, UK 
Mini-PROTEAN® Electrophoresis system   Bio-Rad laboratories, Hertfordshire, 
       UK  
PowerPac™ Basic power supply    Bio-Rad laboratories, Hertfordshire, 
       UK  
 
Protein purification equipment 
ÄKTAprime plus      GE healthcare, Little Chalfont, UK 








UVIKON 930       Kontron Instruments, UK 
 
Microplate reader 
FLUOstar Galaxy plate reader    BMG Labtech, Aylesbury, Bucks, UK 
 
Other equipment  
Jenway 3020 pH meter      Bibby Scientific, Stone, UK 
PTC-100 Programmable Thermal Controller  GMI-Inc, Minneapolis, MN, USA 
Techne Dri-Block Heater DB-2A    Bibby Scientific, Stone, UK 
Grant JB1 Unstirred Waterbath    Grant Instruments, Shepreth, UK 
 
2.1.2 Chemicals 
Agarose      Melford Laboratories, Suffolk, UK 
Ammonium Acetate     Fisher Scientific, Loughborough, UK 
Ammonium Bicarbonate    Acros Organics (Fisher Scientific) 
D-Arabinose      Sigma-Aldrich, Dorset, UK 
Agar       Melford Laboratories, Suffolk, UK 
Agarose      Melford Laboratories, Suffolk, UK 
Ammonium persulfate     Acros Organics (Fisher Scientific) 
Acetone      Fisher Scientific, Loughborough, UK 
Acrylamide, 30%     Severn Biotech, Kidderminster, UK 
Ampicillin      Formedium, Norfolk, UK 
N-Acetyl- D-Glucosamine    Sigma-Aldrich, Dorset, UK 
N-Acetyl- D-mannosamine    Carbosynth, Berkshire, UK 
N-Acetylneuraminic acid    Carbosynth, Berkshire, UK 
Bovine serum albumin     Bio-Rad, Hertfordshire, UK 
Bromophenol blue     Sigma-Aldrich, Dorset, UK 
β-mercaptoethanol     Stratagene , Cambridge, UK 
Coomassie Brilliant Blue    BDH Biochemical, Poole, UK 
Benzyl Mercaptan     Sigma-Aldrich, Dorset, UK 
Bradford reagent      Bio-Rad, Hertfordshire, UK 
L-Cysteine      Sigma-Aldrich, Dorset, UK 
D-Cysteine hydrochloride    MP Biomedicals, Cambridge, UK 
44 
 
Cyclohexanone      Sigma-Aldrich, Dorset, UK 
N,N-Dimethylformamide    Sigma-Aldrich, Dorset, UK 
Dimethyl sulphoxide, DMSO    Sigma-Aldrich, Dorset, UK 
1,2-Dithiothreitol, DTT     Formedium, Norfolk, UK 
Ethanol       Fisher Scientific, Loughborough, UK 
Ethylenediamine tetra acetic acid, EDTA   Sigma-Aldrich, Dorset, UK  
D-Erythrose      Sigma-Aldrich, Dorset, UK 
2-Furanmethanethiol     Sigma-Aldrich, Dorset, UK 
Formic acid      Sigma-Aldrich, Dorset, UK 
D-Galactose      Fluka (Sigma-Aldrich) 
Glycerol      Fisher Scientific, Loughborough, UK 
Glycine       Fisher Scientific, Loughborough, UK 
D-Glucose      Fisher Scientific, Loughborough, UK 
Isopropyl β- D- 1-thiogalactopyranoside   Generon, Berkshire, UK  
Imidazole      Acros Organics (Fisher Scientific)  
Lactate Dehydrogenase     Sigma-Aldrich, Dorset, UK 
Lysozyme-from chicken egg white   Sigma-Aldrich, Dorset, UK 
D-Lyxose      Sigma-Aldrich, Dorset, UK 
Mannose      MP Biomedicals, Cambridge, UK 
Mercaptopropionic acid     Sigma-Aldrich, Dorset, UK 
MES monohydrate     Alfa Aesar, Lancashire, UK 
2-Mercaptoethanol     Sigma-Aldrich, Dorset, UK 
4-Mercapto-1-butanol     Sigma-Aldrich, Dorset, UK 
1-Mercapto-2-propanol     Sigma-Aldrich, Dorset, UK 
4-Mercapto-1-butanol     Sigma-Aldrich, Dorset, UK 
Methylthioglycolate     Sigma-Aldrich, Dorset, UK 
3-Mercaptopropionic acid    Sigma-Aldrich, Dorset, UK 
β-Nicotinamide Adenine Dinucleotide reduced  Sigma-Aldrich, Dorset, UK 
Orthophosphoric acid     Sigma-Aldrich, Dorset, UK 
2-Propene-1-thiol     Sigma-Aldrich, Dorset, UK 
Polyethylene glycol 3350    Sigma-Aldrich, Dorset, UK 
Polyethylene glycol 400     Sigma-Aldrich, Dorset, UK 
Propan-2-ol      Fisher Scientific, Loughborough, UK 
D-Ribose      Fluka (Sigma-Aldrich) 
Sodium chloride, NaCl     Fisher Scientific, Loughborough, UK 
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Sodium dodecyl sulphate, SDS    Sigma-Aldrich, Dorset, UK 
Sodium hydroxide, NaOH    Fisher Scientific, Loughborough, UK 
Sodium phosphate dibasic, Na2HPO4   Sigma-Aldrich, Dorset, UK 
Sodium phosphate dibasic, NaH2PO4   Sigma-Aldrich, Dorset, UK 
Tetramethylethylenediamine (TEMED)   Sigma-Aldrich, Dorset, UK 
Tris Base      Fisher Scientific, Loughborough, UK 
Tryptone      Fluka (Sigma-Aldrich) 
Trichloroacetic acid     Sigma-Aldrich, Dorset, UK 
2-Thiobarbituric acid     Sigma-Aldrich, Dorset, UK 
Urea       Sigma-Aldrich, Dorset, UK 
D-Xylose      Sigma-Aldrich, Dorset, UK 
Yeast extract      Fluka (Sigma-Aldrich) 
2,5-dibromohexan-1,6-diamide (diBr) was synthesised and supplied by Alun Myden (University 
of Leeds, UK) and Robert Smith (University of Leeds, UK). 
 
2.1.3 Media 
Unless otherwise stated all bacterial cultures were grown in 2 TY media which had been 
sterilised by autoclaving at 121˚C for 20 min. 1 L of media was prepared using distilled water 
and contained 16g tryptone, 10 g yeast, 5 g NaCl, if solid phase media was required this was 
supplemented with 1.5% (w/v) agar. 
2.2 General Methods 
2.2.1 Centrifugation 
Centrifugation of samples above 1.5 mL and 96 well plates was performed in an Avanti J-26 XP 
Centrifuge (Beckman Coulter, Brea, CA, USA) at a temperature of 4 ˚C unless otherwise stated. 
Centrifugation of samples <1.5 mL was performed using either a GenFuge 24D Centrifuge 
(Progen Scientific, London, UK) or a SANYO Micro Centaur  Centrifuge (MSE, London, UK 
2.2.2 pH measurements 
pH measurements were performed using a Jenway 3020 pH meter (Bibby Scientific, Stone, UK) 





2.2.3 Aseptic technique 
Aseptic technique was used throughout. All heat resistant materials and both solid and liquid 
phase media were sterilised by autoclaving at 121 ˚C for 20 min. Solutions which were heat 
labile were sterilised by filter sterilisation using Millex® Syringe Filter unit (EMD Millipore, 
Hertfordshire, UK) and equipment which could not be heat sterilised was cleaned down with 
70 % (v/v) ethanol. 
2.2.4 Antibiotic stocks 
Ampicillin was the antibiotic used throughout at a final concentration of 50 µg mL-1 in both 
solid and liquid phase media. Ampicillin was made to a stock concentration of 50 mg mL-1 using 
distilled water; this stock was sterile filtered before use or before storage at -20 ˚C.  
2.2.5 Culture growth 
Single colonies were picked from 2 TY agar plates supplemented with 50 µg mL-1 ampicillin and 
used to inoculate 5 mL starter cultures of 2 TY supplemented with 50 µg mL-1 ampicillin. These 
starter cultures were incubated for 16 hours at 37°C, with shaking at 200rpm in an orbital 
incubator.  50 µL of starter culture was used to inoculate a 50 mL day culture (unless stated 
otherwise) and incubated for 8 hours at 37°C, with shaking at 200rpm in a 250 mL conical flask. 
10 mL of day culture was used to inoculate 1 L of 2 TY supplemented with 50 µg mL-1 ampicillin 
in a 2.5 L conical flask. Cultures were incubated at 37°C, with shaking at 200rpm until an 
optical density (O.D) of 0.6 at 600 nm was reached, and then protein expression was induced 
by addition of IPTG to a final concentration of 0.1 mM. 
2.2.6 Glycerol stocks 
Glycerol stocks were made from starter cultures that had been incubated for 16 hours at 37°C, 
with shaking at 200rpm. A 1:1 v/v solution of culture to sterile glycerol was made and stored in 
a sterile Nunc CryoTube™ (Thermo Fisher Scientific) at -80˚C. Bacteria could then be streaked 







2.3 DNA Methods 
2.3.1 Bacterial strains and plasmids 
Bacterial strains used in DNA manipulation were; 
E. coli XL1-Blue (Agilent Technologies, Cheshire, UK) 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIqZΔM15 Tn10 (Tetr)]  
E.coli XL10-Gold (Agilent Technologies, Cheshire, UK) 
Tetr∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB 
lacIq Z∆M15 Tn10(Tetr) Amy Camr] 
Bacterial strains used for protein expression were; 
E. coli BL21-Gold (DE3) (Agilent Technologies, Cheshire, UK) 
(B F- ompT hsdS(rB– mB–) dcm+ Tetr  gal λ(DE3) endA Hte 
The pKnanA_S.aureus-His6 plasmid was provided by Professor A. Berry (University of Leeds, 
UK) 
2.3.2 Plasmid purification  
5mL starter cultures, of 2 TY media supplemented with 50 µg mL-1 ampicillin, were inoculated 
with either single colonies or glycerol stocks of bacteria and grown for 16 hours at 37°C, 
200rpm in an orbital incubator. Plasmid DNA was then purified from these starter cultures 
using Wizard® Plus SV Minipreps DNA Purification System (Promega, Southhampton) according 
to manufacturer’s guidelines. 
2.3.3 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed with 0.7 % (w/v) agarose gel for nucleic acids 
<1.5 kb. Agarose gels were prepared by dissolving agarose in TAE buffer and run with a 1 kb 
ladder for determining the size of DNA fragments. 
10 x TAE buffer 
10 mM EDTA 
200 mM Glacial acetic acid 




2.3.4 DNA quantification 
DNA quantification was carried out spectrophotometrically at 260nm. An absorbance reading 
of 1.0 is equal to 50 ng µL-1 of double stranded DNA. Agarose gels were performed with an 
appropriate  
2.3.5 DNA sequencing 
DNA sequencing was carried out by Beckman Coulter Genomics (Essex, UK) 
2.3.6 Site-directed Mutagenesis 
Mutagenesis was carried out using OuikChange Lightning site-directed mutagenesis kit (Agilent 
Technologies LDA UK Limited). Site-directed mutagenesis primers were designed as per the 
manufacturer’s guidelines. 
2.3.7 Transformation 
Transformations were carried out using a heat shock method according to the method 
provided with the mutagenesis kit. Plasmid DNA was transformed into both E. Coli XL10-Gold 
Ultracompetant cells and E. Coli BL21-Gold (DE3) cells. 
 
2.4 Protein methods 
2.4.1 Affinity chromatography purification of His6-tagged proteins 
E. coli cells with the plasmid containing the target gene for protein expression were cultured as 
in Section 2.2.5. His6-tagged proteins were purified using Chelating SepharoseTM fast flow resin, 
chelated with nickel ions, in a batch purification method. 
Cell pellet was harvested from 1 L of bacterial culture by centrifugation at 12 000 g for 20 min. 
The cell pellet was re-suspended in 50 mL of washing buffer per 10 g of cells using a manual 
homogeniser. The re-suspended cells were then lysed at 20 KPSI using a Cell Disruptor from 
Constant Cell Disruption Systems (Northamptonshire, UK). Insoluble cell debris was separated 
from the soluble protein by centrifugation at 40 000 g for 45 min at 4 °C.  
The supernatant containing the soluble protein fraction was then loaded onto 5 mL of 
Chelating SepharoseTM fast flow resin in a 50 mL falcon tube, and incubated for 30 min with 
agitation at 4 °C.  Centrifugation at 4 000 g for 6 min at 4 °C produced a supernatant containing 
any non-bound proteins, which was discarded. The resin was then thoroughly re-suspended 
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using 40 mL of washing buffer and centrifuged at 4 000 g for 6 min at 4 after which the 
supernatant was discarded, this step was repeated three times. Elution of the His6-tagged 
protein was achieved by addition of 20 mL elution buffer and incubation for 1 hour at 4 °C with 
agitation, after centrifugation at 4 000 g for 6 min at 4 °C the supernatant containing the His6-
tagged protein was collected. The protein was then dialysed (Section 2.4.3) either against 
20 mM Tris/HCl then sterile filtered and stored at 4 °C, or against 20 mM ammonium acetate 
pH 7.0 and lyophilised (Section 2.4.6) 
 
Washing buffer 
50 mM Tris/HCl pH7.4 
20 mM Imidazole 
500 mM NaCl 
 
Elution buffer 
50 mM Tris/HCl pH7.4 
500 mM Imidazole 
500 mM NaCl 
2.4.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) was performed with 
resolving gel containing 15% acrylamide and stacking gel containing 3.75% acrylamide. Gels 
were made up containing the components listed below, the two polymerisation initiators, APS 
and TEMED, were the final components to be added. Gels were set between two glass plates. 
The resolving gel was set first with a layer of isopropanol to prevent drying, once the resolving 
gel was set the isopropanol was discarded and the stacking gel added with a comb inserted to 
form sample wells. 
Protein samples were prepared for SDS PAGE by addition of an equal volume of 2 x loading 
buffer (recipe below) incubating at 100 °C for 5 min and then centrifugation for 5 min at 
13 000 g before being loaded onto the gel. Separation by electrophoresis was carried out at 
30-60 mA for approximately 1-2 hour. SDS-PAGE gels were then stained for 1 hour using a 
methanol : acetic acid : water (5:1:1, v/v/v) solution containing 0.1 % (w/v) coomassie Brilliant 
Blue R250 solution and then destained using the same solution without the Coomassie Brilliant 
Blue R250. For more rapid development SDS-PAGE gels were also stained using Quick 




7,500 µL 30% (w/v) acrylamide 
3,750 µL 1.5 M Tris/HCl pH8.8 
3,500 µL H2O  
150 µL 10% (w/v) SDS 
50 µL 25% (w/v) APS 
5 µL TEMED  
 
Stacking gel: 
625 µL 30% (w/v) acrylamide 
625 µL 1.0 M Tris/HCl pH 6.9 
3,650 µL H2O  
50 µL 10% (w/v) SDS 
50 µL 25% (w/v) APS 
5 µL TEMED 
 
Running buffer: 
14.4 g glycine 
3 g Tris base 
1g SDS 
140 µL β-mercaptoethanol 
H2O made up to 1L 
2 x loading buffer for SDS PAGE: 
2 mL 10% (w/v) SDS 
200 µL 0.2% (w/v) bromophenol blue in ethanol 
154 mg DTT 
1 mL glycerol 
170 µL 1 M Tris/HCl pH 6.9 







2.4.3 Protein dialysis 
Dialysis of proteins was carried out using BioDesign dialysis tubing (Thermo Fisher Scientific, 
Loughborough, UK) with a 14 kDa molecular weight cut off. Proteins were dialysed into an 
appropriate buffer for the downstream application of the protein. The volume of dialysis 
buffer used was at least 500 fold larger than the protein sample to be dialysed. Dialysis was 
carried out with stirring either at room temperature for 2 hours or 4 ˚C for 4 hours, then the 
dialysis buffer was replaced with fresh buffer and the process repeated.  
2.4.4 Protein concentration determination 
Protein concentration was determined by reading the protein sample absorbance at 280 nm. 
The protein concentration was then calculated using the Beer Lambert law. 
 
𝑨 = 𝜺𝒄𝒍 
Equation 1. Beer-Lambert law for calculation of protein concentration. A is the absorbance 
value at 280 nm, ε is the molar extinction coefficient of the protein, l is the path length and c 
is the concentration of the protein.  
To determine the protein concentration of a protein with very few aromatic groups, or when 
imidazole was present, the Bradford assay was used. Bradford reagent (Bio-Rad Laboratories, 
Hertfordshire, UK) was used as per manufacturer’s guidelines. A calibration curve was 
produced using a range of known concentrations of bovine serum albumin (BSA) and this was 
used to determine unknown protein concentrations. 
2.4.5 Increasing protein concentration 
Protein samples were concentrated using an appropriately sized Vivaspin Protein Concentrator 
(10 kDa molecular weight cut off) (Generon, Berkshire, UK) for the sample volume. Proteins 
were concentrated as per the manufacturer’s guidelines  
2.4.6 Lyophilisation 
Proteins were first dialysed (Section 2.4.3) into 50 mM ammonium acetate pH 7.0. Once 
dialysis was complete the protein concentration was determined and aliquots containing 
between 2 and 20 mg of protein were pipetted into either 1.5 mL eppendorfs or 15 mL falcon 
tubes with pierced lids. The aliquots were then flash frozen in liquid nitrogen before being 




2.4.7 Sample preparation for ESI mass spectrometry 
Protein samples were prepared for mass spectrometry by desalting 70 µL of sample into 
50 mM ammonium acetate pH 7.0. Samples were prepared using Micro Bio-Spin™ 
Chromatography Columns (Bio-rad Laboratories, Hertfordshire, UK); columns were 
equilibrated with 4 column volumes of 50 mM ammonium acetate pH 7.0 before use as per 
manufacturer’s guidelines. For the preparation of protein samples which were taken from 
chemical modification reactions, 70 µL was desalted through two desalting columns 
equilibrated with 50 mM ammonium acetate pH 7.0. 
2.4.8 ESI mass spectrometry of proteins 
Mass spectrometry of proteins was performed by Dr James Ault using a quadrupole-ion 
mobility-orthogonal time of flight mass spectrometer (Synapt G2-S, Waters, Manchester, UK). 
Samples were analysed in acetonitrile : 1 % aqueous formic acid (50:50 v/v). Nano Flow 
electrospray ionisation was used and the mass spectrometer operated in positive mode time 
of flight (TOF). A capillary voltage of 1.2 kV and cone voltage of 50 V was used, nano-
electrospray nitrogen gas pressure of 0.1 bar and backing pressure of 1.78 mbar. The source 
and desolvation temperatures were set at 80 ˚C and 150 ˚C, respectively. Nitrogen was used as 
buffer gas at a pressure of 8.0 x 10-3 mbar in the trap and transfer regions and 3.6 x 10-4 mbar 
in the ion mobility cell. Mass calibration was performed using sodium iodide (2 µg µL-1) and 
data was analysed using Mass Lynx v4.1 software. 
2.4.9 Conversion of cysteine to dehydroalanine by 2, 5-dibromohexan-1, 6-diamide 
(diBr) 
2.5 mg of lyophilised cysteine-containing saNAL was resuspended thoroughly in 1.25 mL 
prewarmed (37 ˚C) 50 mM sodium phosphate buffer pH 8.0 containing 6 M urea. A stock 
solution was made of 0.13 mg µL-1 or 0.08 mg µL-1 diBr in DMF, the lower concentration of diBr 
was used if alkylation adducts were seen in the modification as discussed in Section 4.3.1. 
100 µL of diBr stock was added to the protein solution followed by vortexing for 30 s. This 
solution was then left to incubate for 1 hr 30 min at 37 °C, with shaking at 200rpm in an orbital 
incubator. After incubation a 70 µL sample was taken and desalted into 20 mM ammonium 
acetate pH 7.0 (Section 2.4.7) for analysis by positive mode ESI mass spectrometry. Mass 
spectrometry was used to assess whether full conversion of the cysteine to dehydroalanine 
had occurred; if full conversion had not occurred reactions were incubated for a further 20 
min. This dehydroalanine-containing protein solution was used immediately in the Michael 
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addition thiol reaction. For the production of larger quantities of dehydroalanine-containing 
protein all concentrations and volumes in this procedure were scaled up accordingly, up to a 
50 mg scale. 
2.4.10 Conversion of dehydroalanine to non-canonical amino acid side chains using 
sulphur nucleophiles 
Addition of sulphur nucleophiles was performed on dehydroalanine-containing protein 
(2 mg mL-1) in 50 mM sodium phosphate pH 8.0 containing 6 M urea. All thiol compounds were 
prepared in the fume hood. For the production of larger quantities of ncAA-containing protein 
all concentrations and volumes in this procedure were scaled up accordingly. 
2.4.10.1 Aminoethanthiol 
A stock solution was made of 0.1 mg µL-1 of aminoethanethiol in 2 M Tris/HCl pH 8.8 and the 
pH checked to ensure a pH of 8-9. 40 µL of this solution was added to 1.25 mL of 2 mg mL-1 
dehydroalanine-containing protein in 50 mM sodium phosphate pH 8.0 containing 6 M urea. 
The solution was incubated for 2 hours at 37 ˚C with shaking at 200 rpm. After incubation a 
70 µL sample was taken and desalted into 20 mM ammonium acetate pH 7.0 (Section 2.4.7) for 
analysis by positive mode ESI mass spectrometry. Mass spectrometry was used to assess 
whether full conversion of the dehydroalanine to the sulphur containing side chain had 
occurred.  
2.4.10.2 Mercaptoacetic acid 
A stock solution was made of 0.1 mg µL-1 of mercaptoacetic acid in 2 M Tris/HCl pH 8.8 and the 
pH checked to ensure a pH of 8-9. 40 µL of this solution was added to 1.25 mL of 2 mg mL-1 
dehydroalanine-containing protein in 50 mM sodium phosphate pH 8.0 containing 6 M urea. 
The solution was incubated for 2 hours at 37 ˚C with shaking at 200 rpm. After incubation a 
70 µL sample was taken and desalted into 20 mM ammonium acetate pH 7.0 (Section 2.4.7) for 
analysis by positive mode ESI mass spectrometry. Mass spectrometry was used to assess 









A stock solution was made of 2:1:1 (v/v/v) mercapto-1-butanol:DMF:Tris/HCl (2 M, pH 8.8), 
and the pH checked to ensure a pH of 8-9. 40 µL of this solution was added to 1.25 mL of 
2 mg mL-1 dehydroalanine-containing protein in 50 mM sodium phosphate pH 8.0 containing 
6 M urea. The solution was incubated for 2 hours at 37 ˚C with shaking at 200 rpm. After 
incubation a 70 µL sample was taken and desalted into 20 mM ammonium acetate pH 7.0 
(Section 2.4.7) for analysis by positive mode ESI mass spectrometry. Mass spectrometry was 
used to assess whether full conversion of the dehydroalanine to the sulphur containing side 
chain had occurred.  
2.4.10.4 Mercapto-2-propanol 
A stock solution was made of 50:50 (v/v) mercapto-2-propanol:Tris/HCl (2 M, pH 8.8), and the 
pH checked to ensure a pH of 8-9. 40 µL of this solution was added to 1.25 mL of 2 mg mL-1 
dehydroalanine-containing protein in 50 mM sodium phosphate pH 8.0 containing 6 M urea. 
The solution was incubated for 2 hours at 37 ˚C with shaking at 200 rpm. After incubation a 
70 µL sample was taken and desalted into 20 mM ammonium acetate pH 7.0 (Section 2.4.7) for 
analysis by positive mode ESI mass spectrometry. Mass spectrometry was used to assess 
whether full conversion of the dehydroalanine to the sulphur containing side chain had 
occurred. 
2.4.10.5 Methylthioglycolate 
A stock solution was made of 2:1:1 (v/v/v) methylthioglycolate:DMF:Tris/HCl (2 M, pH 8.8), and 
the pH checked to ensure a pH of 8-9. 40 µL of this solution was added to 1.25 mL of 2 mg mL-1 
dehydroalanine-containing protein in 50 mM sodium phosphate pH 8.0 containing 6 M urea. 
The solution was incubated for 2 hours at 37 ˚C with shaking at 200 rpm. After incubation a 
70 µL sample was taken and desalted into 20 mM ammonium acetate pH 7.0 (Section 2.4.7) for 
analysis by positive mode ESI mass spectrometry. Mass spectrometry was used to assess 
whether full conversion of the dehydroalanine to the sulphur containing side chain had 
occurred.  
2.4.10.6 Thioglycerol 
A stock solution was made of 50:50 (v/v) thioglycerol:Tris/HCl (2 M, pH 8.8), and the pH 
checked to ensure a pH of 8-9. 40 µL of this solution was added to 1.25 mL of 2 mg mL-1 
dehydroalanine-containing protein in 50 mM sodium phosphate pH 8.0 containing 6 M urea. 
The solution was incubated for 2 hours at 37 ˚C with shaking at 200 rpm. After incubation a 
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70 µL sample was taken and desalted into 20 mM ammonium acetate pH 7.0 (Section 2.4.7) for 
analysis by positive mode ESI mass spectrometry. Mass spectrometry was used to assess 
whether full conversion of the dehydroalanine to the sulphur containing side chain had 
occurred.  
2.4.10.7 Sodium mercaptopyruvate 
A stock solution was made of 0.1 mg µL-1 of sodium mercaptopyruvate in 2 M Tris/HCl pH 8.8 
and the pH checked to ensure a pH of 8-9. 80 µL of this solution was added to 1.25 mL of 
2 mg mL-1 dehydroalanine-containing protein in 50 mM sodium phosphate pH 8.0 containing 
6 M urea. The solution was incubated for 2 hours at 37 ˚C with shaking at 200 rpm. After 
incubation a 70 µL sample was taken and desalted into 20 mM ammonium acetate pH 7.0 
(Section 2.4.7) for analysis by positive mode ESI mass spectrometry. Mass spectrometry was 
used to assess whether full conversion of the dehydroalanine to the sulphur containing side 
chain had occurred.  
2.4.10.8 Benzylmercaptan 
A stock solution was made of 1:2 (v/v) benzylmercaptan:DMF, and the pH checked to ensure a 
pH of 8-9. 30 µL of this solution was added to 1.25 mL of 2 mg mL-1 dehydroalanine-containing 
protein in 50 mM sodium phosphate pH 8.0 containing 6 M urea. The solution was incubated 
for 2 hours at 37 ˚C with shaking at 200 rpm. After incubation a 70 µL sample was taken and 
desalted into 20 mM ammonium acetate pH 7.0 (Section 2.4.7) for analysis by positive mode 
ESI mass spectrometry. Mass spectrometry was used to assess whether full conversion of the 
dehydroalanine to the sulphur containing side chain had occurred.  
2.4.10.9 4-Pyridylethylmercaptan 
A stock solution was made of 1:2 (v/v) pyridylethylmercaptan:DMF, and the pH checked to 
ensure a pH of 8-9. 30 µL of this solution was added to 1.25 mL of 2 mg mL-1 
dehydroalanine-containing protein in 50 mM sodium phosphate pH 8.0 containing 6 M urea. 
The solution was incubated for 2 hours at 37 ˚C with shaking at 200 rpm. After incubation a 
70 µL sample was taken and desalted into 20 mM ammonium acetate pH 7.0 (Section 2.4.7) for 
analysis by positive mode ESI mass spectrometry. Mass spectrometry was used to assess 





2.4.10.10   2-Furanmethanethiol 
A stock solution was made of 2:1:1 (v/v/v) furanmethanethiol:DMF:Tris/HCl (2 M, pH 8.8), and 
the pH checked to ensure a pH of 8-9. 40 µL of this solution was added to 1.25 mL of 2 mg mL-1 
dehydroalanine-containing protein in 50 mM sodium phosphate pH 8.0 containing 6 M urea. 
The solution was incubated for 2 hours at 37 ˚C with shaking at 200 rpm. After incubation a 
70 µL sample was taken and desalted into 20 mM ammonium acetate pH 7.0 (Section 2.4.7) for 
analysis by positive mode ESI mass spectrometry. Mass spectrometry was used to assess 
whether full conversion of the dehydroalanine to the sulphur containing side chain had 
occurred.  
2.4.10.11  L-Cysteine 
A stock solution was made of 0.13 mg µL-1 of L-cysteine in 2 M Tris/HCl pH 8.8 and the pH 
checked to ensure a pH of 8-9. 120 µL of this solution was added to 1.25 mL of 2 mg mL-1 
dehydroalanine-containing protein in 50 mM sodium phosphate pH 8.0 containing 6 M urea. 
The solution was incubated for 2 hours at 37 ˚C with shaking at 200 rpm. After incubation a 
70 µL sample was taken and desalted into 20 mM ammonium acetate pH 7.0 (Section 2.4.7) for 
analysis by positive mode ESI mass spectrometry. Mass spectrometry was used to assess 
whether full conversion of the dehydroalanine to the sulphur containing side chain had 
occurred.  
2.4.10.12  D-Cysteine 
A stock solution was made of 0.13 mg µL-1 of D-cysteine in 2 M Tris/HCl pH 8.8 and the pH 
checked to ensure a pH of 8-9. 120 µL of this solution was added to 1.25 mL of 2 mg mL-1 
dehydroalanine-containing protein in 50 mM sodium phosphate pH 8.0 containing 6 M urea. 
The solution was incubated for 2 hours at 37 ˚C with shaking at 200 rpm. After incubation a 
70 µL sample was taken and desalted into 20 mM ammonium acetate pH 7.0 (Section 2.4.7) for 
analysis by positive mode ESI mass spectrometry. Mass spectrometry was used to assess 
whether full conversion of the dehydroalanine to the sulphur containing side chain had 
occurred.  
2.4.10.13 Propene-1-thiol 
A stock solution was made of 2:1:1 (v/v/v) propene-1-thiol:DMF:Tris/HCl (2 M, pH 8.8), and the 
pH checked to ensure a pH of 8-9. 40 µL of this solution was added to 1.25 mL of 2 mg mL-1 
dehydroalanine-containing protein in 50 mM sodium phosphate pH 8.0 containing 6 M urea. 
The solution was incubated for 2 hours at 37 ˚C with shaking at 200 rpm. After incubation a 
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70 µL sample was taken and desalted into 20 mM ammonium acetate pH 7.0 (Section 2.4.7) for 
analysis by positive mode ESI mass spectrometry. Mass spectrometry was used to assess 
whether full conversion of the dehydroalanine to the sulphur containing side chain had 
occurred.  
2.4.11 Refolding of non-canonical amino acid containing enzymes 
Chemical modification of the proteins is carried out under denaturing conditions in buffer 
containing 6 M urea. After chemical modification the proteins were subsequently refolded by 
dialysis. Dialysis was first performed in buffer containing 6 M urea to allow removal of excess 
modifying reagents that would otherwise cause aggregation of the protein upon refolding. 
Dialysis (Section 2.4.3) was performed twice against 50 mM sodium phosphate pH 8.0 
containing 6 M urea for between 2 and 4 hours at room temperature. Then dialysis against an 
appropriate urea free buffer was performed twice for between 2 and 4 hours at room 
temperature. 
2.4.12 Size exclusion chromatography 
Size exclusion chromatography was performed for further purify proteins and carried out using 
an ÄKTA Prime purification system (GE Healthcare Life Sciences) with a Superdex S200 column. 
Size exclusion chromatography was carried out in an appropriate buffer, usually 50 mM 
Tris/HCl pH 7.4, depending on the downstream application for the protein. Buffers were sterile 
filtered using Nalgene Sterile Mach V Supor Filter Unit, 0.2 um pore size, 500 ml (Thermo 
Fisher Scientific, Loughborough, UK) and degassed, using a vacuum tap, before use in size 
exclusion chromatography. Protein was injected onto the column at a concentration of 
between 5-10 mg mL-1 and a flow rate of 2 mL min-1. 
2.4.13 Lactate dehydrogenase coupled enzyme kinetic assay 
Kinetic parameters for the aldol cleavage of reaction were determined using a lactate 
dehydrogenase (LDH) coupled enzyme assay. This assay couples the production of pyruvate 
from the aldol cleavage, to the LDH catalysed conversion of pyruvate to lactate which utilises 




Figure 2.1 Schematic of lactate dehydrogenase (LDH) coupled enzyme assay. The aldol 
substrate is cleaved to form an aldehyde and pyruvate, the pyruvate is then converted to 
L-lactate by LDH which oxidises NADH to NAD+ and causes a drop in absorbance at 340 nm. 
 
Reactions were performed at 30 ˚C unless otherwise stated. Reactions contained 0.5 units of 
LDH, 0.2 mM NADH, 2-300 µL of the substrate (100 mM stock in 1 M Tris/HCl pH 7.4), a volume 
of 50 mM Tris/HCl pH 7.4 to make a total reaction volume of 1 mL and reactions were initiated 
by addition of NAL or variant NAL (in 50 mM Tris/HCl pH 7.4). For reactions with wild-type 
saNAL 50 µL of 0.2 mg mL-1 enzyme was added to initiate reactions, for reactions with K165C 
saNAL 200 µL of 2 mg mL-1 enzyme was added to initiate reactions and for reactions with 
K165-γ-thialysine saNAL 50 µL of 2 mg mL-1 enzyme was added to initiate reactions. Reactions 
were assembled and performed in a 1 mL quartz cuvette. Once the desired enzyme had been 
added to the reaction it was inverted to mix and the absorbance at 340 nm was measured 
every 6 s for 1-5 min. The absorbance change of the reaction was measured in a UVIKON 930 
spectrophotometer (Kontron Instruments, UK). Specific activity in nmol of substrate cleaved 
per min per nmol of enzyme was calculated using the molar extinction coefficient of NADH 
(6620 M-1 cm-1) and the Beer-lambert law (Equation 1). Kinetic parameters could then be 
determined by non-linear regression analysis.   
2.4.14 pH profiles 
The pH profiles were determined at 30 °C using a 3 component buffering system. The three 
component buffering system allows a pH range between 4 and 9 to be covered whilst 
maintaining a constant ionic strength (Ellis and Morrison, 1982). A stock of the three 
component buffer was made containing 0.75 M MES, 1.5 M Tris, and 0.75 M acetic acid. The 
substrate was made up in 1 M 3 component buffer and the pH adjusted to the desired pH 
using HCl or NaOH. Reactions were performed in a 1 mL quartz cuvette. The reaction cuvette 
contained 0.5 units LDH, 0.2 mM NADH, varying volumes of substrate between 2 µL and 300 µL 
59 
 
(stock concentration 50 mM) and 50 mM of the correct pH 3 component buffer system. 50 µL 
of the desired enzyme (made up in 50 mM Tris/HCl pH 7.4) was added last followed by 
inversion and placed in the spectrophotometer. The absorbance change at 340 nm was 
measured over 1 min in a UVIKON 930 spectrophotometer (Kontron Instruments, UK). The pH 
was checked, using pH paper, before the enzyme was added and after the reaction had been 
measured over 1 min to ensure no change in pH had occurred. Specific activity in nmol of 
substrate cleaved per min per nmol of enzyme was calculated using the molar extinction 
coefficient of NADH (6620 M-1 cm-1) and the Beer-lambert law (Equation 1). The kinetic 
parameters for each protein at each pH were determined using non-linear regression analysis. 









1 + 10(𝑝𝐾𝑎1−𝑝𝐻) + 10(𝑝𝐻−𝑝𝐾𝑎2)
 
Equation 2 Equation used to fit the data shown in panels A and B, where kcat/ Km is the 
specificity constant for N-acetylneuraminic acid cleavage, (kcat/ Km )max is the theoretical 
maximum value for kcat/ Km and pKa1 and pKa2 are the first and second ionisable groups 
 
 
2.4.15 Far UV circular dichroism spectroscopy 
CD spectra were obtained at room temperature using a Chirascan CD spectrometer (Applied 
Photophysics, Leatherhead, UK). All spectra were recorded in a quartz cuvette with path length 
1.0 mm. Protein samples were prepared in Tris/HCl (50 mM, pH 7.4) to a concentration of 
6 µM. Modified protein samples were prepared by chemical modification of the protein as in 
Sections 2.4.9 and 2.4.10 followed by refolding via dialysis. Modified protein samples were also 
analysed after size exclusion chromatography had been performed. Samples of non-modified 
proteins were prepared by dialysis into Tris/HCl (50 mM, pH 7.4). Samples of refolded 
non-modified proteins were first dialysed into Tris/HCl (50 mM, pH 7.4) containing 6 M urea 






2.4.16 Thiobarbituric acid assay (TBA assay) 
To each sample, 11 µL of sodium periodate (0.2 M in 9 M phosphoric acid) was added, the 
samples were then vortexed for 30 s and centrifuged at 1000 g for 2 min at room temperature. 
Samples were incubated at room temperature for 20 min. After the incubation time 45 µL of 
sodium arsenite (10% w/v in 0.5 M Na2SO4 containing 0.05 M H2SO4) was added and samples 
were agitated to cause dissipation of any brown discolouration that had formed. Once all 
samples had turned clear 135 µL of thiobarbituric acid (TBA, 0.6% in 0.5 M Na2SO4) was added 
to each and then incubated at 70 ˚C for 30 min. After incubation samples were centrifuged at 
4000 g for 5 min to separate any precipitate, 85 µL of each sample was then transferred to a 
shallow, flat bottomed 96 well plate and the absorbance of each well read at 550 nm in a 
FLUOstar Galaxy plate reader (BMG labtech, Germany). 
2.4.16.1 Screening of modified proteins using TBA assay 
Aldehydes used to screen for activity were ManNAc, GlcNAc, mannose, glucose, galactose, 
lyxose, xylose, ribose, arabinose, erythrose. All aldehydes and pyruvate were made up in 
50 mM sodium phosphate pH 7.4. Reactions were set up containing 100 µL of each aldehyde 
(stock concentration 20  mM, final concentration 8 mM) and 100 µL of sodium pyruvate (stock 
concentration 200  mM, final concentration 80 mM). Reactions were set up in a, 96 deep well 
plate and incubated for 16 hours at room temperature with 50 µL of modified enzyme (stock 
concentration 1 mg mL-1, final concentration 0.2 mg mL-1). Each screen also contained 
reactions of each aldehyde and pyruvate incubated with wild-type saNAL as a comparison and 
blanks containing each aldehyde and pyruvate and enzyme was replaced with an equal volume 
of buffer (50 mM sodium phosphate pH 7.4). 
After the 16 hour incubation, the TBA assay was performed as in Section 2.4.16.  Absorbance 
data was then analysed to determine whether activity had been increased or decreased over 
that of the wild-type with each aldehyde.  
2.4.16.2 Standard curve of sialic acid by TBA assay 
To obtain a standard curve of sialic acid twelve 100 µL samples were prepared containing 
between 0 and 0.08 µmoles of sialic acid. The TBA assay was performed as in Section 2.4.16 on 
each sample and then 85 µL of each sample was then transferred to a shallow, flat bottomed 
96 well plate and the absorbance of each well read at 550 nm in a FLUOstar Galaxy plate 
reader (BMG labtech, Germany). This data was then plotted and the gradient of the line could 
be used to calculate the quantity of aldol product present from an unknown reaction.  
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2.4.16.3 Kinetic assays using the TBA assay 
Kinetic assays were performed in 96 well deep well plates. Reactions were set up with varying 
concentrations of aldehyde (0.4 mM -15 mM final concentration) and a fixed pyruvate 
concentration (80 mM final concentration) made up in 50 mM sodium phosphate pH 7.4. 50 µL 
of aldehyde and 50 µL of pyruvate were added to each well and the reaction initiated by the 
addition of 25 µL of enzyme. For each aldehyde concentration a blank was also carried out 
which contained the aldehyde and pyruvate but the enzyme was replaced with an equal 
volume of buffer (50 mM sodium phosphate pH 7.4).  For wild-type kinetic assays a stock 
concentration of 0.7 mg mL-1 was used in all assays giving a final concentration of 0.14 mg mL-1. 
For F190Dpc kinetic assays with ManNAc as the aldehyde substrate a stock concentration of 
0.7 mg mL-1 was to give a final concentration of 0.14 mg mL-1 and for F190Dpc kinetic assays 
with erythrose as the aldehyde substrate a stock concentration of 0.3 mg mL-1 was used to give 
a final concentration of 0.06 mg mL-1. After the enzyme had been added to each well the plate 
was vortexed for 30 s and then centrifuged at room temperature for 1 min at 1000 g. The 
reactions were then allowed to incubate for 2 hours at room temperature. 
Once the incubation time was complete 100 µL of each reaction was transferred to a new 
96 deep well plate and 10 µL of TCA (12 % w/v) was added to stop the reactions. The TBA assay 
was then performed as in Section 2.4.16.  To convert the absorbance data into the amount of 
product formed a standard curve of sialic acid was used. The data was then analysed by 
non-linear regression. 
2.4.17 Purification of DOH by anion exchange 
Erythrose (500mg, 4.2 mmol) and sodium pyruvate (2.29g, 21 mmol) were dissolved in sodium 
phosphate buffer (50 mM pH 7.4 10mL) and F190TG (250µL, 0.8mg) was added. This reaction 
was incubated at room temperature for a minimum of 48 hours before being purified by anion 
exchange chromatography. Anion exchange chromatography was carried out on AG1x8 resin 
(HCO3-, 100-200 mesh) and product was eluted using a 0-0.4M ammonium bicarbonate linear 
gradient (Auge and Gautheron-Le Narvor, 1997). Fractions containing product were identified 
using the TBA assay on a 20µL sample and then analysed by NMR. Four different forms of the 
product were identified in the proton NMR spectrum and 2D NMR methods, COSY and TOCSY, 
were used to assign the different forms. 
Form 1 was assigned as ∂H (500 MHz; D2O) 3.99-3.90 (1H, m, 4-H), 3.78-3.74 (1H, m, 6-H), 
3.66-3.62 (2H, m, 7-H), 3.45 (1H, appt, J 9.5, 5-H), 2.19 (1H, dd, J 13.1, 5.1, 3-Heq), 1.8 (1H, dd, 
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J 12.9, 11.6, 3-Hax. Form 2 was assigned as ∂H (500 MHz; D2O) 4.2 (1H, m, 4-H), 4.05 (1H, m, 
6-H), 3.70 (1H, dd, J 10.3, 3.3, 5-H), 2.16 (1H, dd, J 14.8, 3.6, 3-HA), 2.05 (1H, dd, J 14.7, 3.1, 
3-HB). Form 3 was assigned as ∂H (500 MHz; D2O) 4.53 (1H, m, 4-H), 2.38 (1H, dd, J 13.7, 7.0, 
3-HA), 2.32 (1H, dd, J 13.5, 5.3, 3-HB). Form 4 was assigned as ∂H (500 MHz; D2O) 4.53 (1H, m, 
4-H), 4.15 (1H, m, 5-H), 3.83 (1H, m, 6-H), 2.55 (1H, dd, J 14.3, 7.2, 3-HA), 2.08 (1H, dd, J 14.4, 
2.8, 3-HB). 
2.4.18 Proton NMR 
Proton NMR spectra were recorded on a Bruker Advance 500 or a DRX500 with an internal 
deuterium lock. COSY and TOCSY pulse sequences were also used to aid the assignment of 
spectra  
2.4.19 ESI Mass spectrometry of small molecules 
Accurate mass spectrometry using electrospray ionisation was carried out on an automated 
system for either a Micromass LCT-KA111 (Waters, Manchester, UK) or Bruker MicroTOF 
(Bruker Massachusetts, USA) mass spectrometer. 
 
2.5 Crystallographic methods 
2.5.1 Protein crystallisation 
Crystallisation conditions for S. aureus NAL were optimised from those previously found for 
the E. coli NAL (Campeotto et al., 2010). Conditions used were; 100 mM Tris/HCl (pH 7.0-8.5), 
200 mM NaCl, 18-28% (w/v) polyethylene glycol (PEG) 3350. These crystallisation conditions 
were also used for all the modified proteins as well. Crystals were grown by hanging drop 
vapour diffusion and yielded crystals in 7-10 days.  
2.5.2 Cryoprotection and production of enzyme-pyruvate complexes 
Cryoprotection of crystals was carried out by soaking in mother liquor with 15% PEG 400 for 
1 min, before being sequentially transferred for 1 min into mother liquor with 5% increments 
of PEG 400. The final soak contains 25% PEG 400 then the crystals were flash cooled in liquid 
nitrogen. To produce the enzyme-pyruvate complexes cryoprotection was carried out as stated 




2.5.3 Data collection  
Data collection was carried out at Diamond Light Source macromolecular crystallography beam 
lines I24, I04-1, I03 and I02.  Datasets were collected from single crystals for all structures at 
100 K.  
2.5.4 Data processing 
Integration and scaling of data was carried out using MOSFLM (Leslie, 2006) and SCALA (Evans, 
2006). The wild-type NAL structure had been previously solved by molecular replacement in 
PHASER (Mccoy, 2007, Mccoy et al., 2007) using the H. influenza structure (PDB code IF74) 
(Barbosa et al., 2000). Structures that were found to be in the same space group as the wild-
type saNAL structure were solved using direct Fourier methods and structures found to be in 
different space groups than the wild-type saNAL were solved using molecular replacement in 
either PHASER or MOLREP using the wild-type saNAL structure (PDB code 4ahp)(Timms et al., 
2013). 
2.5.5 Refinement 
Refinement was carried out in REFMAC 5 (Murshudov et al., 2011, Murshudov et al., 1997)with 
subsequent rounds of model building carried out in COOT (Emsley et al., 2010) after each cycle 
of refinement. For all structures initially 10 rounds of rigid body refinement was carried out 
followed by multiple rounds of restrained refinement and model building. If it was appropriate 
TLS regions were applied to structures in REFMAC 5 and TLS refinement was carried out during 
the cycles of refinement. To generate the co-ordinate and restraint files for model building of 
ligands and non-canonical amino acids, PRODRG (Schuttelkopf and Van Aalten, 2004) was used 
for earlier structures and for later structures the in-built ligand builder in COOT was used. 




Chapter 3 Production and Characterisation of K165-γ-thialysine 
saNAL 
The aim of this work was to utilise non-canonical amino acids (ncAAs) to alter enzyme 
substrate specificities. There have been many studies into introducing ncAAs into proteins 
using both global and site-specific incorporation methods (Link et al., 2003, Davis and Chin, 
2012, Dumas et al., 2015). Due to the nature of this work it was necessary to use a site-specific 
method, so that the effect of introducing a single ncAA could be analysed. The two main 
methods of site-specific incorporation of ncAAs are; firstly the genetic method of using an 
orthogonal tRNA/tRNA synthetase pair to insert an ncAA at an amber stop codon (Liu and 
Schultz, 2010, Young and Schultz, 2010), and secondly a variety of chemical methods (Diaz-
Rodriguez and Davis, 2011, Desantis and Jones, 1999). The further aim of this work was to 
investigate the effects of individually incorporating multiple different ncAAs, throughout an 
enzyme, on the enzyme activity. It was therefore necessary to have a method that could 
incorporate many different ncAAs, quickly and efficiently. Due to the length of time it would 
take to evolve each tRNA/tRNA synthase pair for every ncAA to be inserted into the protein, 
the chemical modification approach was taken. The method chosen was a two-step method, 
that involved targeting a cysteine residue and first converting to dehydroalanine (dha) via a 
bis-alkylation-elimination method using the compound 2, 5-dibromohexane-1,6-diamide (diBr) 
(Chalker et al., 2011) . The dha is then converted into the ncAA side chain by a subsequent 
Michael addition of a thiol (Figure 3.1). Therefore the first step was to optimise this method for 





Figure 3.1. Schematic of the chemical modification method used to convert a cysteine 
residue into a non-canonical amino acid (ncAA). The first stage of the modification is to 
convert the cysteine residue into dehydroalanine using the compound 2, 
5-dibromohexane-1,6-diamide (diBr). Subsequent incubation with a thiol compound should 
yield the side chain of the ncAA. 
 
Previous work, carried out by Dr Nicole Timms, had identified the S. aureus variant of 
N-acetylneuraminic acid lyase (saNAL) as an ideal candidate for incorporation of ncAAs by 
chemical modification (Nicole Timms, PhD thesis, University of Leeds)(Timms et al., 2013). Due 
to saNAL being a naturally cysteine-free variant of N-acetylneuraminic acid lyase it allows for 
site-specific incorporation of ncAAs. Using site-directed mutagenesis, a cysteine residue can be 
inserted at the desired position within saNAL, and subsequent modification of the cysteine 
residue will incorporate the ncAA site-specifically. Surface-exposed cysteines, on folded 
proteins, have been shown to readily convert to ncAAs using this method (Chalker et al., 2012, 
Rowan et al., 2013). However, previous work had identified that residues located within the 
active site of saNAL and were not accessible to the modification reagents (Nicole Timms, PhD 
thesis, University of Leeds). Therefore it was necessary to carry out the modification process 
under denaturing conditions. saNAL was shown to be a highly robust protein that could 
undergo unfolding in 6 M urea with subsequent refolding without significant loss in activity, 
this allowed modifications to be carried out whilst the protein was in a denatured state (Timms 
et al., 2013). The combination of being able to site-specifically introduce ncAAs into saNAL and 
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being able to access any residue for modification, by denaturing the protein, meant that saNAL 
was an excellent system to evaluate the effects of ncAA incorporation.  This chapter will 
describe the use of this chemical method to replace the catalytic lysine, in saNAL, with the 
ncAA γ-thialysine, and the kinetic and structural characterisation of this modified protein. 
3.1 Incorporation of γ-thialysine into saNAL 
The first residue targeted for conversion to an ncAA was the catalytic lysine at position 165 and 
this was to be converted into a thioether analogue of lysine; the ncAA γ-thialysine (Figure 3.2).  
This modification was selected as a ‘proof of principle’, since it had previously been shown that 
aldolase activity in fructose-1,6-bisphosphate aldolase (FBPA) could be knocked out by 
replacing the active site lysine with cysteine, and that subsequent direct alkylation with 
bromoethylamine, to produce γ-thialysine, restored activity (Hopkins et al., 2002)(Figure 3.2). 
Direct alkylation with halides has been used extensively to modify cysteine residues and 
introduce ncAAs into proteins (Hegazy et al., 2006, Gloss and Kirsch, 1995a, Hopkins et al., 
2002, Bochar et al., 1999); however not only cysteine residues may be modified using this 
method. Nucleophilic side chains of lysine and histidine residues may also undergo alkylation 
(Heinrikson, 1966) and careful control of pH is needed to ensure preferential alkylation at 
cysteine residues (Hopkins et al., 2005, Chalker et al., 2009). Therefore the 
bis-alkylation-elimination method to produce a dehydroalanine is a more selective 
modification method as it produces and electrophilic centre that is not present in the twenty 






Figure 3.2. Comparison of the direct alkylation method and the bis-alkylation-elimination 
followed by a Michael addition method, to incorporation a γ-thialysine residue into a 
protein. A) Schematic of the conversion of the catalytic lysine at position 107 in fructose 
1,6-bisphosphate aldolase (FBPA) into  the non-canonical amino acid (ncAA) γ-thialysine. The 
first stage of the conversion is to produce a cysteine mutant at position 165 using 
site-directed mutagenesis and then direct alkylation with bromoethylamine produces the 
γ-thialysine. B) Schematic of the conversion of the catalytic lysine at position 165 in saNAL 
into the ncAA γ-thialysine. The first stage of the conversion is to produce a cysteine mutant 
at position 165 using site-directed mutagenesis. The cysteine variant can then be converted 
to dehydroalanine (dha) using the compound 2, 5-dibromohexan(1,6)diamide (diBr). Once 
the cysteine residue is fully converted to dha, aminoethanethiol can then be used to convert 
the dha residue into γ-thialysine 
 
3.1.1 Characterisation of wild-type and K165C saNAL 
To target K165 for modification, a cysteine mutant at position 165 was needed. The K165C 
mutant had previously been produced by site-directed mutagenesis, and both K165C and wild-
type saNAL DNA were kindly provided by Prof. Alan Berry (University of Leeds, UK).  Wild-type 
and K165C saNAL were expressed and purified using previously described methods (Williams 
et al., 2005, Timms et al., 2013). SDS PAGE was used to assess protein purity; in the elution 
fraction a clear band of protein could be seen at approximately 34 kDa indicating successfully 
purified protein (Figure 3.3). To further assess whether the proteins had been successfully 
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produced, positive mode ESI mass spectrometry was used. This identified the molecular mass 
of wild-type saNAL to be 33992.5 Da and the molecular mass of the K165C variant to be 
33969 Da, both in agreement with the masses predicted from the amino acid sequences, 
33995 Da and 33970 Da respectively (Figure 3.3).   
Once proteins had been purified they were either stored at 4˚C where they were stable for up 
to three months, or they were lyophilised and stored at -80°C. Proteins were prepared for 
lyophilisation by first dialysing into a volatile buffer, usually 50 mM ammonium acetate pH 7.0, 
and then flash freezing in liquid nitrogen. Lyophilised proteins were stable for up to 9 months. 
Kinetic parameters, kcat, Km and kcat/Km, were determined for wild-type saNAL and for K165C 
saNAL (shown in Table 3.1) using the LDH coupled assay described in Section 2.4.13.  Kinetic 
characterisation of the wild-type saNAL and K165C variant revealed that the kcat/Km for 
N-acetylneuraminic acid (Neu5Ac) cleavage was reduced 1000-fold in the K165C variant and 
the kcat was also reduced 625-fold. This significant reduction in activity caused by replacement 
of the catalytic lysine with a cysteine has also been found in previous aldolase studies (Hopkins 





Figure 3.3. Purification and ESI mass spectra of wild-type and K165C saNAL. Panel A shows 
and example SDS-PAGE gel of the batch nickel affinity purification of wild-type saNAL. A 
broad range (7-175 kDa) molecular weight marker is shown in lane M. Whole cell lysate can 
be seen in lane 1 with a clear band of overexpressed protein at approximately 34 kDa. 
Insoluble and soluble fractions can be seen in lane 2 and 3 respectively, in the soluble 
fraction the overexpressed protein band is clearly visible. Samples from the load and 3 wash 
steps carried out are shown in lanes 4 to 7 and purified eluted protein is shown in lane 8. 
Panels B and C show ESI mass spectra of wild-type and K165C saNAL, raw data is shown 
above in each panel and deconvoluted spectra are shown below. The mass spectra show the 
molecular mass of the wild-type and K165C proteins to be 33993 Da and 33969 Da 
respectively which are in agreement with their predicted molecular masses of 33995 Da and 
33970 Da, respectively. 
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Enzyme kcat (min-1) Km (mM) kcat/Km (min-1.mM-1) 
Wild-type 250 ± 4.6 2.2 ± 0.12 114 
K165C 0.4 ± 0.014 3.8 ± 0.45 0.11 
 
Table 3.1. Steady-state kinetic parameters for the cleavage of N-acetylneuraminic acid 
(Neu5Ac) by both the wild-type and K165C saNAL. Kinetic parameters were determined 
using the LDH coupled assay (Section 2.4.13). 
 
3.1.2 Conversion of K165C saNAL into K165dha saNAL 
The first step of the modification to introduce γ-thialysine at position 165 was to convert the 
cysteine variant, K165C, into K165dha. This conversion was carried out using the compound 
diBr, the diBr used in all experiments was synthesised by Robert Smith and Alun Myden 
(University of Leeds. UK). DiBr causes a bis-alkylation-elimination mechanism, with the 
cysteine residue, producing a dehydroalanine residue (Figure 3.1). Small scale modifications 
(2.5 mg) were initially carried out: 2.5 mg of lyophilised K165C protein was taken and 
resuspended in 1.25 mL of pre-warmed (37 ˚C) sodium phosphate buffer (50 mM, pH 8.0) 
containing 6 M urea. To this protein solution, 100 µL of diBr (0.13 mg µL-1 in DMF) was added 
(581 equivalents of diBr relative to protein), and then incubated for 1 hr 30 min at 37 ˚C with 
shaking at 200 rpm. After the incubation period, a 70 µL sample was taken and buffer 
exchanged into 50 mM ammonium acetate pH 7.0, using a Micro Bio-Spin™ Chromatography 
Column, for analysis by ESI mass spectrometry, which was performed by Dr James Ault 
(University of Leeds). Using ESI mass spectrometry it was possible to assess whether 
conversion from K165C into K165dha had occurred. The expected mass for K165dha was 
33934 Da and the observed mass was 33936.6 Da (Figure 3.4) indicating conversion had 




Figure 3.4. ESI mass spectra of K165dha saNAL. The raw data is shown above and the 
deconvoluted spectrum below. Mass spectrum of K165dha was obtained after 1 hr 30 min 
incubation (37 ˚C, 200 rpm) of K165C saNAL (1.25 mL, 2 mg mL-1) with diBr (100 µL, 
0.13 mg µL-1). ESI-MS showed the molecular mass of K165dha to be 33936.6 Da which is in 
agreement with the expected mass of 33934 Da, the mass spectrum shows no evidence for 
any remaining K165C protein which has the molecular mass 33970 Da. 
 
3.1.3 Modification of K165dha saNAL into K165-γ-thialysine saNAL 
Once K165C had been successfully converted to K165dha, the next step of the modification 
was carried out. Aminoethanethiol was used to produce the ncAA γ-thialysine via a Michael 
addition onto the dehydroalanine residue at position 165.  40 µL of aminoethanethiol 
(0.1 mg mL-1 in 2 M Tris/HCl pH 7.4) was added to the 1.25 mL of denatured K165dha 
(2 mg mL-1 in 50 mM sodium phosphate buffer, pH 8.0, containing 6 M urea) and incubated for 
2 hours at 37 ˚C with shaking at 200rpm.  To monitor the conversion, after 2 hours a 70 µL 
sample was taken from the reaction mixture for analysis by ESI mass spectrometry, which was 
performed by Dr James Ault. The sample was first buffer exchanged into 50 mM sodium 
phosphate buffer, pH 8.0, containing 6 M urea to remove excess aminoethanethiol, as this had 
previously been shown to cause the protein to stick to the spin column matrix (Nicole Timms, 
PhD thesis, University of Leeds), and then desalted into 50 mM ammonium acetate pH 7.0. The 
observed mass of K165-γ-thialysine was 34011 Da - in agreement with the expected mass of 




Figure 3.5 ESI mass spectrum of K165-γ-thialysine saNAL. The raw data is shown above and 
the deconvoluted spectrum below. Mass spectrum of K165-γ-thialysine saNAL was obtained 
after 2 hour incubation (37 ˚C, 200 rpm) of K165dha saNAL (1.25 mL, 2 mg mL-1) with 
aminoethanethiol (40 µL, 0.1 mg µL-1). ESI mass spectrometry showed the molecular mass of 
K165-γ-thialysine to be 34012Da - in agreement with the expected mass of 34012 Da. 
 
After the conversion to K165-γ-thialysine had been achieved, the protein was refolded by 
removing the urea by dialysis. As before, when preparing the protein for mass spectrometry, it 
was observed that excess aminoethanethiol caused the protein to precipitate on removal of 
the urea. Therefore the protein was first dialysed against sodium phosphate buffer (50 mM, 
pH 8.0) containing 6 M urea and then against the same buffer containing no urea.  
3.1.4 Large scale conversion of K165C saNAL into K165-γ-thialysine saNAL 
For further studies of the modified protein, K165-γ-thialysine, larger quantities of the protein 
were required. To produce these larger quantities scale up of the modification procedure was 
carried out; modifications were carried out on a 20 mg scale and up to a 50 mg scale if needed. 
The modification was carried out in the same manner as with the small scale modification, 
20 mg of lyophilised K165C protein was resuspended in 10 mL of sodium phosphate buffer 
(50 mM pH 8.0) containing 6 M urea which had been pre-warmed to 37 ˚C. The protein 
solution was vortexed for 30 s to ensure the lyophilised protein was thoroughly redissolved, 
then 800 µL of diBr (0.13 mg µL-1 in DMF; 581 equivalents), was added and the solution 
incubated for 1 hr 30 min at 37 ˚C, with shaking 200 rpm. Once conversion to K165dha was 
confirmed using ESI mass spectrometry, then 320 µL of aminoethanethiol (0.1 mg µL-1 in 2 M 
Tris/HCl pH 8.8) was added and incubated at 37 ˚C, with shaking at 200 rpm for 2 hours. 
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3.2 Characterisation of K165-γ-thialysine saNAL 
ESI mass spectrometry indicated that full conversion of the variant K165C into 
K165-γ-thialysine had been successfully achieved. Now that correctly modified protein had 
been produced, characterisation of the ncAA-containing protein was carried out. Far UV 
circular dichroism (CD) was used to access the fold of the modified protein and LDH coupled 
kinetics were used to obtain kinetic parameters. 
3.2.1 Far UV circular dichroism and initial kinetic assays of K165-γ-thialysine 
The modification of K165C saNAL into K165-γ-thialysine had been performed under denaturing 
conditions and then the urea was removed by dialysis. Removal of urea in this manner had 
been shown to refold wild-type saNAL successfully (Nicole Timms, PhD thesis, University of 
Leeds)(Timms et al., 2013); to determine whether the modified protein had refolded correctly, 
far UV CD was used (Section 2.4.15). 
Far UV CD was carried out on samples of refolded, modified K165-γ-thialysine enzyme and 
both wild-type saNAL and wild-type saNAL that had undergone refolding in the same manner 
as the modified protein. CD spectra indicated that the refolded modified protein did not have 
an identical CD spectrum to wild-type saNAL (Figure 3.8). Therefore further investigation was 
carried out to determine whether refolding had been successful for K165-γ-thialysine saNAL 
and whether this modified protein was active.   
If the modified protein had refolded correctly it is likely that it would be more active compared 
to the K165C variant. Therefore, kinetic assays were carried out with the modified 
K165-γ-thialysine protein to determine if there was a regain of activity. LDH coupled kinetics 
were carried out as in Section 2.4.13. Kinetic assays showed that incorporation of the 
γ-thialysine residue had restored significant activity compared to the K165C variant, showing a 
90-fold increase in kcat/Km (Table 3.2). However, kinetic assays also showed that the activity of 
the K165-γ-thialysine enzyme was considerably lower compared to that of the wild-type 
saNAL, showing an 11-fold decrease in kcat/Km.  
This restoration of activity indicated that, although the CD spectrum of the modified protein 
appeared not to be identical to the wild-type protein, it was a protein containing a 
non-canonical side chain that regained some wild-type enzyme activity. Therefore further 
investigation was carried out to assess whether the difference in CD spectra was a 
consequence of the modification procedure. 
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Enzyme kcat (min-1) Km (mM) kcat/Km (min-1.mM-1) 
Wild-type 250 ± 4.6 2.2 ± 0.12 114 
K165C 0.40 ± 0.014 3.8 ±0.45 0.11 
K165-γ-thialysine 11 ± 0.23 1.1 ± 0.11 10 
Table 3.2. Steady-state kinetic parameters for the cleavage of N-acetylneuraminic acid by 
both the wild-type, K165C and the ncAA containing protein K165-γ-thialysine saNAL. Kinetic 
parameters were determined using the LDH coupled assay. 
 
During the modification procedure the dehydroalanine intermediate produced from reaction 
of the cysteine residue with diBr is planar. Therefore the Michael addition of the thiol, to 
produce the non-canonical side chain, could occur on either face of the double bond. This 
means that it is possible to generate either a D or L non-canonical amino acid from the 
dehydroalanine intermediate (Zhu and Van Der Donk, 2001, Chalker et al., 2012). It was 
therefore hypothesised that any protein that had been modified could have produced a mixed 
population of both D and L non-canonical side chains, and potentially the protein that had 
modified to the D form of the non-canonical amino acid may not have refolded correctly 




Figure 3.6. Schematic representation of chemical modification producing both D and L forms 
of the ncAA γ-thialysine. Michael addition of aminoethanethiol is shown occurring on either 
faces of the dehydroalanine (dha) leading to both D and L forms of γ-thialysine. It is 
hypothesised that protein containing L-γ-thialysine will refold whereas protein containing 
D-γ-thialysine will aggregate. 
 
To see whether a mixed species of K165-γ-thialysine had been produced during the 
modification procedure, size exclusion chromatography was used. Correctly modified 
K165-γ-thialysine protein underwent size exclusion chromatography using a Superdex S200 
preparative grade column (GE Healthcare Life Sciences). During gel filtration of the modified 
protein, the elution profile was significantly different to that of either wild-type or K165C 
saNAL. These unmodified proteins eluted in one peak at approximately 180 mL whereas the 
modified protein was seen to elute in two peaks. In the elution profile of K165-γ-thialysine the 
first protein eluted in the void volume at approximately 110 mL and the second protein peak 
eluted at approximately 180 mL (Figure 3.7) - the elution volume expected for a tetramer 
made up of 34 kDa monomers, as in wild-type saNAL. This indicated that the modification 
procedure produced a mixed species of ncAA-containing protein. From the ESI-MS analysis all 
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of the protein is seen to contain γ-thialysine however a proportion of the modified protein 
must not refold correctly and therefore elutes in the void volume.  
 
 
Figure 3.7. Size exclusion chromatography of K165-γ-thialysine. Panel A shows the A280 nm 
trace of the modified protein with the peak of the void volume at 110-125 mL and the peak 
for the modified protein at 180-210 mL. Panel B shows the SDS-PAGE gel of samples from the 
gel-filtration peak at 180-210 mL showing protein bands at approximately 34 kDa, broad 
range (7-175 kDa) molecular weight markers are shown in lane M. 
 
Far UV CD was then used to analyse samples from both the void volume peak and the peak at 
180 mL, which will be referred to as gel-filtered K165-γ-thialysine. The far UV CD spectrum for 
the void volume peak showed that it did not have the same CD spectrum as the wild-type 
protein. Whereas the sample for gel-filtered K165-γ-thialysine has a spectrum identical to that 
of the wild-type protein (Figure 3.8). This data shows that incorrectly folded protein is formed 
during the modification process, potentially due to production of a D amino acid at the 
modification position. However by using size exclusion chromatography this material can be 





Figure 3.8. Far UV circular dichroism of wild-type and K165-γ-thialysine. CD spectra of 
wild-type saNAL (black), wild-type saNAL that has undergone unfolding in 6 M urea and 
subsequent refolding (red), K165-γ-thialysine saNAL produced using the chemical 
modification procedure and therefore unfolded in 6 M urea and then refolded (blue) and 
K165-γ-thialysine saNAL that has undergone gel-filtration: both the protein that eluted at 
the correct elution volume gel-filtered K165-γ-thialysine (purple) and the void volume 
(green). 
 
3.2.2 Kinetic comparison of wild-type saNAL and K165-γ-thialysine saNAL 
Kinetic analysis was carried out with the gel-filtered K165-γ-thialysine protein, using LDH 
couple kinetics in 50 mM Tris/HCl pH 7.4. This showed an approximate doubling in activity for 
both kcat and kcat/ Km over that of the modified protein before gel-filtration (Table 3.3). This 
data indicates that during the modification process although the protein is correctly modified 
to contain γ-thialysine (as is shown from the mass spectrometry data), some of the protein 
may not refold correctly. Using size exclusion chromatography this incorrectly folded material 
can be separated from correctly folded protein, and upon removal of the incorrectly folded 
material the modified protein regains more activity, indicating the incorrectly folded protein is 
either inactive or far less active that the correctly folded modified protein. Therefore the 
gel-filtered K165-γ-thialysine saNAL was used in all further experiments. 
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Enzyme kcat (min-1) Km (mM) kcat/ Km (min-1.mM-1) 
Wild-type 
K165C  
250 ± 4.6 
0.40 ± 0.014 






11 ± 0.23 1.1 ± 0.11 10 
Gel-filtered 
K165-γ-thialysine  
26 ± 0.9 1.4 ± 0.2 19 
Table 3.3. Steady-state kinetic parameters for the cleavage of N-acetylneuraminic acid by the 
wild-type saNAL, K165C saNAL and the ncAA-containing protein K165-γ-thialysine saNAL 
before and after undergoing size exclusion chromatography. Kinetic parameters were 
determined using the LDH coupled assay. 
 
This decrease in activity compared to the wild-type enzyme, but increase in activity compared 
to the cysteine variant K165C, brought about by the insertion of the ncAA γ-thialysine has also 
been seen in previous γ-thialysine studies, where direct alkylation of a cysteine was used to 
insert the ncAA (Gloss and Kirsch, 1995a, Hopkins et al., 2002). The decrease in activity in the 
previous studies was attributed to incomplete conversion of the cysteine to the non-canonical 
side chain. However in this current study there is no evidence in the ESI-MS that there is any 
remaining dha or cysteine residue, at position 165. Therefore the decrease in activity may be 
due to structural differences between the lysine and γ-thialysine side chains.  
3.3 Crystallographic studies of K165-γ-thialysine saNAL 
To determine the structural effects of inserting the non-canonical amino acid, γ-thialysine into 
the active site of saNAL, the crystal structures of the K165-γ-thialysine, wild-type and K165C 
enzymes were solved. To investigate whether the incorporation of a sulphur atom into the 
lysine chain affected the structural binding of pyruvate in the active site, which could have led 
to the decrease in activity when compared to the wild-type enzyme, the structures of both 





3.3.1 Crystallisation  
Crystallisation conditions had been previously determined for the E .coli NAL enzyme 
(Campeotto et al., 2009, Campeotto et al., 2010), and so these conditions were optimised for 
wild-type saNAL. Optimisation of crystallisation conditions of the wild-type saNAL was carried 
out by Dr Chi Trinh (University of Leeds, UK) and Anna Polyakova (University of Leeds, UK). 
Crystallisation conditions used were 200 mM NaCl, 100 mM Tris/HCl (pH 7.0-8.5), and 18-28% 
(w/v) PEG 3350. These conditions were also used for crystallisation of K165-γ-thialysine and 
K165C saNAL enzymes. Wild-type and K165C saNAL were prepared for crystallisation by 
purification using nickel affinity chromatography (Section 2.4.1) and then size exclusion 
chromatography (Section 2.4.12). K165-γ-thialysine saNAL was prepared for crystallisation by 
first purifying K165C protein by nickel affinity chromatography. The K165C protein was 
modified to K165-γ-thialysine which then underwent size exclusion chromatography, and 
correctly folded K165-γ-thialysine which eluted at approximately 180 mL was used for 
structural studies. Proteins were concentrated to 7-10 mg mL-1 prior to crystallisation. 
Crystallisation trays were set up using hanging drop vapour diffusion, with drops containing 
1:2, 2:2 and 2:1 of protein to mother liquor. Hanging drop vapour diffusion yielded crystals in 
7-10 days and crystals usually formed in either hexagonal or rectangular blocks (Figure 3.9). 
To produce cryo-cooled crystals for data collection, the cryoprotectant used was PEG 400. 
Crystals were soaked in mother liquor supplemented with increasing amounts of PEG 400. The 
first soak contained 15% PEG 400 (w/v) and increased in 5% increments to 25% PEG 400 (w/v). 
Crystals were soaked in each concentration of PEG400 for approximately 1 min and then flash 
cooled in liquid nitrogen ready for data collection. 
   
Figure 3.9. K165-γ-thialysine saNAL crystal formed from hanging drop vapour diffusion in 
200 mM NaCl, 100 mM Tris/HCl (pH 7.0-8.5), PEG 3350 (18-28% w/v).  
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The structures of the apo wild-type and K165-γ-thialysine saNAL were solved, and the 
structures of their pyruvate bound complexes were also solved.  To produce the complexes of 
K165-γ-thialysine and wild-type saNAL with pyruvate, the crystals were soaked with sodium 
pyruvate. Soaking was carried as with the apo structures with mother liquor supplemented 
with 15-25% PEG400 (w/v)  but soaks also contained 100 mM pyruvate (Campeotto et al., 
2009). Attempts were also made to solve the structure of the K165C saNAL in complex with 
pyruvate; however despite soaking the crystals with 100 mM pyruvate the subsequent 
structures showed no evidence of pyruvate in the active site. 
3.3.2 Data collection and processing 
Data collection for all crystals was carried out at Diamond Light Source (Oxfordshire, UK), and 
data sets were produced from single crystals. Data sets for wild-type and K165-γ-thialysine 
saNAL structures, both the apo and pyruvate soaked, were collected on beamline I02 and data 
for the K165C saNAL structure were collected on beamline I04-1. Data processing for the wild-
type saNAL structures, both the apo and in complex with pyruvate, was carried out by Dr Chi 
Trinh and Anna Polyakova. Integration and scaling of all datasets was performed using the 
CCP4 programs MOSFLM and SCALA (Leslie, 2006, Evans, 2006) and full structural statistics can 
be seen in Table 3.4. The wild-type saNAL apo structure was determined by molecular 
replacement methods using the program PHASER (Mccoy, 2007, Mccoy et al., 2007), using the 
H. influenza NAL structure (pdb code 1F74) (Barbosa et al., 2000) as the search model. Since 
the other structures have a very similar unit cell parameters to the wild-type saNAL structure 
(see Table 3.4), and the same space group, P212121, it was possible to determine these 
structures using the refined structure of wild-type saNAL apo structure as a starting model for 
refinement and rebuilding into both 2Fobs-Fcal and Fobs-Fcal maps using REFMAC (Murshudov et 
al., 1997, Murshudov et al., 2011) and COOT (Emsley et al., 2010). All crystal structures had an 








K165C saNAL K165C-γ-thialysine 
saNAL 
K165C-γ-thialysine 
saNAL  pyruvate 
Diamond beamline I02 I02 I04-1 I02 I02 
PBD accession code 4ahp 4ah7 4ahq 4aho 4ama 
Resolution (Å) 2.10 2.30 1.95 2.00 2.35 
Space group P212121 P212121 P212121 P212121 P212121 
a (Å) 82.5 82.3 82.2 82.3 82.9 
b (Å) 109.6 109.9 110.0 109.7 110.3 
c (Å) 131.3 131.7 133.7 131.4 132.2 
Rmerge §* 0.075(0.350) 0.117(0.361) 0.067(0.47) 0.064(0.435) 0.11(0.498) 
Rpim+* 0.044(0.20) 0.065(0.201) 0.03(0.225) 0.036(0.248) 0.065(0.289) 
Observed reflections 258,615 212,634 499,678 320,723 193,152 
Unique reflections 68,405 53,415 86,766 80,641 50,421 
Completeness (%)* 97.7(92.8) 99.4(100) 97.8(93.4) 99.6(100) 98.5(99.0) 
Multiplicity* 3.8(3.7) 4.0(4.0) 5.8(5.1) 4.0(4.1) 3.8(3.9) 
<I/σ> I/σ * 10.8(3.4) 9.7(3.7) 14.9(3.2) 14.6 (3.5) 11.4(3.2) 
Refinement 
Rfactor (%) 0.19 0.20 0.19 0.19 0.18 
Rfree (%)† 0.24 0.25 0.23 0.23 0.24 
No. of protein atoms 9015 9189 9222 8922 9261 
No. of solvent molecules 381 130 368 362 356 
No of ligand atoms - 20 - - 20 












Average ligand B-factor 
(Å2)  
- 13.5 - - 26.6 
Average solvent B-factor 
(Å2)  
26.8 14.3 35.8 31.9 22.8 
RMS bond lengths (Å) ξ 0.013 0.013 0.015 0.013 0.013 
RMS bond angles (Å) ξ 1.441 1.617 1.78 1.441 1.586 
Ramachandran analysis, the percentage of residues in the regions of plot (%) ‡  
Most favoured 98.8 98.1 99.1 98.7 98.3 
Outliers 0 0 1' 0 0 
 
§ Rmerge= ΣhklΣi|Ii(hkl)-<I(hkl)>|/ ΣhklΣi|Ii(hkl) 
+ Rpim - precision-indicating (multiplicity-weighted) Rmerge, relative to all I+ or I-. 
* Values given in parentheses correspond to those in the outermost shell of the resolution range. 
† Rfree was calculated with 5% of the reflections set aside randomly. 
ξ Based on the ideal geometry values of Engh & Huber (Engh and Huber, 1991). 
‡ Ramachandran analysis using the program MolProbity (Lovell et al., 2003) 
'The side chain of Tyr111 is in close proximity to Leu142, Thr143 and Phe110 from an adjacent chain causing the phi and psi angles 
of Tyr111 to lie in an unfavoured region of the Ramachandran plot 
Table 3.4. Structural data statistics for the X-ray crystallographic structures of wild-type and 
K165-γ-thialysine saNAL both apo and in complex with pyruvate and K165C saNAL. 
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The CCP4 program REFMAC (Murshudov et al., 2011, Murshudov et al., 1997) was used for 
refinement of all structures. Initially ten rounds of rigid body refinement were carried out, 
followed by multiple rounds of restrained refinement, and TLS (translation, libration, 
screw-motion) refinement was also used. After each round of refinement, model building was 
performed in COOT (Emsley et al., 2010). For the refinement of the structures wild-type saNAL, 
wild-type saNAL in complex with pyruvate, K165C saNAL, K165-γ-thialysine saNAL and 
K165-γ-thialysine saNAL in complex with pyruvate, a wild-type model with the lysine at 
position 165 modelled as an alanine was used as a starting structure to produce non-biased 
electron density around this position. The structure for K165C saNAL, when initially refined 
with an alanine at position 165 showed extending electron density from the Cβ that fitted a 
cysteine residue. The structure for wild-type saNAL, when initially refined with an alanine at 
position 165 showed extending electron density from the Cβ that fitted a lysine residue. The 
structure of the wild-type saNAL in complex with pyruvate had positive electron density 
around position 165 that appeared to be a lysine residue; however there was continuous 
positive electron density extending from where the amine group of the lysine residue would 
be. This extended electron density indicated the lysine was covalently linked to another 
molecule, most likely the pyruvate group. Therefore the lysine residue in complex with 
pyruvate was modelled and refined.  To build in this non-standard residue restraint and 
coordinate files for the pyruvate bound lysine had to be generated using the online PRODRG 
server (Schuttelkopf and Van Aalten, 2004). The files generated were compared to the 
standard restraint and coordinate files for a lysine residue, manually edited and given the 
HETATM code KPI. Once the residue was built, rounds of restrained refinement were carried 
out and the positive electron density around the 165 side chain was no longer present 




Figure 3.10 Model building of the γ-thialysine side chain into chain C of the K165-γ-thialysine 
apo crystal structure. The 2Fobs-Fcal map is shown in grey and the Fobs-Fcal map is shown in 
green. Panel A shows the initial model with an alanine at position 165, electron density can 
be seen extending from the Cβ, and positive electron density is shown in green. Panel B 
shows the electron density at position 165 modelled as a lysine residue, positive electron 
density, shown in green, can be seen at the γ position indicating an atom that is more 
electron dense than a carbon. Panel C shows electron density at position 165 modelled as a 
γ-thialysine residue and no positive electron density can be seen, indicating the side chain is 
correctly modelled. 
 
A starting structure with an alanine modelled at position 165 was used for the refinement of 
the ncAA-containing protein K165-γ-thialysine saNAL both apo and in complex with pyruvate. 
For the K165-γ-thialysine saNAL apo structure, clear positive electron density could be seen 
extending from the Cβ of the alanine residue which looked to fit the side chain of a lysine, 
however when a lysine residue was built in and refined into the model there was still excess 
positive electron density around the γ position of the side chain (Figure 3.10). This increased 
electron density at the γ position indicated that it was not a carbon atom at this position and 
was in fact a more electron dense atom such as a sulphur (Figure 3.10). When refining the 
K165-γ-thialysine saNAL structure in complex with pyruvate a similar process was carried out 
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as for the apo structure. It was seen that the atom at the γ position was more electron dense 
than a carbon atom, indicating a sulphur atom at this position, and there was extending 
electron density from the terminal amine indicating the residue was covalently linked to 
pyruvate. Therefore restraint and coordinate files for a γ-thialysine and γ-thialysine in complex 
with pyruvate were generated using the online server PRODRG and given the HETATM codes 
SLZ and KPY respectively (Schuttelkopf and Van Aalten, 2004). These files were compared to 
the standard coordinate files for cysteine and methionine to compare the Cβ-Sγ bond angles 
and bond lengths, and then manually edited before being used in model building and 
refinement. Once the γ-thialysine residue had been built into K165-γ-thialysine apo structure a 
round of refinement was performed, and the excess positive electron density around the γ 
position of the side chain was no longer present indicating the γ-thialysine residue was 
correctly modelled. The same process was used for the K165-γ-thialysine structure in complex 




Figure 3.11. Electron density 2Fobs-Fcal maps for the side chains at position 165. Panel A shows 
electron density for the lysine at position 165 in the wild-type saNAL apo crystal structure. 
Panel B shows electron density for the γ-thialysine (HETATM SLZ) at position 165 in the 
K165-γ-thialysine saNAL apo crystal structure. Panel C shows electron density for the 
cysteine at position 165 in the K165C saNAL crystal structure. Panel D shows electron density 
for the lysine in complex with pyruvate (HETATM KPI) at position 165 in the wild-type saNAL, 
in complex with pyruvate, crystal structure. Panel E shows electron density for the 
γ-thialysine in complex with pyruvate (HETATM KPY) at position 165 in the K165-γ-thialysine 
saNAL, in complex with pyruvate, crystal structure. 
 
All solved structures contained homotetramers in the unit cell with each monomer having an 
(α/β)8 TIM barrel fold (Figure 3.12). Excitingly in all four subunits for the ncAA containing 
protein K165-γ-thialysine saNAL, in both the apo and pyruvate bound structures, the density 
clearly showed the non-canonical side chain for γ-thialysine showing efficient and complete 
incorporation of γ-thialysine into the protein. Interestingly in all subunits there was no 
evidence for the D enantiomer of the γ-thialysine. This indicates that if the D γ-thialysine does 
form in the modification process, it is highly likely that this is the aggregated fraction that is 




3.3.3 Crystal structures 
The crystals structures of wild-type saNAL, K165C saNAL and K165-γ-thialysine saNAL were 
solved to determine the structural effects of incorporating the non-canonical side chain 
γ-thialysine. No major structural effects were seen from the incorporation of γ-thialysine into 
saNAL as all structures were seen as homotetramers (panel A Figure 3.12) in the unit cell. Each 
monomer within the tetramer has the same fold of an (α/β)8 TIM barrel (panel B Figure 3.12), 
which is also seen in the E. coli and H. influenza NAL structures (Izard et al., 1994, Barbosa et 
al., 2000). In each TIM barrel monomer, the α helices form the outer wall of the monomer and 
enclose the parallel β sheets. Therefore neither the cysteine mutant nor the incorporation of 
γ-thialysine altered the overall fold of the protein.  Alignment at Cα atoms of the wild-type and 
K165-γ-thialysine saNAL apo structures, gives an overall RMSD of only 0.13 Å and alignment of 
K165C and wild-type saNAL gives an overall RMSD of 0.49 Å. The overall fold of the protein was 
also not affected when both wild-type and the modified enzymes were in complex with 
pyruvate, as when these structures were aligned by C-α atoms the overall RMSD was 0.31 Å. 
The main structural differences could be seen when comparing the apo and pyruvate bound 
structures of both the wild-type and K165-γ-thialysine saNAL. In both the apo structures there 
is a region of disordered electron density which corresponds to a loop (residues 138-146), 
however once pyruvate is bound in both the wild-type and K165-γ-thialysine structures this 
loop becomes ordered and can clearly be seen in the structure. This loop (residues 138-146) in 
both of the pyruvate bound structures lies over the entrance to the active site as can be seen 
in panel C of Figure 3.12. In both the wild-type and K165-γ-thialysine saNAL structures in 
complex with pyruvate, this rearrangement of the loop region causes a significant change in 
the positioning of Tyr137, which can be seen in panel C of Figure 3.12. Tyr137 is a residue that 
has been shown to be essential for catalysis (Daniels et al., 2014) and so this repositioning of 
Tyr137, where it is shifted towards the terminal amine end of both the lysine and γ-thialysine, 
may help to stabilise the pyruvate binding in the active site. Surprisingly, in the K165C 
structure the loop region between residues 138-146 has clear ordered electron density even 
though there is no evidence for pyruvate in the active site.  
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Figure 3.12. Structural comparison of wild-type and K165-γ-thialysine saNAL. Panel A shows 
the homotetramers for wild-type (cyan) and K165-γ-thialysine (purple) saNAL structures in 
complex with pyruvate. Both structures are shown separately and overlaid. Panel B shows 
the (α/β)8 TIM barrel fold of the monomer for both wild-type (cyan) and K165-γ-thialysine 
(purple) saNAL structures in complex with pyruvate, both structures are shown separately 
and overlaid. Panel C shows overlays of the apo and pyruvate complex structures for 
wild-type and K165-γ-thialysine saNAL structures; wild-type saNAL apo is shown in green 
and wild-type saNAL in complex with pyruvate is shown in cyan. The rearrangement of 
Tyr137 and the appearance of the loop region of residues 138-146 can be seen in the 
structure in complex with pyruvate. K165-γ-thialysine saNAL apo is shown in orange and 
K165-γ-thialysine saNAL in complex with pyruvate is shown in purple, again the 
rearrangement of Tyr137 and the appearance of the loop region of residues 138-146 can be 
seen in the structure in complex with pyruvate.  
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From the structural comparison, the incorporation of γ-thialysine at position 165 does not 
affect the overall fold of the protein. Also the structural changes that occur in the wild-type 
saNAL structure when pyruvate binds also occur in the K165-γ-thialysine structure when 
pyruvate binds; the repositioning of Tyr137 and residues 138-146 forming an ordered loop 
over the entrance to the active site. This identical structural behaviour during the first stage of 
the catalytic mechanism, pyruvate binding, therefore provides no rationale for the reduction in 
activity of the ncAA containing enzyme. 
 The presence of the sulphur atom in the side chain of γ-thialysine may cause localised 
structural differences that affect the binding of pyruvate, and reduce activity in the modified 
enzyme compared to the wild-type enzyme. The sulphur at the gamma position in the side 
chain would affect both the bond lengths and angles around this position compared to those in 
the wild-type lysine side chain (Ammon et al., 1991). In their respective structures, both the 
lysine and the γ-thialysine residues at position 165 are seen in the fully extended anti 
configuration, both when they have formed a Schiff base with pyruvate and when they have 
not. In the Lys165 residue, within the wild-type saNAL structures, the Cβ-Cγ and Cγ-Cδ bond 
lengths, and the Cβ-Cγ-Cδ bond angle are very similar to the values for the bond lengths and 
angle for free lysine (shown in Table 3.5). In the γ-thialysine residue, within the 
K165-γ-thialysine structures, the Cβ-Sγ and Sγ-Cδ bond lengths, and the Cβ-Sγ-Cδ bond angle 
are also very similar to the values for free γ-thialysine (Ammon et al., 1991). Comparison of the 
γ-thialysine residue to the lysine residue shows that the Cβ-Sγ and Sγ-Cδ bond lengths are 
0.3 Å longer than the respective Cβ-Cγ and Cγ-Cδ in the lysine. This increase in bond length 
may cause the γ-thialysine residue to extend further into the active site of the enzyme. 
However the Cβ-Sγ-Cδ is a tighter bond angle than the respective Cβ-Cγ-Cδ found in the 
wild-type lysine residue, which counteracts the increase in the Cβ-Sγ and Sγ-Cδ bond lengths. 
Comparison of the Cα-NZ distances in the Lys165 and γ-thialysine 165 residues (Figure 3.13) 
show that the γ-thialysine residue is approximately 0.3 Å longer than the lysine residue, when 
comparing the apo structures and 0.3 Å longer when comparing the structures in complex with 
pyruvate. The overlays at Cα of the γ-thialysine and lysine residues show that the increased 
bond lengths at Cβ- Sγ and Sγ-Cδ does appear to be compensated by the decreased Cβ-Sγ-Cδ 
bond angle. In the overlay of the apo lysine and γ-thialysine the terminal amine in the 
γ-thialysine is positioned 0.5 Å (averaged value from all 4 subunits) away from the terminal 
amine of the lysine. In the pyruvate bound structures the terminal amine of the γ-thialysine 
89 
 
residue is positioned 0.3 Å (averaged value from all 4 subunits) away from the terminal amine 
of the lysine (Figure 3.13). 
In the catalysis of NAL, Schiff base formation is critical for activity. The difference in bond angle 
and lengths in the γ-thialysine side chain may place the terminal amine into a position that is 
not optimal for Schiff base formation. Therefore this repositioning of the terminal amine may 









Cβ- Cγ bond 
length 










110.14 ° 110° Cβ-Sγ-Cδ 
bond angle 
97.2° 102.9° 
Table 3.5. Comparison of bond lengths and angles at the γ position of residue 165 in the 
wild-type and K165-γ-thialysine saNAL crystal structures to the bond lengths and angles at 








Figure 3.13. Comparison of Cα-NZ distances in lysine and γ-thialysine at position 165 in the 
wild-type and K165-γ-thialysine saNAL structures. The table in panel A shows the averaged 
Cα-NZ distances from all four subunits for the wild-type saNAL structures both apo and in 
complex with pyruvate and for the K165-γ-thialysine saNAL structures both apo and in 
complex with pyruvate. Panel B shows overlays at Cα of Lys165 (green) and γ-thialysine165 
(orange) and overlays at Cα of Lys165 in complex with pyruvate (cyan) and γ-thialysine165 in 
complex with pyruvate (purple). 
 
To further investigate the effects of the 0.3 Å repositioning of the terminal amine found in the 
γ-thialysine residue, the pyruvate binding pocket was examined. In the structure of the 
wild-type saNAL in complex with pyruvate the lysine forms a Schiff base with pyruvate and the 
carboxylate end of the pyruvate hydrogen bonds to both the back bone and side chain of 
Ser48 and Ser49 (Figure 3.14). The K165-γ-thialysine structure in complex with pyruvate is seen 
to make the same interactions, within the pyruvate binding pocket, as the wild-type. 
Therefore, the introduction of the non-canonical side chain does not appear to structurally 




Figure 3.14. Comparison of the pyruvate binding site in the wild-type and K165-γ-thialysine 
crystal structures. A shows the pyruvate binding site in the wild-type saNAL structure in 
complex with pyruvate (cyan). B shows the pyruvate binding site in the K165-γ-thialysine 
saNAL structure in complex with pyruvate (purple). In both structures, the carboxylate end 
of the pyruvate is seen to form hydrogen bonds with the side chain and backbone of Ser48 
and Ser49. 
 
Through analysis of the wild-type and K165-γ-thialysine saNAL crystal structures, it appears 
there is very little structural difference. Upon pyruvate binding, both wild-type and 
K165-γ-thialysine undergo the same structural changes and the interactions within the 
pyruvate binding site are very similar in both proteins. The main structural difference between 
the wild-type and K165-γ-thialysine is the 0.3 Å repositioning of the terminal amine of the 
γ-thialysine residue caused by the altered Cβ-Sγ and Sγ-Cδ bond lengths and the Cβ-Sγ-Cδ 
bond angle. This repositioning of the amine group may contribute to the decrease in activity 
seen in the modified enzyme, as the repositioning could affect Schiff base formation. However, 
since the modified enzyme does not appear to have any other significant structural 
differences, it was investigated whether another property of the modified enzyme was also 
contributing to the decrease in activity. 
3.4 Further kinetic studies of K165-γ-thialysine saNAL 
From initial kinetic studies of the modified protein it was seen that once the K165-γ-thialysine 
protein had been gel filtered and any incorrectly folded material removed, the activity of the 
modified protein was still reduced compared to the wild-type enzyme. The kcat/Km of the 
modified protein is 6-fold lower and the kcat is approximately 10-fold lower than that of the 
wild-type enzyme, however the Km of the two proteins differs very little. This decrease in 
activity could not be attributed to incomplete modification of the protein as the mass 
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spectrometry data shows no peak for any remaining unmodified K165C or K165dha protein. 
The crystal structures also show that, as expected, γ-thialysine is an excellent structural mimic 
of lysine. Structurally, the K165-γ-thialysine protein is extremely similar to the wild-type 
protein and there are no significant structural differences between the pyruvate binding 
interactions. The inclusion of a sulphur atom in the side chain of γ-thialysine causes slight 
structural differences between lysine and γ-thialysine which alters the position of the terminal 
amine by 0.3 Å, however this does not appear to affect the pyruvate binding site. Therefore 
the decrease in activity may be caused by the intrinsic chemical properties of having a sulphur 
atom in the side chain of the γ-thialysine. 
The catalytic lysine at position 165 is critical for the Class I aldol mechanism of NAL. A Schiff 
base is formed between Lys165 and pyruvate; the amine of group of the lysine residue is 
deprotonated and acts as a nucleophile to attack the carbonyl of pyruvate, forming the Schiff 
base. The pKa of free lysine is 10.5 and therefore would not be easily deprotonated at 
physiological pH, therefore the pKa of Lys165 must be perturbed to achieve this activity. 
Perturbations in amino acid pKas are commonly seen in enzyme catalysis and can be achieved 
by the microenvironment of the enzyme active site (Harris and Turner, 2002, Isom et al., 
2011). To determine how much the pKa of the lysine at position 165 is perturbed from free 
lysine the programme PROPKA was used (Bas et al., 2008). PROPKA allows the pKa of side 
chains within a crystal structure to be calculated. The pKa of Lys165 was calculated to be 7.3; 
therefore the pKa is 3.2 units lower than the pKa of free lysine. The pKa of free γ-thialysine is 9.5 
(Hermann and Lemke, 1968); assuming that the same perturbation in pKa occurs within the 
active site of the K165-γ-thialysine enzyme, the pKa of γ-thialysine would be reduced to 6.3. 
Therefore, the lysine residue has a pKa which is 1 unit higher than γ-thialysine. This difference 
in pKa seen in the catalytic residue of the two enzymes, which is responsible for Schiff base 
formation, may cause the proteins to have different pH optimums. This may be the reason for 
reduced activity in the K165-γ-thialysine enzyme, as all assays to date have been carried out at 
pH 7.4.   
To investigate whether the pH optimum of the modified enzyme has been altered compared to 
that of the wild-type pH curves for both wild-type and K165-γ-thialysine were measured. pH 
profiles were measured using LDH coupled kinetics in a three-component buffer system, to 
ensure constant ionic strength over the full pH range (Ellis and Morrison, 1982). The kinetic 
parameters were determined and the data were then fit using the equation shown in panel C 
of Figure 3.15 (Gloss and Kirsch, 1995a). 
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Figure 3.15. pH curves for wild-type and K165-γ-thialysine saNAL. A shows the pH curve for 
wild-type saNAL. B shows the pH curve for K165-γ-thialysine saNAL. C shows the equation 
used to fit the data shown in panels A and B, where kcat/ Km is the specificity constant for N-
acetylneuraminic acid cleavage, (kcat/ Km )max is the theoretical maximum value for kcat/ Km 
and pKa1 and pKa2 are the first and second ionisable groups. D shows the theoretical values 
for (kcat/ Km)max, pKa1 and pKa2 determined from the data fits for both the wild-type and 
K165-γ-thialysine pH curves. E shows comparison of kinetics parameters kcat, Km and kcat/ Km 
at the pH optima of wild-type saNAL, 7.4 from the experimental data, and the pH optima of 
K165-γ-thialysine saNAL, 6.8 from the experimental data. Kinetic parameters for all pH 
curves were determined from LDH coupled kinetics carried out in a three component buffer 




The pH profiles for the wild-type and K165-γ-thialysine enzymes show that both the shape of 
the pH curve and the pH optimum of the modified enzyme are altered from that of the wild-
type. The theoretical pH optimum, determined from the fit of the pH profiles, of the wild-type 
enzyme is 7.3 whereas the pH optimum for the modified enzyme is lowered to 7.0 (panels A, B 
and D Figure 3.15). Comparison of kinetic parameters for the wild-type and K165-γ-thialysine 
enzymes at their respective experimental pH optima shows that the kcat/Km of the wild-type is 
3.5-fold greater than the kcat/Km of the modified enzyme, therefore the modified enzyme 
regains approximately 30 % of the wild-type activity.   
The difference in pH optima is not the only difference between the two pH curves, the shape 
of the K165-γ-thialysine saNAL is also narrower than that of the wild-type. The wild-type 
enzyme shows a bell shaped pH profile where the pKas of the two ionisable groups are 5.84 
and 8.68, approximately 3 pH units apart, which should allow the theoretical (kcat/Km)max to 
essentially be achieved (panel A Figure 3.16). From the fit of the data the theoretical 
(kcat/Km)max is 116 min-1mM-1 which compares well with the observed  (kcat/Km) of the wild-type 
at pH 7.4, which is 114 min-1mM-1. The pH profile for K165-γ-thialysine saNAL is significantly 
narrowed, compared to the wild-type. This narrowing of the pH curve brings the pKas of the 
two ionisable groups into much closer proximity than in the wild-type (panel D Figure 3.15). 
The pKas of the two ionisable groups are 6.84 and 7.12, approximately 0.3 pH units apart. 
Therefore, in the case of the K165-γ-thialysine, the theoretical (kcat/Km)max of 71 min-1mM-1 can 
never be achieved since the pKas are much closer than 3.5 pH units apart and so the enzyme 
will never, fully, be in the correct ionisation state for catalysis. From the theoretical titration 




Figure 3.16. pH titration curves. Individual titration curves for two residues, with pKas 
determined in Figure 3.15D, are calculated and plotted using the Henderson-Hasselbach 
equation. In both curves the blue line represents the titration of the first ionisable group and 
the purple line represents the titration of a second ionisable group. A) Represents the 
wild-type saNAL where the pKa of the first ionisable group is 5.84 and second is 8.68 
therefore the pKas are approximately 3 pH units apart and almost all of the enzyme would be 
in the active form at the pH optima of 7.4. B) Represents K165-γ-thialysine saNAL where the 
pKa of the first ionisable group is 6.84 and second is 7.12 therefore the pKas are 0.28 pH units 
apart and so only 30% of the enzyme would be in the active form.  
 
From the theoretical fit of the K165-γ-thialysine saNAL pH curve, this enzyme should be an 
excellent catalyst with a theoretical (kcat/Km)max  of 71 min-1mM-1. However due to the 
imbalance of the pKas in the active site K165-γ-thialysine saNAL can only achieve 32 min-1mM-1. 
The wild-type saNAL has evolved to have perfectly synergistic active site and replacing the 
catalytically essential residue with a structural mimic, which has a much lowered pKa, has 
altered the catalysis. 
3.5 Summary 
The main aim of this chapter was to develop and optimise a method to incorporate ncAAs into 
the enzyme saNAL. Complete incorporation of the ncAA, γ-thialysine, was achieve at position 
165, as assessed by mass spectrometry. The chemical modification to introduce γ-thialysine 
has been well tolerated by the enzyme saNAL, producing correctly folded and active protein. 
Excitingly the ncAA-containing protein can be produced on a scale of up to 50 mg which has 
allowed extensive structural and kinetic studies.  
Initial kinetic studies showed the modified enzyme activity to be 11-fold lower than that of 
wild-type saNAL. However by using size exclusion chromatography it was possible to remove 
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incorrectly folded material, and by investigating the pH dependency of the enzyme it was 
possible to find that the pH optima had been shifted, from the wild-type at pH 7.4, to pH 6.8. 
These further studies showed that the modified K165-γ-thialysine activity is 3.5-fold lower than 
the wild-type, as judged by kcat/Km. From further structural and kinetic studies it was possible 
to attribute this decrease in activity to the perturbation in pKas in the active site caused by the 
sulphur atom in the side chain of γ-thialysine, and also the 0.3 Å shift in the position of the 
terminal amine group seen in the crystal structure. The perturbation in pKa of the 165 side 
chain brings the pKas of the two ionisable groups within 3 pH units meaning that the 
theoretical Vmax of the enzyme cannot be achieved. 
Although the modified enzyme does not achieve the full wild-type activity, a robust method to 
incorporate ncAAs has been developed that can be carried out routinely. This work sets the 
scene to extend the incorporation of novel ncAAs throughout the active site of NAL and 




Chapter 4 Production and Screening of Modified Enzymes for 
Altered Activities 
In the previous chapter the incorporation of the ncAA γ-thialysine, via chemical modification, 
at position 165 in saNAL was described. By carrying out this modification, as a proof of 
principle, it was possible to develop a robust incorporation method for ncAAs into saNAL. 
Excitingly, using this method, full conversion to the ncAA was observed via mass spectrometry 
and ncAA-containing protein was obtained in high yield for both kinetic and crystallographic 
studies. This chemical method could now be used to introduce a variety of ncAAs individually 
throughout the active site of saNAL to investigate whether they could be used to alter the 
activity of the enzyme.  
This chapter will describe the use of the chemical ncAA incorporation method to introduce up 
to 13 different non-canonical side chains at a variety of different positions throughout the 
active site of saNAL. It will also describe screening these ncAA-containing enzymes for altered 
substrate specificity with a variety of different aldehydes. 
4.1 Selection of residues for modification  
The aim of this work was to use ncAAs to alter substrate specificity, and so the first stage was 
to select the sites at which the non-canonical side chains were to be incorporated. There are 
many directed evolution studies that have shown residues away from the active site can have 
a significant effect on substrate specificity (Leferink et al., 2014, Romero and Arnold, 2009, 
Shimotohno et al., 2001). However, in this instance, to reduce the sequence space to be 
screened and since an X-ray crystal structure of wild-type saNAL had been solved, we decided 
to look at replacing residues within the active site of the protein, and within close proximity 
(~5 Å) to the substrate. Unfortunately there is no crystal structure of saNAL with the full length 
N-acetylneuraminic acid (Neu5Ac) product bound; however there is a structure of the E. coli 
NAL with Neu5Ac in the active site (Daniels et al., 2014). Therefore using the E. coli NAL 
structure, residues within approximately 5 Å (Table 4.1) of the product were selected for 
conversion to cysteine, and subsequently modified. In Figure 4.1 the residues selected for 
mutagenesis to cysteine can be seen, and their proximity to the, enzyme-bound, full length 
Neu5Ac product is shown in Table 4.1. In total thirteen sites were selected to be converted 




   
Figure 4.1. Image of the wild-type S. aureus NAL active site (PDB 4ah7 shown in cyan) (Timms 
et al., 2013) with the full length N-acetylneuraminic acid (Neu5Ac) taken from the E. coli NAL 
in complex with Neu5Ac, overlaid (PDB 4bwl shown in magenta) (Daniels et al., 2014). The 
residues that were targeted for site-directed mutagenesis into cysteine and subsequent 















Residue  Distance to Neu5Ac (Å) Residue  Distance to Neu5Ac (Å) 
I139 3.0 S208 3.2 
L142 4.2 T209 4.8 
K165 - I243 4.1 
F172 5.7 L247 4.3 
F190 5.3 I251 4.6 
E192 2.9 Y252 3.5 
G207 3.3   
Table 4.1 Residues in the S. aureus NAL selected for conversion to cysteine, and their relative 
distances from the product Neu5Ac in the active site. Distances were calculated by 
overlaying the saNAL X-ray crystal structure, in complex with pyruvate, with the E. coli NAL 
in complex with Neu5Ac and the distances between the closest residue atom and product 
atom were measured. A distance is not shown for K165 as it forms a covalent link to the 
product. 
 
Previous studies on NAL have shown that it is highly specific for the ketone donor, pyruvate, 
however NAL is far more promiscuous regarding the aldehyde acceptor (Fitz et al., 1995, Kim 
et al., 1988). Therefore the majority of sites selected for mutagenesis were towards the 
aldehyde end of the active site, as this end may be more easily manipulated. As can be seen 
from Figure 4.1 a wide variety of residues were selected to be exchanged for ncAAs, from very 
small residues like glycine to much bulkier side chains like tyrosine and phenylalanine. All the 
residues selected would be converted to non-canonical side chains using the chemical 
modification method described in the previous chapter.  
4.2 Production of cysteine mutants 
To allow incorporation of non-canonical side chains at the selected sites in the active site of 
saNAL (shown in Figure 4.1.), it was necessary to produce cysteine mutants at these positions. 
Site-directed mutagenesis was used to produce the cysteine mutants, and the mutant genes 
were provided by Sam Hickman (University of Leeds).  
Once the cysteine mutants were successfully generated they were expressed and purified in 
the same way as wild-type saNAL using batch nickel affinity chromatography (Section 2.4.1). 
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All cysteine variants expressed at reduced yields compared to the wild-type. Wild-type saNAL 
expresses at approximately 100 mg per litre growth medium, whereas the cysteine variants 
expressed at between 30-80 mg per litre growth medium depending on the variant. All 
cysteine variants expressed in high enough yields for modifications to be carried out.  Once the 
cysteine variants were expressed and purified, they were lyophilised (Section 2.4.6) before 
being modified to incorporate ncAAs. Before modifications were carried out, ESI mass 





Figure 4.2 ESI mass spectra of cysteine variants. In all spectra the raw data is shown to the 
left and the deconvoluted data shown to the right. Panel A shows mass spectrum for Y252C, 
the expected mass was 33934 Da and the observed mass was 33935 Da. Panel B shows mass 
spectrum for L247C, the expected mass was 33984 Da and the observed mass was 33983 Da. 
Panel C shows mass spectrum for I139C, the expected mass was 33984 Da and the observed 
mass was 33984 Da a peak at 34082 Da can also been seen in the spectrum which is +98 Da 
and most likely corresponds to a phosphate adduct. Panel D shows mass spectrum for I251C, 
the expected mass was 33984 Da and the observed mass was 33986 Da a peak at 34084 Da 
can also been seen in the spectrum which is +98 Da and most likely corresponds to a 
phosphate adduct. Panel E shows mass spectrum for F190C, the expected mass was 





4.3 Modifications to generate a variety of ncAAs  
Once cysteine variant proteins had been expressed and purified, it had to be established that 
the modification protocols, developed to convert K165C into K165-γ-thialysine, would also 
work on these variants.  Modifications to convert the cysteine variants into dha-containing 
proteins were carried out first to ensure the first stage of the modification worked. Once it was 
possible to produced dha-containing proteins then the conditions to produce a variety of 
ncAAs were developed. 
4.3.1 Conversion of cysteine variants to dha 
To determine whether the same conditions to convert K165C into K165dha were applicable for 
the other cysteine variants, the same procedure to convert the cysteine to dehydroalanine was 
used. 2.5 mg of lyophilised protein was taken up in 1.25 mL of pre-warmed (37˚C) sodium 
phosphate buffer (50 mM, pH 8.0) containing 6 M urea. The protein solution was vortexed to 
ensure that the protein had fully redissolved, and then 100 µL of the diBr (0.13 mg µL-1in DMF) 




   
Figure 4.3. ESI mass spectra, showing various modifications of cysteine variants into 
dehydroalanine (dha) raw data is shown on the left and deconvoluted data on the right. All 
panels show mass spectra of dehydroalanine-containing proteins which have been modified 
using the conditions; 2.5 mg of cysteine variant dissolved in 1.25 mL of pre-warmed (37˚C) 
sodium phosphate buffer (50 mM, pH 8.0) containing 6 M urea, then 100 µL of diBr 
(0.13 mg µL-1 or 0.08 mg µL-1 in DMF) added and incubated for 1 hr 30 min. Panel A shows 
mass spectrum of F190dha, the expected mass was 33917 Da and the observed mass was 
33916 Da. Panel B shows mass spectrum of G207dha, the expected mass was 34007 Da and 
the observed mass was 34010 Da. Panel C shows mass spectrum of S208dha, the expected 
mass was 33977 Da and the observed mass was 33980 Da. Panel D shows mass spectrum of 
L247dha, the expected mass was 33951 Da and the observed mass was 33950 Da. Panel E 
shows mass spectrum of Y252dha, the expected mass was 33901 Da and the observed mass 




Once the reaction had been incubated a 70 µL sample was taken and analysed by ESI mass 
spectrometry. If a peak of correct molecular mass for the dha-containing protein was 
observed, the modification was considered successful. If no peak was observed for any 
remaining cysteine-containing protein, the modification was considered to have gone to 
completion. Due to samples for mass spectrometry being taken from the reaction mixture, 
containing 6 M urea, the sample preparation was sometimes not as efficient, reducing the 
intensity of the protein in the mass spectra, as can be seen from the noise in the deconvoluted 
spectra. However if there was a single main peak, of the correct molecular mass, the 
modification was considered successful.  
In some of the modifications, two peaks were observed in the ESI-mass spectra, the first had 
the correct molecular mass for the dehydroalanine intermediate and a second was 174 Da 
larger in mass (Figure 4.4). It was determined that this extra mass was caused by an uncyclized 
sulfonium intermediate, that comes from the dehydroalanine not eliminating from the protein 
after it has reacted (Nathani et al., 2012, Chalker et al., 2011). Incubation at 37 ˚C is reported 
to remove this uncyclized intermediate (Chalker et al., 2011). However, since the modifications 
had already been carried out at 37 ˚C, it was hypothesised that this 174 Da adduct could be 
caused by the excess of diBr in the reaction mixture. Modifications were therefore carried out 
under the same conditions as before but using 0.08 mg µL-1 of diBr. Conversion of the cysteine 
residue into dehydroalanine still went to completion after 1 hr 30 min but no evidence for the 
174 Da adduct was seen, therefore the lower concentration of 0.08 mg µL-1diBr was used in all 




Figure 4.4. ESI mass spectra of I251C modifications to I251dha. In both spectra the raw data 
is shown above and the deconvoluted data shown below. Panel A shows mass spectra of 
I251dha which has been modified using the conditions; 2.5 mg of I251C protein dissolved in 
1.25 mL of pre-warmed (37˚C) sodium phosphate buffer (50 mM, pH 8.0) containing 6 M 
urea, then 100 µL of diBr (0.13 mg µL-1in DMF) added and incubated for 1 hr 30 min. Two 
peaks are clearly visible in the spectrum the first at 33950 Da corresponding to correctly 
modified I251dha which has an expected molecular mass of 33950 Da, and the second peak 
174 Da larger than the first peak which corresponds to the uncyclized sulfonium ion. Panel B 
shows mass spectra of I251dha which has been modified using the conditions; 2.5 mg of 
I251C protein dissolved in 1.25 mL of pre-warmed (37˚C) sodium phosphate buffer (50 mM, 
pH 8.0) containing 6 M urea, then 100 µL of diBr (0.08 mg µL-1in DMF) added and incubated 
for 1 hr 30 min. Only one distinct peak can be seen in this spectrum with a molecular mass of 
33951 Da corresponding to the correctly modified I251dha which has an expected molecular 






4.3.2 Selection of ncAA side chains 
Having demonstrated it was possible to routinely produce dha-containing proteins from the 
cysteine variants, the dha-containing proteins could now be modified with thiols to produce 
non-canonical side chains. All thiols chosen for use in the modification procedure were 
commercially available, to allow easy and scalable modifications, as the process would not be 
dependent on the amount of thiol that could be synthesised. The thiols selected were chosen 
to produce a wide variety of non-canonical side chains (Table 4.2). Some thiols produced 
elongated versions of canonical amino acids and some produced side chains with chemistries 
not present, or uncommon, within the twenty proteogenic amino acids.  
 
Cysteine variants Thiols 
K165C    S208C 
L247C    I251C 
L142C    F190C 
Y252C    G207C 
E192C    I139C 
F172C    N170C 
T209C    I243C 
 
Table 4.2. Cysteine variants and thiols used in the chemical modification procedure. The first 
column shows the positions converted to cysteine for subsequent conversion to ncAAs. The 
second column shows the thiols used to produce the ncAA side chains. Thiols 1-14 are 
3-mercaptopropionic acid, aminoethanethiol, benzylmercaptan, methylthioglycolate, 
sodium mercaptopyruvate, mercapto-2-propanol, D-cysteine, L-cysteine, 
4-pyridylethylmercaptan, mercapto-1-butanol, mercaptoacetic acid, thioglycerol, 2-








4.3.3 Optimisation of Michael addition of thiols 
The next step was to convert the dha residue into a range of different ncAAs. The thiols had 
been chosen to produce a variety of different non-canonical side chains (Table 4.2). For 
production of the various ncAA-containing proteins, we investigated whether a single set of 
modification conditions could be found. However, due to the variation in the physical 
properties of the thiol compounds, for example some were provided as liquids, other solids, 
each had to have conditions optimised for use in the modification procedure. Optimised 
conditions for the conversion of dehydroalanine into the non-canonical side chains are shown 
in Table 4.4. The protein F190dha was chosen for use in the optimisation experiments. 
Optimisations were carried out on a 2.5 mg scale, 1.25 mL (2 mg mL-1) of F190dha was taken 
and a Michael addition with a thiol compound was then carried out, this was performed with 
each thiol shown in Table 4.2.  
For initial test modifications the conditions used to convert K165dha to K165-γ-thialysine were 
used as a starting point as they had been previously successful. In the K165-γ-thialysine study 
the aminoethanethiol was dissolved in Tris/HCl (2 M, pH 8.8) to a concentration of 0.1 mg µL-1 
before being added to the dha-containing protein; therefore this was used for the solid thiol 
compounds (aminoethanethiol (2 Table 4.2), mercaptopyruvate (5), mercaptoacetic acid (11), 
L-cysteine (8) and D-cysteine (7)), which were all soluble in aqueous solvent. In the selection of 
thiol compounds a number of them were provided as liquids; from the literature undiluted 
β-mercaptoethanol was added to dehydroalanine-containing protein which produced 
conversion to the non-canonical side chain (Chalker et al., 2011). However, to ensure a 
constant pH in the reactions with the liquid thiols, Tris/HCl (2 M, pH 8.0) was added to the thiol 
compounds, in a 1:1 ratio, before addition to the reaction.  For the thiols that were soluble in 
aqueous solvent (mercapto-2-propanol (6) and thioglycerol (12)), addition of Tris/HCl and then 
incubation with the dehydroalanine containing protein worked well, but it was found that 
some of the thiol compounds were not soluble in aqueous solvent. Mercapto-1-butanol (10), 
methylthioglycolate (4), benzylmercaptan (3), 4-pyridylethyl mercaptan (9), 2-furanmethane 
thiol (13) and 2-propene-1-thiol (14) would not solubilise in the aqueous reaction mixture and 
would cause precipitate to form if they were added directly to the reaction. Therefore these 
compounds were first solubilised in DMF and then Tris/HCl (2 M, pH 8.0) added to ensure the 
pH was approximately 8.0 before being added to the reaction mixture. This approach worked 
well for mercapto-1-butanol, methylthioglycolate, 2-furanmethane thiol and 
2-propene-1-thiol, but it was seen that benzylmercaptan and 4-pyridylethylmercaptan would 
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still cause some precipitate in the reaction mixture which was aggravated with the addition of 
Tris/HCl. Therefore these were solubilised in DMF, before being added to the dehydroalanine 
containing protein. Some precipitate still formed in the reactions with benzylmercaptan and 
4-pyridylethylmercaptan but it could be easily removed by centrifugation, after the incubation 
time was completed, and did not affect the modification to produce the non-canonical side 




Thiol Conditions Incubation 
Aminoethanethiol 40 µL (0.1 mg µL-1 Tris/HCl (2 M pH 8.0))) 2 hours, 37 ˚C, 200 rpm 
Mercaptoacetic acid 40 µL (0.1 mg µL-1 Tris/HCl (2 M pH 8.0))) 2 hours, 37 ˚C, 200 rpm 
Mercapto-1-butanol 40 µL (20 µL thiol, 10 µL DMF, 10 µL Tris/HCl 
(2 M pH 8.0)) 
2 hours, 37 ˚C, 200 rpm 
Mercapto-2-propanol 40 µL (20 µL thiol, 20 µL Tris/HCl (2 M pH 8.0)) 2 hours, 37 ˚C, 200 rpm 
Methylthioglycolate 40 µL (20 µL thiol, 10 µL DMF, 10 µL Tris/HCl 
(2 M pH 8.0)) 
2 hours, 37 ˚C, 200 rpm 
Thioglycerol 40 µL (20 µL thiol, 20 µL Tris/HCl (2 M pH 8.0)) 2 hours, 37 ˚C, 200 rpm 
Sodium mercaptopyruvate 40 µL (0.1 mg µL-1 Tris/HCl (2 M pH 8.0))) 2 hours, 37 ˚C, 200 rpm 
Benzylmercaptan 30 µL (10 µL thiol, 20 µL DMF) 2 hours, 37 ˚C, 200 rpm 
4-Pyridylethylmercaptan 30 µL (10 µL thiol, 20 µL DMF) 2 hours, 37 ˚C, 200 rpm 
2-Furanmethane thiol 40 µL (20 µL thiol, 10 µL DMF, 10 µL Tris/HCl 
(2 M pH 8.0)) 
2 hours, 37 ˚C, 200 rpm 
L-cysteine 120 µL (0.13 mg µL-1 Tris/HCl (2 M pH 8.0))) 2 hours, 37 ˚C, 200 rpm 
D-cysteine 120 µL (0.13 mg µL-1 Tris/HCl (2 M pH 8.0))) 2 hours, 37 ˚C, 200 rpm 
2-Propene-1-thiol 40 µL (20 µL thiol, 10 µL DMF, 10 µL Tris/HCl 
(2 M pH 8.0)) 
2 hours, 37 ˚C, 200 rpm 
Table 4.3. Conditions for modification with thiol compounds to produce non-canonical side 
chains. The conditions shown are to convert 2.5 mg of dha-containing protein into 2.5 mg of 




Once the thiol compound had been added to the dha-containing protein the reaction was 
incubated at 37 ˚C with shaking at 200 rpm. To assess whether the Michael additions with the 
thiol compounds had been successful, ESI-mass spectrometry was used, performed by Dr 
James Ault. Samples were taken during the incubation period and it was seen that a 2 hour 
incubation time was optimal for the modification process to go to completion. These 
conditions for ncAA incorporation were optimised using F190dha protein and the ESI 
mass spectra are shown for the successful modifications at this position (Figure 4.5 and Figure 
4.6). It was seen that the conditions used for modification, with the various thiols, at position 
190 could also be used for modification at the other positions selected. The successful 
reactions had produced ncAAs in the protein, and so it was necessary to develop a naming 




Figure 4.5 ESI mass spectra of modifications of F190dha with various thiols using conditions 
stated in Table 4.3. Each panel shows the raw mass spectrometry data with the 
deconvoluted data inset with a grey back ground, the ncAA side chain incorporated is also 
shown. Panels show mass spectra of F190dha modified with; A) aminoethanethiol to 
produce F190Aec, expected mass 33993 Da observed mass 33993 Da, B) thioglycerol to 
produce F190Dpc, expected mass 34025 Da observed mass 34025 Da, C) L-cysteine, to 
produce F190(2R)Acc, expected mass 34038 Da observed mass 34036 Da, D) D-cysteine to 
produce F190(2S)Acc, expected mass 34038 Da observed mass 34036 Da, E) 
pyridylethylmercaptan to produce F190Pec, expected mass 34056 Da observed mass 
34056 Da, F) mercaptopyruvate to produce F190Coc, expected mass 34059 Da observed 
mass 34059 Da, G) benzylmercaptan to produce F190Bc, expected mass 34041 Da observed 
mass 34039 Da, H) methylthioglycolate to produce F190Moc, expected mass 34023 Da 





Figure 4.6 ESI mass spectra of modifications of F190dha with various thiols using conditions 
stated in Table 4.3. Each panel shows the raw mass spectrometry data with the 
deconvoluted data inset with a grey back ground, the ncAA side chain incorporated is also 
shown. Panels show mass spectra of F190dha modified with; I) propene-1-thiol to produce 
F190Sac, expected mass 33991 Da observed mass 33989 Da, J) furanmethane thiol to 
produce F190Fmc, expected mass 34031 Da observed mass 34029 Da, K) mercapto-1-butanol 
to produce F190Hbc, expected mass 34023 Da observed mass 34022 Da, L) mercaptoacetic 
acid to produce F190Cmc, expected mass 34009 Da observed mass 34008 Da, M) 










Thiol compound ncAA side chain ncAA name Abbreviation 
Aminoethanethiol 
 
2-aminoethyl cysteine Aec 
Mercaptoacetic acid 
 
carboxymethyl cysteine Cmc 
Mercapto-1-butanol 
 
4-hydroxybutyl cysteine Hbc 
Mercapto-2-propanol 
 
2-hydroxypropyl cysteine Hpc 
Methythioglycolate 
 
2-methoxy-2-oxoethyl cysteine Moc 
Thioglycerol 
 
2, 3-dihydroxypropyl cysteine Dpc 
Mercaptopyruvate 
 









2-(pyridin-4-yl)ethyl cysteine Pec 
Furanmethane thiol 
 













S-allyl cysteine Sac 
Table 4.4. Table showing ncAA side chains, names and abbreviations produced from 






4.4 Screening modified enzymes for activity 
Having established methods for producing a variety of ncAAs at different positions in saNAL, 
these modified enzymes could be screened to determine the effects of introducing the 
non-canonical side chain on enzyme substrate specificity. It was decided that the enzymes 
would be screened for activity in the synthetic, aldol condensation direction as this would 
produce variations of sialic acid that may be of use in complex oligosaccharide syntheses. In 
the screening process, the donor in the aldol condensation would remain as pyruvate and 
modified enzymes would be screened for altered aldehyde acceptor activities. A variety of 
different aldehyde acceptors were chosen for screening which would allow the effect of ncAA 
on altered substrate length, stereochemistry and group substitutions to be assessed. Ten 
aldehydes in total were chosen (shown in Figure 4.7). 
 
                  
Figure 4.7. Aldehydes used for screening modified enzymes for activity. The aldehydes from 
15-24 are; N-acetyl-D-mannosamine (15), D-mannose (16), D-ribose (17), D-lyxose (18), 









4.4.1 TBA assay for screening 
To screen the modified enzymes for aldol condensation activity, it was necessary to have an 
assay that would detect the new carbon-carbon bond formation. The thiobarbituric acid assay 
(TBA assay) has been used for the detection and quantification of sialic acids (Warren, 1959). 
The TBA assay is a colorimetric assay that has previously been used to follow the enzyme 
catalysed aldol condensation of pyruvate and aldehyde (Wolterink-Van Loo et al., 2009, 
Buchanan et al., 1999), and so this assay was used to screen the modified enzymes for activity. 
In the screening procedure when an aldol condensation reaction has occurred, the TBA assay 
can be used to detect the aldol condensation product. The aldol condensation product is first 
cleaved using periodic acid to form a 1, 3-dicarbonyl, which will then react with TBA to form a 
highly conjugated pink product (Figure 4.8). For the TBA assay to be viable the group attached 
to the C2 of the aldehyde acceptor (X in Figure 4.8) must be either a hydroxyl or an N-acetyl 




Figure 4.8. Schematic of the thiobarbituric acid (TBA) assay, used to assay modified variants 
activity with various aldehydes. The 1, 3-dicarbonyl reacts with TBA to form a highly 
conjugated product (shown in pink) which turns pink and can be easily detected by eye or at 






To allow screening to be carried out in a plate based format the volumes used in the assay 
needed to be significantly reduced from the original procedure. Previous work within our 
group had used the TBA assay in a plate format (Angela Kinnell, PhD thesis, University of 
Leeds) and so this method was used when screening the modified enzymes. 
4.4.2 Screening modified enzymes for activities  
When screening the modified enzymes for activity, reactions were carried out in deep well 
96-well plates. Reactions were set up containing sodium pyruvate (100 µL, final concentration 
80 mM, in 50 mM sodium phosphate buffer, pH 7.4), aldehyde (100 µL, final concentration 
8 mM, in 50 mM sodium phosphate buffer, pH 7.4) and modified enzyme (50 µL, 1.0 mg mL-1). 
Reactions were performed for each modified enzyme with each one of the aldehydes shown in 
Figure 4.7. All screens contained blanks containing no enzyme, and reactions with each of the 
aldehydes was also performed containing wild-type saNAL, which would provide a comparison 
to identify modified enzymes with increased activity. Once reactions were set up they were 
incubated for 16 hours at room temperature. After incubation the TBA assay was performed to 
assess activity; 11 µL of sodium periodate (0.2 M in 9 M H3PO4) was added to each reaction, 
the plate was vortexed and then centrifuged for 2 min at 1000 g before being incubated at 
room temperature for 20 min. Periodate oxidation was terminated by addition of 45 µL of 
sodium arsenite (10% w/v in 0.5M Na2SO4 and 0.05M H2SO4), this caused a brown 
discolouration to form, which was dissipated by vortexing the plate for 30 s. Once the brown 
discolouration had dissipated, 135 µL TBA (0.6 % w/v in 0.5M Na2SO4) was added to each well, 
the plate was centrifuged for 2 min at 1000 g before being incubated in a heat block at 70 ˚C 
for 30 min.  
Once the assay had been performed, hits were easily identifiable by eye, but for further 
corroboration absorbance data at 550 nm was also acquired. Samples (85 µL), of each assayed 
reaction, were transferred into shallow flat bottomed 96-well plates so that the absorbance 
could be read in a plate reader. Unfortunately, initial attempts at measuring accurate 
absorbance data were not successful due to turbidity in the samples. It was found that by 
centrifuging the deep well plate (10 min 6000 g) after the assay had been performed it was 
possible to separate a clear layer that could then be analysed by absorbance spectroscopy in 
shallow 96-well plates. Figure 4.9 shows an example of a screen carried out at position 190, 
where the wild-type phenylalanine residue has been replaced with multiple different 
non-canonical amino acids. When analysing the screens, the activity of each modified variant 
with a specific aldehyde was compared to the wild-type with that same aldehyde. Absorbance 
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data at 550 nm could also be processed to show whether a modified variant had increased or 
decreased the activity with a specific aldehyde compared to the wild-type level. The processed 
data for Figure 4.9 is shown in Figure 4.10 where the non-canonical side chains have been 
grouped according to their chemistry. 
  
Figure 4.9. Image of screening carried out at position 190 and analysed by TBA assay. The 
phenylalanine at position 190 was replaced with ncAAs listed on the left-hand side of the 
image, and then screened for activity with the aldehydes shown along the top of the image. 
Screening reactions were set up containing sodium pyruvate (100µL, final concentration 
80mM, in 50 mM sodium phosphate buffer, pH 7.4), aldehyde (100µL, final concentration 
8mM, in 50 mM sodium phosphate buffer, pH 7.4) and modified enzyme (50µL, 1.0 mg mL-1) 
and incubated for 16 hours at room temperature. Reactions were then assayed using the 





Figure 4.10. Heat map of absorbance data, at 550 nm, from screening carried out by TBA 
assay at position 190. ncAAs inserted at position 190 are shown down the left-hand side 
(grouped according to their side chain chemistry), and aldehydes screened with are shown 
along the top. Samples from reactions were analysed by TBA assay (Section 2.4.16.1) and 
absorbance data at 550 nm recorded. Absorbance data for each modified enzyme was then 
compared to the wild-type absorbance data for each aldehyde, and colour coded; blue 
indicating a decrease in activity and pink indicating an increase in activity compared to the 
wild-type.  
 
From the screening carried out at position 190 it can be seen that the majority of modified 
variants either decreased activity with certain aldehydes or retained the same activity as 
wild-type saNAL, which was typical in many of the screens carried out, other examples of 
screens are shown in Figure 4.11. In the screen showed at position 190 there were three 
modified variants that appeared to significantly increase the activity with erythrose over that 
of the wild-type saNAL. Therefore any modified variants that showed a distinct increase in 
activity over the wild-type with a specific aldehyde were classed as ‘hits’. These ‘hits’ were 
then produced on a larger scale, size exclusion chromatography was performed to remove any 




Figure 4.11 Images of screening carried out at positions S208 and F172 which have been 
analysed by TBA assay. The image on the left shows screening of modified enzymes that 
were produced by replacing the serine at position 208 with various ncAAs. The image on the 
right shows screening of modified enzymes that were produced by replacing the 
phenylalanine at position 172 with various ncAAs. The ncAAs which have been inserted at 
each position are listed down the left side of the plate images. The modified enzymes were 
screened for activity with the aldehydes shown along the top of the plate images. Screening 
reactions were set up containing sodium pyruvate (100µL, final concentration 80mM, in 
50 mM sodium phosphate buffer, pH 7.4), aldehyde (100µL, final concentration 8mM, in 
50 mM sodium phosphate buffer, pH 7.4) and modified enzyme (50µL, 1.0 mg mL-1) and 
incubated for 16 hours at room temperature. Reactions were then assayed using the TBA 
assay (Section 2.4.16.1). 
 
4.5 Investigation of hits from screening 
During the screening a number of hits were found that increased the activity with a specific 
aldehyde over that of wild-type saNAL, including the ‘hits’ found in the position 190 screening 
(Figure 4.9 and Figure 4.10). However some of these ‘hits’ only produced minor increases in 




4.5.1 F172Bc activity with GlcNAc and pyruvate 
One ‘hit’ that was found in the screening at position 172, produced an increase in activity with 
the aldehyde N-acetyl-D-glucosamine (GlcNAc) by replacing the wild-type phenylalanine with a 
benzylcysteine side chain (F172Bc) (Figure 4.12). Although the activity seen with F172Bc and 
GlcNAc was modest, this activity was very interesting as it has been reported in the literature 
and from the results shown that wild-type NAL does not utilise GlcNAc as a substrate (Hsu et 
al., 2005, Gijsen et al., 1996).   
 
Figure 4.12. Modified enzyme F172Bc showing an increased activity with GlcNAc and 
pyruvate, over that of the wild-type. Panel A shows the absorbance data at 550 nm, from the 
TBA assay, for F172Bc and wild-type enzymes with GlcNAc and pyruvate. Panel B shows an 
image of TBA assayed samples from reactions of the F172Bc and wild-type enzymes, with 
GlcNAc and pyruvate. Panel C shows the reaction between GlcNAc and pyruvate to form the 
full length aldol product. 
 
From the TBA assay there is a clear increase in the pink colour when F172Bc has been 
incubated with GlcNAc and pyruvate compared to wild-type saNAL, under the same 
conditions, indicating an increase in activity. Once this hit had been identified, it was necessary 
to further confirm the activity with GlcNAc using mass spectrometry. ESI mass spectrometry 
was carried out on a sample from the reaction of F172BC with GlcNAc and pyruvate (Figure 
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4.13). The reaction was carried out using the same conditions as were used in the TBA assay 
and incubated for 16 hours at room temperature. Then a sample from the reaction was taken 
and ESI negative ion mode mass spectrometry was performed (Section 2.4.19). From the mass 
spectrum there was a clear peak at 308 Da which correlates to the molecular mass of the full 
length product, 309 Da, minus 1 hydrogen due to the negative ion mode. 
 
 
Figure 4.13. ESI negative ion mode mass spectrum of the product formed from reaction of 
GlcNAc and pyruvate with F172Bc. A peak a 308 Da can be seen; indicating the full length 
product has been formed, which has a molecular mass of 309 Da minus a hydrogen due to 
the negative ion mode. 
 
It was possible to confirm the F172Bc activity with GlcNAc using both the TBA assay and 
ESI-negative ion mode mass spectrometry, however when proton NMR was used to 
characterise the product there was no evidence for the full length product in the spectrum. 
NMR analysis was carried out on larger scale reactions, 80 mg of GlcNAc and a 10-fold molar 
excess of pyruvate, in sodium phosphate buffer (50 mM, pH 7.4), with 3.0 mg of F172Bc 
enzyme, the reaction was incubated for 24 hours but there was still no evidence for the full 
length product. Therefore it was hypothesised that the reason that the full length product was 
not seen in NMR was due to the low yield of the reaction. It was possible to quantify the 
amount of product produced from the F172Bc reaction, using a sialic acid standard curve. 
Quantification revealed only 1.85 mg of the full length product was produced after a 24 hour 
incubation, and so further characterisation was not carried out. 
4.5.2 F190Dpc activity with erythrose and pyruvate 
Screening at position 190 revealed that there were three ncAA-containing enzyme variants 
which had increased the activity with the aldehyde erythrose and pyruvate to produce the full 
length product 3-deoxy-2-heptulosonic acid (DOH). Analysis by TBA assay showed by replacing 
the phenylalanine at position 190 with 2-hydroxypropyl cysteine, 4-hydroxybutyl cysteine or 
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2, 3-dihydroxypropyl cysteine, the activity with erythrose and pyruvate was increased over 
that of the wild-type with erythrose and pyruvate (Figure 4.14). By comparing the TBA assay 
data F190Dpc appeared to produce the greatest increase in activity with erythrose and so this 
enzyme was taken forwards to characterise.  
 
 
Figure 4.14. Modified enzymes F190Hpc, F190Hbc and F190Dpc showing increased activity 
with erythrose and pyruvate, over that of the wild-type. Panel A shows the absorbance data 
at 550 nm, from the TBA assay, for the F190Hpc, F190Hbc, F190Dpc and wild-type enzymes 
with erythrose and pyruvate. Panel B shows an image of TBA assayed samples from 
reactions of the F190Hpc, F190Hbc, F190Dpc and wild-type enzymes, with erythrose and 
pyruvate. Panel C shows the reaction between erythrose and pyruvate to form 
3-deoxy-2-heptulosonic acid (DOH). 
 
The F190Dpc enzyme was produced on a large scale for further characterisation to be carried 
out with it. Large scale modification was performed on a 20 mg scale in the same manner as 
with the small scale modification. 20 mg of lyophilised K165C protein was resuspended in 
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10 mL of sodium phosphate buffer (50 mM pH 8.0) containing 6 M urea which had been pre-
warmed to 37 ˚C. The protein solution was vortexed for 30 s to ensure the lyophilised protein 
was thoroughly redissolved, then 800 µL of diBr (0.08 mg µL-1 in diBr), was added and the 
solution incubated for 1 hr 30 min at 37 ˚C, 200 rpm. Once conversion to F190dha was 
confirmed using ESI mass spectrometry, then 320 µL of thioglycerol (160 µL thiol, 160 µL 2 M 
Tris/HCl pH 8.0) was added and incubated at 37 ˚C, 200 rpm for 2 hours. Correctly modified 
protein (shown in Figure 4.15) was then refolded by dialysis and underwent size exclusion 
chromatography, to remove any incorrectly folded material. 
 
 
          
Figure 4.15. ESI mass spectrum showing correctly modified F190Dpc. The expected mass of 
F190Dpc is 34025 Da and the observed mass was 34025 Da. 
 
To further confirm that the product being produced in the reaction of erythrose and pyruvate 
with F190Dpc was in fact DOH, ESI-negative ion mode mass spectrometry performed. A 
reaction was set up containing erythrose, pyruvate and F190Dpc; using the same conditions as 
in the TBA assay and then incubated for 16 hours at room temperature, before being analysed 
by mass spectrometry. The mass spectrum shows a clear peak at 207 Da which correlates to 
the molecular mass of the full length product, 208 Da, minus 1 hydrogen due to the negative 
ion mode (Figure 4.16). Both mass spectrometry and the TBA assay indicated that the reaction 
of the modified enzyme, F190Dpc, with erythrose and pyruvate was producing the expected 
product DOH. Therefore, using a sialic acid standard curve, the amount of DOH produced was 
quantified. A large scale reaction was set up with 60 mg of erythrose, a 10-fold molar excess of 
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pyruvate, in sodium phosphate buffer (50 mM, pH 7.4), and incubated with 0.5 mg of F190Dpc 




Figure 4.16. ESI negative ion mode mass spectrum of the product formed from reaction of 
erythrose and pyruvate with F190Dpc. A peak a 207 Da can be seen; indicating the product 
3-deoxy 2-heptulosonic acid (DOH) has been formed, which has a molecular mass of 208 Da 
minus a hydrogen due to the negative ion mode.  
 
To characterise the product from the F190Dpc reaction with erythrose and pyruvate proton 
NMR was used. Comparison of the proton NMR spectrum of the reaction mixture, to a 
standard of erythrose and pyruvate showed differences in chemical shifts and splitting 
patterns of some of the peaks. These differences indicated that a reaction had occurred and 
that an aldol condensation product was present. However it was not possible to characterise 
the product due to high levels of impurities, in the spectra, that were present from the 
erythrose starting material. To allow analysis by NMR the reaction mixture had to be purified. 
A large scale reaction was set up, erythrose (500 mg, 4.2 mmol) and sodium pyruvate (2.29 g, 
21 mmol) in sodium phosphate buffer (50 mM, pH 7.4) were incubated with F190Dpc (250µL, 
3.2 mg mL-1) for 24 hours before the product was purified by anion exchange chromatography. 
Anion exchange chromatography was carried out on AG1x8 resin (HCO3-, 100-200 mesh) and 
product was eluted using a 0-0.4 M ammonium bicarbonate linear gradient. Due to the 
product, DOH, having no distinctive wavelength absorbance, the fractions were analysed by 
TBA assay to find where the product had eluted. The product was seen to elute, by the TBA 
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Figure 4.17. Anion exchange of 3-deoxy 2-heptulosonic acid (DOH). Panel A shows the linear 
gradient of (NH4)HCO3 used to elute DOH on a AG1x8 resin (HCO3-, 100-200 mesh) column. 
Panel B shows fractions collected from the anion exchange and analysed by TBA assay. DOH 
is seen to elute in fractions B14-B5 which corresponds to between 5 and 20 % (NH4)HCO3. 
 
4.5.3 NMR analysis of DOH 
Once the DOH product had been purified by anion exchange, 500 MHz H NMR spectroscopy, in 
D2O, was carried out on the purified fractions (Section 2.4.18).  From the proton NMR 
diagnostic aldol condensation peaks could be seen in the region 1.95-2.65 ppm. When an aldol 
condensation occurs, the protons which are originally from the methyl group of pyruvate will 
undergo changes in chemical shift and splitting pattern, as they form a diastereotopic pair of 
protons at the new carbon-carbon centre, between C3 and C4. This produces the peaks at 




Figure 4.18. Proton NMR spectrum of DOH purified by anion exchange. 
 
The peaks at 1.95-2.65 ppm in the proton NMR indicate that an aldol condensation between 
erythrose and pyruvate has occurred to form DOH. DOH is a seven carbon sugar and so it may 
cyclise to produce multiple different forms (shown in Figure 4.19). DOH has the potential to 
form both pyranose and furanose rings, each of which can adopt either the α or β anomer of 
the ring structure, also the stereochemistry at the new carbon-carbon centre of DOH could be 
in either the R or S configuration. Therefore it is unsurprising that the proton NMR spectrum 
looks highly complicated (Figure 4.18), peaks in the region 1.95-2.65 ppm indicated that four 
different forms of the product were present in the sample. Since four different forms of the 
product were found in the proton NMR it was necessary to use 2D NMR techniques to assign 





Figure 4.19 Aldol condensation of pyruvate and D-erythrose to form deoxyheptulosonic acid 
(DOH). DOH can then cyclise in multiple different ways, shown in structures A-H. A shows 
the α or β (4R)DOH pyranose, B shows the α or β (4S)DOH pyranose C shows the α or β 
(4R)DOH furanose, D shows the α or β (4S)DOH furanose. 
 
To allow characterisation of the different forms of the product, both COSY (correlation 
spectroscopy) and TOCSY (total correlation spectroscopy) 2D NMR techniques were used. 
COSY allows the protons that are coupling to each other to be easily identifiable, and TOCSY 
allows protons, which may not be directly coupled to each other but are in the same spin 
system to be identified. In the 2D NMR spectra shown in Figure 4.20 the spin systems (shown 
in the TOCSY spectrum) and the coupled protons (in the COSY spectrum) can be seen for the 
four distinct forms seen of the product. NMR spectroscopic data is summarised in Table 4.5 
however even using the 2D NMR techniques, it was not possible to assign coupling constants 
and chemical shifts for some of the protons in the different DOH forms due to overlapping 





Figure 4.20. Proton COSY and TOCSY NMR spectra of the product DOH. Panel A shows the 
proton NMR spectrum of DOH with easily isolatable peaks corresponding to form 1 
highlighted in pink, form 2 highlighted in yellow, form 3 highlighted in blue and form 4 
highlighted in green. Panel B shows COSY spectrum on the left-hand side and TOCSY 
spectrum is shown on the right-hand side. The spin systems for each of the different forms of 
DOH have been highlighted by black lines. 
 
Previously published data for the compound methyl 3-deoxy-L-arabino-2-heptulosonate (Fitz et 
al., 1995) could be used as a comparison for the NMR data of DOH as it is the enantiomer of 
(4R) DOH, and the methyl ester group would not affect the NMR spectrum of the rest of the 
sugar. The NMR spectroscopic data for form 1 of the product corresponded to the previously 
published data, indicating that the product produced was DOH as expected (shown in Table 4.5 
and Table 4.6).  
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Previously published NMR data of the (4R,5R,6R)- and (4S,5R,6R)-6-dipropylcarba-moyl-2-oxo-
4,5,6-trihydroxy-hexanoic acid ((4R) and (4S) dipropyl sialic acid) also provides a comparison 
for the DOH forms found, since the ring structure is comparable to DOH (Woodhall et al., 
2005). All forms of DOH seen in the NMR correspond to NMR data seen for the different 
pyranose and furanose forms of (4R) and (4S) dipropyl sialic acid. NMR data for the forms of 
DOH seen in the NMR spectra is summarised in Table 4.5, and previously published data of 
structures similar to DOH that have been used for comparison is summarised in Table 4.6. 
NMR spectroscopic data for form 1 of DOH correlates well with the pyranose (4R) dipropyl 
sialic acid indicating that this form of DOH may have adopted a pyranose ring (Table 4.5 and 
Table 4.6). Also the coupling constants between the protons on C3 and C4 may allow the 
relative configuration at the new carbon-carbon centre to be determined. From the data for 
form 1 of DOH the large 11.6 coupling constant is consistent with diaxial coupling in the 
pyranose ring, and the smaller  5.1 coupling constant is consistent with axial-equatorial 
coupling, and so the hydroxyl group at the C4 position should be equatorial (Figure 4.21). 
Therefore the stereochemistry at C4 is in the R configuration, which corresponds with the data 
for the pyranose (4R) dipropyl sialic acid.  
 
    
Figure 4.21 Approximate coupling constants in pyranose rings. Pyranose rings have been 
shown with groups only at two carbons for simplicity. A shows diaxial coupling which 
produces a large coupling constant ~11, and equatorial axial coupling which produces a 
smaller coupling constant ~5. B shows diequatorial and equatorial axial coupling which both 
produce small coupling constants ~3. Coupling constants shown have been taken from the 
experimental data for form1 and 2 of DOH. 
 
Form 2 of DOH correlates well with the data for a pyranose (4S) dipropyl sialic acid, this may 
indicate that form 2 has also adopted a pyranose form (Table 4.5 and Table 4.6). The coupling 
constants for H3-H4 are both quite small 3.6 and 3.1 therefore there is no diaxial coupling 
between the protons at C3 and C4 in form 2 (Figure 4.21). No diaxial coupling between the 
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protons would indicate that the hydroxyl group at C4 is in the axial position producing the 4S 
configuration at this position.  
Data for form 3 of DOH correlates with a furanose (4S) dipropyl sialic acid (Table 4.5 and Table 
4.6), and the presence of coupling constant of 7 also indicates that form 3 has adopted a five 
membered furanose ring as this coupling constant cannot be present in a pyranose ring. 
Similarities in the coupling constants between form 3 of DOH and the furanose (4S) dipropyl 
sialic acid show that form 3 may have the (4S) configuration. NMR spectroscopic data for form 
4 correlates with the data for the furanose (4S) dipropyl sialic acid which may indicate that 
form four has cyclised to a furanose ring. The coupling constants for form 4 also correlate very 
well with the coupling constants of a furanose (4S) dipropyl sialic acid (Table 4.5 and Table 
4.6), and so form 4 may have the same (4S) stereochemistry. It is quite likely that both form 3 
and form 4 are both furanose rings with (4S) configuration which may indicate that they are 
interconverting α and β anomers. 
To calculate the amount of each form of DOH present an NMR spectrum with a known amount 
of methanol was collected. It was seen that form 1, which is most likely the only (4R) 
configuration present, was present at almost 100 %. Form 2, 3 and 4, which all have the (4S) 
configuration, were present at approximately 30 % each. This is consistent with the data from 
Woodhall et al where the (4R) dipropyl sialic acid was present in one pyranose form at 80 % 
and the (4S) dipropyl sialic acid was present in two pyranose and two furanose forms in the 
ratio 15:10:45:30.   
From the NMR data and assignments, DOH is produced from the reaction of D-erythrose and 
pyruvate with F190Dpc saNAL. It is highly likely, from the NMR spectra, that the DOH product 
is produced with both (4R) and (4S) stereochemistry therefore the aldol condensation of 
D-erythrose and pyruvate by F190Dpc is not stereospecific. Also from the NMR analysis it is 





























<95 2.19, 1.8 3.94* 3.45 3.76* 3.64* 13.0 5.1, 11.6  
Form 2 
 
30 2.16, 2.05 4.25* 3.75 4.05* nd 14.8 3.6, 3.1  
Form 3 
 
30 2.38, 2.32 4.55* nd nd nd 13.6 7.0, 5.3  
Form 4 
 
30 2.55, 2.08 4.53* 4.15* 3.83* nd 14.4 7.2, 2.8  
Table 4.5 NMR spectroscopic data for the four different forms of DOH observed in the NMR 
spectra. The colours underlining the different form of DOH relate back to Figure 1.16. * 



































<95 2.24, 1.82 3.93 3.39 3.82 3.77 13.2 5.1, 11.7 
(4R) dipropyl sialic acid 
Pyranose1 
 
80 2.23, 1.84 3.95 3.64 4.61 - 13.3 5.1, 11.5 
(4S) dipropyl sialic acid 
Pyranose1 
 
15 2.15, 2.11 4.2 3.86 4.95 - 15.0 3.4, 3.4 
(4S) dipropyl sialic acid 
Furanose2 
 
30 2.42, 2.39 4.57 4.10 4.54 - 15 5.8, 6.4 
(4S) dipropyl sialic acid 
Furanose1 
 
45 2.64, 2.09 4.52 4.25 4.46 - 14.5 6.9, 2.6 
Table 4.6 Previously published NMR spectroscopic data of similar structures to DOH (Fitz et 









This chapter has described the insertion of many ncAAs, individually throughout the active site 
of saNAL, and the screening of these modified enzymes for altered activity. 13 different ncAAs 
have been individually incorporated into saNAL, by chemical modification, at a variety of 
different positions. These modified enzymes were then screened for activity with 10 different 
aldehydes and pyruvate. Excitingly, using this approach it has been possible to show that 
ncAAs are well tolerated within the enzyme, with modified enzymes not only retaining activity 
but also showing increased activities. 
Through this methodology it has been possible to bring about an increase in activity with 
GlcNAc, an aldehyde which is not accepted by the wild-type enzyme, by incorporation of a 
benzylcysteine at position 172. It has also been possible to increase the activity with erythrose 
by incorporation of a 2, 3-dihydroxy-propyl cysteine side chain at position 190. This activity 
produces the full length aldol product 3-deoxy-2-heptulosonic acid, which is a related 
compound to 3-deoxy-D-arabino-2-heptulosonate-7-phosphate (DAH7P). DAH7P is an 
important intermediate in the shikimate pathway, found in bacteria and plants, for the 
production of essential aromatic amino acids (Dondoni et al., 1994, Maeda and Dudareva, 
2012). Due to the similarity of DOH to DAH7P, DOH could prove useful as a starter unit for 
compounds with potential herbicidal and antimicrobial effects, there is also interest in DOH 
and other 3-deoxy-2-ulosonic acids due to their potential use in complex oligosaccharide 
syntheses (Hekking et al., 2006, Pradhan et al., 2013, Enders and Gasperi, 2007).  
From this chapter it is clear that enzyme activity can be altered by using ncAAs. By 
incorporation of ncAAs into the active site of saNAL, it has been possible to alter the activity 





Chapter 5 Characterisation of F190Dpc saNAL 
The incorporation of a variety of ncAAs individually, throughout saNAL, and the subsequent 
screening of these modified enzymes for altered substrate specificity, was described in the 
previous chapter. Identification and preliminary investigation of the enzyme F190Dpc, which 
showed an increase in activity with erythrose and pyruvate as substrates (Figure 5.1), was also 
described. This chapter will detail further characterisation of this activity, using both kinetic 
and X-ray crystallographic methods.  
 
  
Figure 5.1 Aldol condensation reactions of wild-type and F190Dpc saNAL. A) aldol 
condensation of N-acetyl-D-mannosamine (ManNAc) with pyruvate to form N-
acetylneuraminic acid (Neu5Ac), catalysed by wild-type saNAL. B) aldol condensation of 
erythrose and pyruvate to form 3-deoxy-2-heptulosonic acid, catalysed by F190Dpc saNAL. 
 
5.1 Kinetic characterisation of F190Dpc saNAL 
Screening experiments, shown in the previous chapter, identified that by replacing the 
phenylalanine side chain at position 190 with the ncAA 2,3-dihydroxypropyl cysteine, an 
increase in activity with the aldehyde erythrose was produced.  To allow quantification of this 
increase in activity, kinetic parameters were determined for both the wild-type and F190Dpc 
enzymes. Kinetic parameters were determined for both enzymes with the substrates erythrose 




5.1.1 Aldol condensation kinetics  
Kinetic parameters were determined for the aldol condensation reaction. To follow this 
reaction the TBA assay was used, which can detect the amount of aldol product formed. 
However the TBA assay is an end point assay and so the kinetic parameters had to be 
determined in a discontinuous manner.  
To determine kinetic parameters using a discontinuous assay, the initial rates at a variety of 
substrate concentrations must be determined. For each initial rate determination, samples at 
various time points must be taken and analysed. This approach would mean, using a minimum 
of 6 substrate concentrations and 6 time points, 36 assays must be performed. Given the fact 
that the TBA assay is fairly complex to perform, and the number of kinetic sets that were to be 
performed, a more streamlined approach was taken. The linear range for the reaction was 
determined and one time point selected. This time point could then be used as the initial rate, 
at each substrate concentration, as all absorbance values for time points below this would be 
linear.  
The linear range was found by taking samples from reactions containing 8 mM erythrose and 
80 mM pyruvate, with either 0.14 mg mL-1 F190Dpc or wild-type saNAL, over a course of 
4 hours. For each time point, the reaction was stopped using trichloroacetic acid (TCA) (12% 
w/v), each sample was then assayed using the TBA assay, and absorbance data at 550 nm was 
collected. The linear range was then determined by plotting the absorbance data against time 
(Figure 5.2). The linear range for the reaction between erythrose and pyruvate with the 
F190Dpc saNAL was found to be between 0 and 2 hours at room temperature, and so 
absorbance values below approximately 0.5 absorbance units were within the linear region. 
For the wild-type enzyme reaction with erythrose and pyruvate, the linear range was between 
0 and 4 hours with absorbance values below 0.1 being in the linear range. Therefore all kinetic 




Figure 5.2 Time course of the aldol condensation between erythrose and pyruvate catalysed 
by F190Dpc and wild-type saNAL. Panel A shows an image of the TBA assayed samples taken 
from reactions containing 8 mM erythrose and 80 mM pyruvate, with either 0.14 mg mL-1 
F190Dpc or wild-type saNAL. Samples were taken at time points between 0.25 and 4 hours 
and stopped using trichloroacetic acid, before being analysed by the TBA assay. Panel B 
shows the plots of the absorbance data at 550 nm of the TBA assayed samples against time, 
the plot for wild-type saNAL is shown in black and the plot for F190Dpc saNAL is shown in 
red. 
 
±The reaction for erythrose and pyruvate is a two-substrate reaction and therefore a 25-point 
matrix varying the concentrations of both substrates should be carried out and then fitted to 
Equation 1 (Figure 5.3). However, as the TBA assay is fairly complex to perform and the 
number of assays that would be needed, it was decided that these kinetic would be carried out 
with one, saturating concentration of pyruvate. Therefore the concentration of pyruvate was 
kept constant and saturating at 80 mM (Appendix Figure 7.1), and the aldehyde concentration 
varied. Using these conditions to carry out the kinetics allows Equation 1 (Figure 5.3) to be 
rearranged to the same form as the Michaelis-Menten equation (rearrangement shown in 
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Figure 5.3), and so the kinetic data could be fitted using non-linear regression to Equation 4 
(Figure 5.3), to give kcatapp, Kmapp and kcatapp/Kmapp for the aldehyde substrate.  Therefore this 


































Figure 5.3. Rate equations for use in kinetic analysis. Equation 1 is the two substrate rate 
equation for an ordered reaction. KA is the Km for substrate A and KB is the Km for substrate B.  
Equations 2 and 3 show the rearrangement of the equation 1 into the same form as the 







+ 𝟏) are constants, therefore equation 3 has the same form 
as the Michaelis-Menten equation (Equation 4) which describes a rectangular hyperbolae.  
 
5.1.2 Kinetic comparison of wild-type saNAL and F190Dpc saNAL 
Kinetic parameters were determined, using the TBA assay, for wild-type saNAL and F190Dpc 
saNAL with the substrates erythrose and pyruvate, and the wild-type substrates ManNAc and 
pyruvate. To convert the absorbance data from the TBA assay into the amount of aldol product 
formed a standard curve of sialic acid was used (Section 2.4.16.2 and Figure 7.2). Sialic acid can 
be used as a reference for any aldol product since the TBA assay works by cleaving any aldol 
product to produce a 1-3 dicarbonyl, which is then detected by TBA to form a highly 
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conjugated pink product. Therefore regardless of the chain length, group substitutions or 
stereochemistry, the compound that is detected in the TBA assay is the same 1-3 dicarbonyl. 
Wild-type saNAL for use in kinetic assays was purified by nickel affinity. F190Dpc for use in 
kinetic assays was produced by purification of F190C saNAL, subsequent conversion to 
F190Dpc by chemical modification (Section 2.4.9 and 2.4.10.6) was carried out and then size 
exclusion chromatography was performed. To determine the kinetic parameters for wild-type 
and F190Dpc saNAL, reactions were carried out in deep well 96-well plates containing 50 μL 
sodium pyruvate (80 mM final concentration), 50 μL of either erythrose or ManNAc (varied 
between 0.4 mM and 15 mM final concentration) and the reactions initiated by addition of 
25 μL of either wild-type or F190Dpc enzyme (0.7 mg mL-1 stock concentration, to give final 
concentration 0.14 mg mL-1). All reactions were carried out in duplicates and blanks were 
performed containing 25 μL of buffer instead of enzyme. After a 2 hour incubation at  room 
temperature, 100 μL of each reaction was transferred into a new well containing 10 μL TCA 
(12%) to stop the reaction, and then each reaction underwent the TBA assay, as previously 
described in Section 2.4.16.3. After the final stage of the TBA assay the plate was centrifuged 
at 4900 g for 6 min to separate any precipitate from the coloured solution. 85 μL of each 
assayed reaction was then transferred into a flat-bottomed 96-well plate so that absorbance 
data at 550 nm could be acquired. Absorbance data for the F190Dpc enzyme, under these 
conditions, revealed that the absorbance values for the reactions with the highest 
concentrations of erythrose were above 1 absorbance unit. Therefore the kinetic assays were 
performed again using a lower concentration of F190Dpc (0.06 mg mL-1 final concentration). 
Once absorbance data had been acquired for the condensation reactions, the amount of aldol 
product was quantified using a standard curve of sialic acid. The quantified data were then 




Figure 5.4 Kinetic comparison of F190Dpc and wild-type saNAL with the substrates erythrose 
and pyruvate, and the substrates ManNAc and pyruvate. Panel A shows an image of TBA 
assayed samples from condensation reactions containing; 80 mM pyruvate, between 0.8 and 
15 mM ManNAc, 0.14 mg mL-1 of wild-type or F190Dpc enzyme, and which had been 
incubated at room temperature for 2 hours. Absorbance data from the TBA assay was 
converted to specific activity using a standard curve to calculate the amount of product 
formed. Plots of specific activity against [ManNAc] for both enzymes are shown on the 
right-hand side. Panel B shows an image of TBA assayed samples from condensation 
reactions containing; 80 mM pyruvate, between 0.4 and 15 mM erythrose, 0.14 mg mL-1 of 
wild-type enzyme or 0.06 mg mL-1 F190Dpc enzyme, and which had been incubated at room 
temperature for 2 hours. Absorbance data from the TBA assay was converted to specific 
activity using a standard curve to calculate the amount of product formed. Plots of specific 
activity against [erythrose] for both enzymes are shown on the right-hand side. 
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F190Dpc Erythrose 7.6 ± 0.56 
 




F190Dpc ManNAc 0.22 ± 0.01 
 
2.5 ±  0.43 
 
0.09 
Wild-type Erythrose 0.5 ± 0.05 
 




Wild-type ManNAc 0.8  ± 0.05 3.1  ± 0.7 0.26 
 
Table 5.1 Kinetic parameters for the aldol condensation of erythrose and pyruvate with both 
the wild-type and F190Dpc saNAL, and the kinetic parameters for the aldol condensation of 
ManNAc and pyruvate with both the wild-type and F190Dpc saNAL. Kinetic parameters were 
determined from the TBA assayed samples using a standard curve to determine the amount 
of aldol condensation product produced for each reaction, and then data was fitted using 
non-linear regression. 
 
From Figure 5.4 it is obvious that F190Dpc saNAL catalyses the reaction between erythrose 
and pyruvate much better than wild-type saNAL. F190Dpc shows a 15-fold increase in kcatapp 
and a 10-fold increase in kcatapp/Kmapp compared to the wild-type enzyme with erythrose and 
pyruvate. Interestingly the F190Dpc reaction with erythrose and pyruvate has a 10-fold higher 
kcatapp and a 7-fold higher kcatapp/Kmapp compared to the wild-type reaction with ManNAc and 
pyruvate. Using Equation 5 shown in Figure 5.5, the specificity switch of the F190Dpc enzyme 
could be calculated, which showed a 30-fold switch in specificity toward the erythrose 
substrate. These results show that the modified F190Dpc saNAL is not only better than the 
wild-type enzyme with the altered substrate erythrose, but is also better than the wild-type 







































Figure 5.5 Equation 5 used to calculate the specificity switch for F190Dpc saNAL with the 
substrates erythrose and pyruvate. 
 
5.2 F190X saturation library  
Clearly F190Dpc saNAL is a better catalyst than wild-type saNAL for the reaction of erythrose 
and pyruvate. However since this activity increase was achieved by use of an ncAA, we were 
interested to see whether it could be achieved by inserting one of the proteogenic amino acids 
at the same position in the enzyme. Therefore to compare the non-canonical Dpc side chain to 
all of the proteogenic amino acids, a saturation library at position 190 was produced. 
5.2.1 Production of F190X saturation library 
The DNA for the wild-type and F190C mutant had already been produced during the course of 
this work, and so there were 18 mutants at position 190 to be made. The F190X saturation 
library was produced by site-directed mutagenesis; primers were designed to insert each of 
the remaining 18 proteogenic amino acids at position 190.  Sequencing was used to confirm 
that the mutations at position 190 had been successfully inserted (data shown in Figure 5.6) 
and that no other mutations had occurred in the DNA. The mutant plasmids were then 
transformed into BL21 competent E. coli cells for expression. Variant proteins were expressed 




Figure 5.6. Sequencing data for the 18 F190 mutants. The 18 different proteogenic amino can 
be seen to have been inserted at position 190.  
 
5.2.2 Kinetic comparison of the F190X library and F190Dpc saNAL 
Kinetic assays were carried out with the purified F190 variants. Kinetic assays were performed 
with 5 different aldehyde concentrations (from 0.8 mM to 15 mM final concentration) using 
the same TBA assay method as for the wild-type and F190Dpc enzymes. Kinetic parameters for 




Table 5.2 Kinetic parameters for the aldol condensation of erythrose and pyruvate for the 
F190X saturation library, wild-type and the modified F190Dpc saNAL. Kinetic parameters 
were determined by using the TBA assay (Section 2.4.16.3) to analyse samples from aldol 
condensation reactions containing; 80 mM pyruvate, between 0.8 and 15 mM erythrose, 
0.14 mg mL-1 of wild-type of F190X enzyme or 0.06 mg mL-1 of F190Dpc which had then been 
incubated for 2 hours at room temperature. The amount of aldol condensation product 




From the kinetic parameters the F190Dpc enzyme has the highest turn-over rate for the 
substrates erythrose and pyruvate. The increase in activity brought about by F190Dpc can be 
seen in panel A of Figure 5.7, which shows an image of TBA assayed samples from the kinetic 
assays performed. Comparison of kcatapp, shows that F190Dpc has a 5-fold higher kcatapp than the 
next best proteogenic variant which is F190E. Therefore this level of increased activity, with 
erythrose and pyruvate, could not have been achieved had we used a traditional protein 
engineering approach, which is restricted to the 20 proteogenic amino acids, at this position. 
Interestingly, the kinetics for the saturation library and F190Dpc show that the Kmapp does not 
change significantly between all the variants and the increase in activity caused by the Dpc side 
chain is produced from a change in kcatapp. 
 
        
Figure 5.7 Kinetic comparison of the F190X saturation library and F190Dpc for the aldol 
condensation of erythrose and pyruvate. Panel A shows an image of the TBA assayed 
samples from condensation reactions containing; 80 mM pyruvate, 10 mM erythrose, 
0.14 mg mL-1 of wild-type of F190X enzyme or 0.06 mg mL-1 of F190Dpc and had been 
incubated at room temperature for 2 hours. Panel B shows a bar chart representation of the 




5.3 Comparison of F190Dpc to directed evolution studies 
The F190Dpc saNAL proves to be a better catalyst for the reaction of erythrose and pyruvate 
than the wild-type saNAL, and it also outperforms all the proteogenic amino acids at position 
190 for this reaction. A previous directed evolution study on the E. coli NAL, carried out by the 
Wong group, produced a variant of the E.coli NAL with an increased activity with L-3-deoxy-
manno-2-octulosonic acid (Hsu et al., 2005), further studies on this enzyme showed that by 
altering the residue at position 251 the substrate specificity could be altered. By producing the 
variant V251R the enzyme had an increased specificity towards erythrose as the aldehyde 
acceptor (Chou et al., 2011). Unfortunately due to the differences in experimental procedure 
for determining the kinetic parameters, it was not possible to directly compare the kinetic 
parameter values. However the E. coli NAL has very high sequence and structural similarity to 
saNAL, therefore we decided to make the equivalent mutation in saNAL (I251R) and determine 
the kinetic parameters for this variant. 
The I251R mutation in saNAL was made using site-directed mutagenesis and once sequencing 
had confirmed the mutation; the variant was expressed and purified.  The I251R saNAL variant 
was purified using nickel affinity chromatography and a sample was taken and analysed by ESI 
mass spectrometry. A peak with the mass 34036 Da was observed in the mass spectrum which 




Figure 5.8. Sequencing and mass spectrometry of the I251R saNAL variant. Panel A shows the 
sequencing data in both forward and reverse directions for the I251R mutation compared to 
the wild-type saNAL. Panel B shows the ESI mass spectrum of the I251R variant after 
purification. 
 
Aldol condensation kinetic parameters for the I251R variant were carried out in the same 
manner as for all the other variants, using the TBA assay. Kinetic parameters for the I251R 
variant, in comparison with both the wild-type and F190Dpc enzymes, are shown in panel B of 
Figure 5.9. Comparison of kcatapp of I251R and F190Dpc shows that F190Dpc has a 6-fold higher 





Figure 5.9 Aldol condensation kinetics, for the condensation of erythrose and pyruvate, 
carried out with the I251R saNAL variant. Panel A shows an image of the TBA assayed 
samples from the condensation reactions which contained; 80 mM pyruvate, between 0.8 
and 15 mM erythrose and 0.14 mg mL-1 I251R enzyme and had been incubated for 2 hours at 
room temperature. Panel B shows the kinetic parameters for the aldol condensation of 
erythrose and pyruvate performed with F190Dpc, wild-type and I251R saNAL. Kinetic 
parameters were determined from the TBA assayed samples by using a standard curve to 
quantify the amount of aldol condensation product (DOH) produced and then data was 
fitted using non-linear regression. Panel C shows bar chart representations to compare the 
kcatapp and kcatapp/Kmapp for the aldol condensation of erythrose and pyruvate catalysed by 
F190Dpc, wild-type and the I251R variant saNAL. F190Dpc shows a 6-fold higher kcatapp than 
the I251R variant and a 30-fold higher kcatapp/Kmapp than the I251R variant. 
 
These experiments show that the ncAA-containing-enzyme F190Dpc has an increased activity, 
with the substrates erythrose and pyruvate, over that of the wild-type enzyme. The Dpc side 
chain also out-performs all of the proteogenic amino acids at position 190. And the F190Dpc 
enzyme is also better than a variant developed through directed evolution, for this activity.    
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5.4 Crystallographic studies of F190Dpc saNAL 
Thorough kinetic analysis had been carried out on the F190Dpc enzyme to determine the 
switch in substrate specificity. Therefore, to try and determine the mechanism by which the 
Dpc side chain achieved this increase in activity with erythrose and pyruvate, X-ray 
crystallographic studies were carried out.  The crystal structure of the F190Dpc enzyme was 
solved in complex with pyruvate, using the same methods as for the wild-type and 
K165-γ-thialysine enzymes. 
5.4.1 Crystallisation of F190Dpc saNAL 
Crystallisation of F190Dpc was carried out using the same conditions as were optimised for the 
wild-type saNAL enzyme (Timms et al., 2013). The F190Dpc enzyme was produced on a 50 mg 
scale using the chemical modification procedure. Once the modification to the Dpc side chain 
had been confirmed using ESI negative ion mode mass spectrometry, the protein was re-folded 
by dialysis and further purified using size exclusion chromatography (Section 2.4.12). F190Dpc 
protein at approximately 7 mg mL-1 was applied to a Superdex preparative S200 column (GE 
life sciences), and fractions containing protein which eluted protein at 180 mL were collected. 
Fractions containing the pure protein were concentrated to between 7-10 mg mL-1 for 
crystallisation. Crystallisation conditions used were 200 mM NaCl, 100 mM Tris/HCl (pH 7.0-
8.5) and 18-28% (w/v) PEG 3350, and crystal trays were prepared by hand using hanging drop 
vapour diffusion. Each well contained 3 drops of either 3 or 4 µL, with the ratios 1:2 2:2 2:1 of 
protein to mother liquor. Using these methods single crystals formed in 7-10 days. 
To produce the cryo-cooled enzyme-pyruvate complex for data collection, the crystals were 
soaked in mother liquor containing PEG 400 and sodium pyruvate. Crystals were first soaked in 
mother liquor supplemented with 15 % PEG 400 (w/v) and 100 mM sodium pyruvate, before 
being transferred to mother liquor supplemented with 20 % PEG 400 (w/v) and 100 mM 
sodium pyruvate and the final soak contained 25 % PEG 400 and 100 mM sodium pyruvate. 
Crystals were soaked in each of the different PEG 400 concentrations for approximately 30 s, 







5.4.2 Data collection, processing and refinement  
Data collection for F190Dpc in complex with pyruvate was performed at Diamond Light Source 
(Oxfordshire, UK). The data set was recorded on beamline I0-4 at 100 K from a single crystal 
(Figure 5.10). Integration and scaling of the data set was performed using the CCP4 programs 
MOSFLM and SCALA (Leslie, 2006, Evans, 2006). Scaling was carried out with a resolution range 
of 1.7-75.52 Å and 1-1400 images were used. Scaling statistics and full structural statistical 
data for the F190Dpc structure, in complex with pyruvate, can be seen in Table 5.3.  
 
   
Figure 5.10. Image of F190Dpc crystal mounted in a loop during data collection.  
 
After scaling had been performed, molecular replacement was used to determine the F190Dpc 
structure. Molecular replacement was carried out using PHASER (Mccoy, 2007), with the 
wild-type apo saNAL structure (PDB code 4ahp) as the search model consisting of chain A of 
the homotetramer with the water molecules removed. By running the CCP4 program 
‘Matthews Coefficient’ (Kantardjieff and Rupp, 2003, Matthews, 1968), which works to 
estimate the solvent content of the unit cell based on the molecular weight of the protein and 
the unit cell parameters, it was estimated that 4 monomers were present in the unit cell and 
so 4 copies were searched for during the molecular replacement. The unit cell parameters 
were a=55.5 Å, b=134.3 Å, c=79.5 Å, α=90, β=108, γ=90 with space group P21 and an upper 
resolution of 1.7 Å. The molecular replacement solution showed the crystal structure to be a 
tetramer, as was seen with the wild-type and K165-γ-thialysine crystal structures. 
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 F190Dpc saNAL in complex 
with pyruvate 
  
Diamond beamline I0-4   
Space group P21     
Resolution (Å) 1.7     
a (Å) 55.5     
b (Å) 134.3     
c (Å) 79.5     
Rmerge §* 0.071(0.42)     
Rpim+* 0.035(0.24)     
Observed reflections 565,256     
Unique reflections 120,355     
Completeness (%)* 99.4(95.7)     
Multiplicity* 4.7(4.0)     
<I/σ> I/σ * 11.2(3.0)     
Refinement 
Rfactor (%) 0.18   
Rfree (%)† 0.21     
No. of protein atoms 9298     
No. of solvent molecules 278     
No of ligand atoms 20     




    
Average ligand B-factor 
(Å2)  
22.1     
Average solvent B-factor 
(Å2)  
27     
RMS bond lengths (Å) ξ 0.019     
RMS bond angles (Å) ξ 2.04     
Ramachandran analysis, the percentage of residues in the regions of plot (%) ‡  
Most favoured 98.0   
Outliers 4'     
 
§ Rmerge= ΣhklΣi|Ii(hkl)-<I(hkl)>|/ ΣhklΣi|Ii(hkl) 
+ Rpim - precision-indicating (multiplicity-weighted) Rmerge, relative to all I+ or I-. 
* Values given in parentheses correspond to those in the outermost shell of the resolution range. 
† Rfree was calculated with 5% of the reflections set aside randomly. 
ξ Based on the ideal geometry values of Engh & Huber (Engh and Huber, 1991). 
‡ Ramachandran analysis using the program MolProbity (Lovell et al., 2003) 
'The side-chain of Tyr111, in all subunits, is in close proximity to Leu142, Thr143 and Phe110 from an adjacent chain 
causing the phi and psi angles of Tyr111 to lie in an unfavoured region of the Ramachandran plot 




Once molecular replacement had been performed and a suitable model found, refinement was 
carried out. The CCP4 program REFMAC5 (Murshudov et al., 2011) was used to carry out 
multiple rounds of refinement. For refinement the starting model was the wild-type apo saNAL 
structure with the waters removed and the residues at position 165 and 190 modelled as 
alanine to prevent any bias in the model. Initial rigid body refinement was carried out, 
followed by iterative rounds of restrained refinement and model building carried out in 
REFMAC and COOT (Emsley et al., 2010) respectively. During the restrained refinement, TLS 
refinement was also carried out. From both the 2Fobs-Fcal and Fobs-Fcal electron density maps it 
was clear that the residue at position 165 did not fit an alanine residue, as there was excess 
positive electron density extending out from the Cβ that indicated a lysine in complex with 
pyruvate. Therefore the lysine in complex with pyruvate was built into the structure in the 
same way as for the wild-type saNAL in complex with pyruvate discussed in Section 3.3.2. The 
lysine in complex with pyruvate was designated the same HET code, KPI, as before and the 
same library file for the bond lengths and angles was used.  
Similarly at position 190 there was also excess positive electron density extending from the Cβ 
when the residue was modelled as an alanine. The positive electron density was quite large at 
the γ position indicating a more electron dense atom such as a sulphur atom. However, when 
the residue was modelled as a cysteine residue there was still excess density extending from 
the γ position. This excess density indicated the presence of the non-canonical side chain Dpc 
(panel A Figure 5.11), and so the Dpc side chain was modelled into all subunits. To generate 
the structure and library file for the Dpc side chain, the ligand builder extension in COOT was 
used. Once the structure file and the library file were produced they were checked and edited 
manually and then modelled into the F190Dpc structure. Subsequent rounds of refinement 
were carried out and the Dpc side chain was observed to be in multiple conformations in two 
out of the four subunits (Figure 5.11). 
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Figure 5.11 Structure of the dihydroxypropylcysteine (Dpc) side and electron density for the 
Dpc side chain found at position 190 in the F190Dpc crystal structure in complex with 
pyruvate. Panel A shows the structure of the Dpc side chain. Panel B shows the 2Fobs-Fcal 
density for the Dpc side chain at position 190 in chain A. Panel C shows the 2Fobs-Fcal density 
for the Dpc side chain at position 190 in chain B. Panel D shows the 2Fobs-Fcal density for the 
Dpc side chain at position 190 in chain C. Panel E shows the 2Fobs-Fcal density for the Dpc side 
chain at position 190 in chain D. In chains A and C the Dpc side chain is seen to adopt two 
conformations and in chains B and D it is seen to adopt one. 
 
5.4.3 Crystallographic comparison of wild-type saNAL and F190Dpc saNAL  
The crystal structure of F190Dpc was determined to try and elucidate the mechanism by which 
this non-canonical side chain produces the increase in activity, with the substrates erythrose 
and pyruvate. The crystal structure of F190Dpc in complex with pyruvate, is a tetramer made 
up of monomers with an (α/β)8 TIM barrel fold, where the α helices enclose the β sheets, 
which was also seen in the wild-type saNAL, E. coli NAL and H. influenza NAL structures (Timms 
et al., 2013, Barbosa et al., 2000, Lawrence et al., 1997). The F190Dpc structure in complex 
with pyruvate had the same ordered loop region from residues 137-146, as was observed in 
the wild-type structure in complex with pyruvate (Timms et al., 2013). Alignment of the 
F190Dpc structure and the wild-type structure, both in complex with pyruvate has an RMSD of 
0.5 Å. Therefore there was very little overall structural change caused by the incorporation of 




Figure 5.12 Crystal structures of F190Dpc and wild-type saNAL both in complex with 
pyruvate. Panel A shows the homotetramer and monomer of F190Dpc saNAL in complex 
with pyruvate. Panel B shows the homotetramer and monomer of wild-type in complex with 
pyruvate. Panel C shows overlays of the homotetramer and monomer of both wild-type 




Comparison of the active site of the F190Dpc structure and the wild-type structure, both in 
complex with pyruvate, shows that the pyruvate binding end of the active site appears to be 
unaffected by the incorporation of the ncAA at the other end of the active site. Comparison of 
the phenylalanine and Dpc side chains (Panel B Figure 5.13) shows the aromatic side chain has 
been exchanged for a more polar side chain which can adopt multiple conformations, as was 
seen in two out of the four subunits, and is also 0.8 Å longer than the phenylalanine.  Panel A 
of Figure 5.13 highlights the positioning of residue 190 in the active site of both the wild-type 
saNAL and F190Dpc. From previous studies it is know that the full-length wild-type product 
Neu5Ac lies in the active site between the catalytic Lys165 and Glu192; Lys165 forms a Schiff 
base with the pyruvate end of the Neu5Ac and Glu192 hydrogen bonds to the glycerol end of 
Neu5Ac (Daniels et al., 2014). The altered substrate specificity, with erythrose and pyruvate, 
which is achieved by the Dpc side chain, produces a shortened C7 product (DOH) compared to 
the wild-type C9 product (Neu5Ac). Therefore it was hypothesised that the positioning of the 
Dpc side chain at 190 meant that it could interact and potentially stabilise the binding of the 
product in the active site, where as the aromatic phenylalanine could not.  
Comparison of the region around position 190 (Panel C Figure 5.13), shows that the side chains 
of Asp141 and Glu192 are within close proximity to the phenylalanine side chain in the 
wild-type structure, and the Dpc side chain in the modified enzyme structure. Due to the two 
hydroxyl groups in the Dpc side chain, Dpc may be able to interact with Asp141 and Glu192 
whereas the aromatic side chain of phenylalanine would not. In the F190Dpc crystal structure 
Asp141 is approximately 3.1 Å away from the Dpc side chain and Glu192 is approximately 3.3 Å 





Figure 5.13 Panel A shows a comparison of the active site of wild-type and F190Dpc crystal 
structures in complex with pyruvate. Lys165 and Glu192 are highlighted as sticks to show 
where the full-length product would lie in the active site and the residue at 190 is also 
highlighted as sticks. Panel B shows a comparison of the phenylalanine side chain found at 
position 190 in the wild-type saNAL and the dihydroxypropylcysteine side chain found at 
position 190 in the modified F190Dpc saNAL, the residue lengths from the Cα to the terminal 
are highlighted by dashed lines. Panel C shows comparison of residues around position 190, 
potential interactions between Dpc190, Asp141 and Glu192 are highlighted by dashed lines.  
 
By overlaying the active sites of the wild-type and F190Dpc structures, in complex with 
pyruvate (shown in Figure 5.14), the structural differences in the active sites can be seen. The 
main difference is at position 167, where the threonine at this position in the F190Dpc 
structure lies further into the active site. The Cα of Thr167 is position 1.0 Å closer to the Lys165 
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bound to pyruvate, in the F190Dpc structure than in the wild-type structure. Thr167 has 
previously been shown to stabilise the transition state of the wild-type reaction by stabilising 
the aldehyde of ManNAc which becomes the C4 hydroxyl of the full length Neu5Ac (Daniels et 
al., 2014).  
 
 
Figure 5.14 Overlay of chain B of F190Dpc crystal structure in complex with pyruvate and 
chain B of the wild-type saNAL crystal structure in complex with pyruvate. Panel A shows the 
active site of both the F190Dpc and the wild-type saNAL crystal structures with active site 
residues highlighted as sticks. Panel B shows Thr167 in F190Dpc and the wild-type saNAL 
crystal structures, with the difference in position of the Cα atoms of Th167 highlighted by a 
dashed line. 
 
By producing a distance matrix of both the wild-type and F190Dpc structures it was possible to 
highlight the regions most affected by the incorporation of the ncAA, Dpc (Figure 5.15). 
Thirteen residues which line the active site and which have side chains directed into the active 
site were selected; distances between each residue were taken in both the wild-type and 
F190Dpc structures. The wild-type values were subtracted from the F190Dpc values to 
highlight which distances had been reduced and which had been increased between the two 
structures. A pink colour in the distance matrix indicates distances that have decreased in the 
F190Dpc saNAL structure and a purple colour indicates distances that have increased in the 




Figure 5.15 Distance matrix of the wild-type and F190Dpc crystal structures. Panels A and B 
show the active site of the wild-type (cyan) and F190Dpc (pink) crystal structures, with the 
residues that distances have been measured between highlighted as sticks. Panel C shows 
the distance matrix where the difference between the wild-type active site distances and the 
F190Dpc active site distances are displayed as follows; a purple colour shows distances that 
have increased in the F190Dpc structure compared to the wild-type structure, and a pink 
colour shows distances that have decreased in the F190Dpc saNAL structure compared to 




The distance matrix shows that in the F190Dpc structure the distances between residue 190 
and all the other 12 residues have decreased, presumably this has occurred as the Dpc side 
chain is a longer side chain than the wild-type phenylalanine.  Interestingly, in the F190Dpc 
structure Thr167 moves away from the catalytic lysine at position 165 and moves closer to the 
residues that line the aldehyde end of the active site, this may bring Thr167 into closer 
proximity to the aldehyde substrate erythrose. The differences in the active site shape can also 
be seen in Figure 5.16 where the active sites of the wild-type and F190Dpc structures, in 
complex with pyruvate are shown as surface representations. The active site of the F190Dpc 
structure appears to be narrowed by the presence of the Dpc side chain compared to the 
wild-type, the narrowing of the active site may help the binding of the shortened aldehyde 
substrate erythrose.  
 
 
Figure 5.16 F190Dpc and wild-type crystal structures, in complex with pyruvate, displayed as 
surface representations to show the differences in shape of the active sites.  
 
Although the crystal structure of F190Dpc, in complex with pyruvate, showed some structural 
differences from the wild-type, there was no clear reasoning for the increase in activity with 
erythrose. To try and further elucidate this and to investigate the binding of the product in the 
active site, attempts were made to determine the crystal structure in complex with the 
full-length DOH product. F190Dpc crystals were soaked with 100 mM DOH but no evidence for 
the full-length product was observed in the electron density maps. Previous studies used an 
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inactive Y137A variant to trap the full-length wild-type substrate Neu5Ac in the active site of 
the wild-type E.coli protein and successfully determine the crystal structure (Daniels et al., 
2014), therefore a Y137A/F190C double mutant was produced in saNAL. Once the 
Y137A/F190C variant was purified the chemical modification procedure was carried out to the 
produce the modified Y137AF190Dpc. This modified protein was then crystallised and soaks 
with 100 mM DOH and also soaks with 100 mM pyruvate and 100 mM erythrose were carried 
out. However, again, no evidence for the full-length DOH product was observed in the 
resultant electron density maps. Co-crystallisation experiments with the Y137A/F190Dpc 
protein were also carried out, where between 15 mM and 75 mM DOH was added into the 
crystallisation conditions. Crystals were obtained but again there was no evidence of the 
full-length product in the active site.  
In the crystal structures of the Y137A/F190Dpc variant the loop region between residue 137 
and 146 could be seen in the electron density, even though there was no evidence for 
pyruvate or anything bound in the active site. In the previous crystallographic studies this loop 
region became visible when a substrate was bound in the active site (Section 3.3.3) (Timms et 
al., 2013). Therefore this rigidity of the 137-146 loop, which lies over the entrance of the active 
site, may have prevented any of the substrates entering the active site. Since it was not 
possible to determine the crystal structure with the full-length DOH product in the active site, 
molecular modelling and energy minimisation experiments were employed to investigate the 
binding of the full-length product in the active site. 
5.5 Modelling and energy minimisations 
Computational modelling and energy minimisations were carried out to try and highlight the 
differences in binding of the F190Dpc and wild-type enzymes with the product DOH, as it was 
not possible to do this by crystallographic methods. These experiments were carried out by Dr 
Katie Simmons (University of Leeds).  
5.5.1 Modelling of DOH into the active site of F190Dpc saNAL and wild-type saNAL 
For the energy minimisation experiments to be performed, models of both the wild-type and 
F190Dpc enzymes with the full-length DOH had to be produced. Models were created in the 
program Maestro. The E.coli NAL structure in complex with the full-length Neu5Ac was used as 
a template to build the full-length DOH into the active site of both the wild-type saNAL and 
F190Dpc saNAL active sites, since the E.coli NAL is an excellent structural mimic of saNAL. The 
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C4 hydroxyl of DOH can adopt either the R or the S configuration (Figure 5.17) when the aldol 
condensation occurs, as was indicated by the NMR studies (Section 4.5.3). Therefore, both the 
(4R) and (4S) forms of DOH were modelled, individually, into the active sites of the F190Dpc 
and wild-type structures. 
 
        
Figure 5.17 Aldol condensation of D-erythrose and pyruvate to form the product (4R, 5S, 6R) 
DOH or (4S, 5S, 6R) DOH.  
 
Once the models of F190Dpc saNAL with (4R) and (4S) DOH in the active site, and wild-type 
saNAL with (4R) and (4S) DOH in the active site, had been produced they were subjected to 
energy minimisation. Energy minimisations were performed by selecting a region within 6 Å of 
the DOH product; the side chains in this area were allowed to minimise to their lowest energy 
state, whilst the back bone was kept rigid. The backbone was kept rigid as there were no 
significant backbone changes between the F190Dpc or wild-type structures, in complex with 
pyruvate, and the E.coli structure in complex with the full-length Neu5Ac product (Daniels et 
al., 2014). The models underwent 500 rounds of energy minimisation and then the values 
were checked to see if they had converged. If the energy values had not converged the models 
underwent a further 500 rounds of energy minimisation, to ensure that the values had 
converged and produced the lowest energy model. These lowest energy models were then 
compared to elucidate potential mechanisms behind the increase in activity with erythrose 




5.5.2 Comparison of F190Dpc saNAL and wild-type saNAL models 
The models generated from the computational energy minimisations revealed that the 
pyruvate binding region of the active site appears unchanged, and the glycerol end of the 
full-length product, DOH, is stabilised by Asp191 and Ser208.  It is clear that the Dpc side chain 
does not directly interact and stabilise the shortened C7 product, as was hypothesised from 
the crystal structure. However the interactions between Asp141, Glu192 and Dpc190, which 
were identified in the F190Dpc crystal structure (Panel C of Figure 5.13), produce significant 
differences in the F190Dpc models compared to the wild-type models. In the F190Dpc models, 
the Dpc side chain forms a hydrogen bonding network between Asp141 and Glu192, where as 
in the wild-type models the phenylalanine cannot form these interactions. These hydrogen 
bonding interactions are present in the F190Dpc models with either the (4R) or (4S) DOH in the 
active site (Figure 5.18). 
The hydrogen bonding network between Dpc190, Asp141 and Glu192 also appears to 
reposition the Dpc side chain in the F190Dpc models, compared to the phenylalanine in the 
wild-type saNAL models. The hydrogen bonding interactions serve to pull the Dpc side chain 
further into the active site (Figure 5.19), whereas the wild-type phenylalanine residue appears 
to be pushed out from the active site. In the F190Dpc model with (4S) DOH the Dpc side chain 
is 2.3 Å closer into the active site and in the model with (4R) DOH it is 1.8 Å closer into the 
active site. This positioning of the Dpc side chain helps to narrow the active site as can be seen 






Figure 5.18 Active site models of F190Dpc and wild-type with the (4R) and (4S) DOH product. 
Models of wild-type and F190Dpc with the (4R) DOH product are shown in panels A and B in 
teal and magenta respectively. Models of wild-type and F190Dpc with the (4S) DOH product 
are shown in panels C and D in cyan and pink respectively. Active site residues are 





Figure 5.19 Overlays of the F190Dpc and wild-type models. Panel A shows the overlay of the 
models with the (4S) DOH product, F190Dpc is shown in pink and wild-type is shown in cyan. 
Panel B shows the overlay of the models with the (4R) DOH product, F190Dpc is shown in 
magenta and wild-type is shown in teal. The distance between the wild-type phenyalanine 
and F190Dpc dihydroxypropylcysteine side chain is highlighted by a dashed line in both of 
the overlays. 
 
From the surface representations, both of the F190Dpc models have smaller, narrower active 
sites than the respective wild-type models (Figure 5.20). This narrowing of the active site was 
seen in the comparison of the crystal structures (Figure 5.16), but is more pronounced in the 
models. Narrowing of the active site is clearly due to the Dpc side chain, and may help to bind 
the shorter C7 DOH product over the longer, wild-type, C9 Neu5Ac. The wild-type models have 
much more open active sites, than the F190Dpc models, and this may allow the smaller C7 





Figure 5.20 Comparison of the active sites of the F190Dpc and wild-type models in surface 
representation. Models of F190Dpc and wild-type with the (4R) DOH product are shown in 
panels A and B in magenta and teal respectively. Models of F190Dpc and wild-type with the 
(4S) DOH product are shown in panels C and D in cyan and pink respectively.  
 
There are also several other significant differences at the aldehyde end of the active site in the 
F190Dpc models compared to the wild-type models. Figure 5.18 shows that in the wild-type 
models, Tyr252 is within hydrogen bonding distance, approximately 3 Å in both the (4R) and 
(4S) DOH models, of the C5 hydroxyl whereas in the F190Dpc it is much further away, 
approximately 4.5 Å in both the (4R) and (4S) DOH models, from the C5 hydroxyl. There are 
also differences in the positioning of Thr167, in the F190Dpc and wild-type models with the 
(4R) DOH Thr167 is positioned so it can hydrogen bond to the C4 hydroxyl in both the 
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wild-type and F190Dpc saNAL models. However when modelled with the (4S) DOH only Thr167 
in the F190Dpc model is with hydrogen bonding distance of the C4 hydroxyl. The hydrogen 
bonding interaction between the C4 hydroxyl and Thr167 has been previously shown to be 
important for transition state stabilisation (Daniels et al., 2014). In the F190Dpc model with the 
(4S) DOH Thr167 is 2.8 Å from the C4 hydroxyl of the product whereas in the wild-type it is 
4.6 Å from the C4 hydroxyl of the product, therefore the wild-type may not be able to stabilise 
the transition state to produce the (4S) DOH product. Since the increase in activity for 
erythrose and pyruvate with the F190Dpc enzyme comes from an enhanced kcat, as shown 
from the kinetic analysis, it is likely that a transition state stabilisation is occurring.  
Therefore from the energy minimised models it seems to be a combination of multiple factors 
that bring about the increase in activity, with the substrates erythrose and pyruvate, in the 
modified F190Dpc saNAL. The combination of the narrowing of the active site brought about 
by the hydrogen bonding network that the Dpc side chain forms and the difference in 
positioning of Thr167, are probably the main reasons behind the activity increase.  
5.6 Summary 
By incorporating an ncAA into an enzyme it has been possible to alter the substrate specificity 
of the enzyme. By exchanging the phenylalanine at position 190, in saNAL, for the 
non-canonical side chain dihydroxypropyl cysteine (Dpc), the kcatapp for the substrates 
erythrose and pyruvate was increased 15-fold and kcatapp/Kmapp was increased 10-fold. 
Interestingly, the F190Dpc saNAL was also a better enzyme with the substrates erythrose and 
pyruvate than the wild-type saNAL with the wild-type substrates ManNAc and pyruvate. 
Kinetic comparison of F190Dpc to a saturation library of all the twenty proteogenic amino 
acids at position 190, showed that the Dpc side chain outperformed all of the proteogenic 
amino acids at this position. F190Dpc saNAL was also a better enzyme with erythrose and 
pyruvate than a variant produced from a previously published directed evolution study.   
X-ray crystallographic studies, along with computational modelling and energy minimisations 
have been used to try and determine the mechanism by which F190Dpc saNAL achieves the 
increase in activity with erythrose and pyruvate. These studies highlighted that the Dpc side 
chain causes the active site to become smaller, which may increase the activity with the 
shortened substrate. Also in the F190Dpc structure and models the positioning of the residue 
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Thr167 is altered compared to the wild-type, and may be altered in a way which allows it to 
more easily stabilise the transition state in the F190Dpc enzyme with the DOH product. 
This work shows that both altering and improving catalysis is something that is achievable 
using ncAAs. It also shows that by further diversifying the side chain chemistries throughout an 
enzyme it might be possible to find activities that wouldn’t have been achievable if only the 
proteogenic amino acids had been available.  




Chapter 6 Summary, Future Perspectives and Conclusions 
6.1 Summary 
The thesis describes the use of a chemical modification method to insert a variety of ncAAs 
individually throughout the active site of saNAL. It also describes the screening of these 
ncAA-containing enzymes for altered activities, and the characterisation of an ncAA-containing 
enzyme (F190Dpc saNAL) with altered substrate specificity. Through the course of the work 
presented in this thesis; the optimisation and insertion of 13 different ncAAs at positions 
within saNAL has been demonstrated, and multiple X-ray crystal structures have been solved, 
including the structures of two ncAA-containing enzymes, to help elucidate the effect of the 
ncAAs on the enzyme structure. 
The introduction to this thesis describes previous examples, from the literature, where ncAAs 
have been used to alter catalysis. Enzyme redesign experiments, using site-specific 
incorporation of ncAAs by nonsense suppression, have been shown to increase catalytic 
efficiencies of a bacterial phosphotriesterase and a nitroreductase (Ugwumba et al., 2011, 
Jackson et al., 2006) and alkylation of a cysteine variant to produce an S-butyl cysteine 
increased the catalytic efficiency of a glutathione transferase (Hegazy et al., 2006). However, 
this work describes the first instance of utilising ncAAs in a way analogous to directed 
evolution or semi-rational redesign experiments, to alter enzyme activities. Incorporation of a 
wide variety of different ncAAs has been used to produce many modified variants, screening of 
the modified variants for activity has been carried out and then the modified enzyme with an 
altered activity was identified and characterised. The chemical modification approach allowed 
a far more diverse range of ncAAs to be inserted at a cysteine residue, than would have been 
achievable had nonsense suppression been used, as the core structural motifs of the ncAAs 
incorporated in this manner are restricted to lysine, phenyalanine and tyrosine, and a new 
orthogonal tRNA/tRNA synthetase pair would be needed for each ncAA to be insterted (Wan 
et al., 2014, O'donoghue et al., 2013, Dumas et al., 2015). The chemical modification approach 
also allowed for facile incorporation of many different ncAA side chains just by the production 
of one cysteine variant, without problems with incomplete incorporation of the ncAA which 
has hampered some nonsense suppression experiments (O'donoghue et al., 2013, Zhang et al., 
2013).  The use of the diBr compound to selectively modify cysteine to the electrophilic 
bio-orthogonal dha, allows a more specific chemical modification method, than the more 
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traditionally used nucleophilic attack onto a cysteine side chain, which could also modify 
histidine and lysine residues (Chalker et al., 2009). Due to the electrophilic nature of dha it can 
undergo a Michael addition with a sulphur nucleophile, producing the side chain of the ncAA, 
this reaction is highly selective due to the lack of highly electrophilic centres within the 
proteogenic amino acids. 
 
 
Figure 6.1 Wild-type and modified F190Dpc saNAL structures and reactions. Panel A shows 
the crystal structure of the wild-type saNAL with the product N-acetylneuraminic acid 
(Neu5Ac) modelled into the active site, and the wild-type saNAL reversible aldol reaction of 
N-acetyl-D-mannosamine (ManNAc) and pyruvate to form Neu5Ac. Panel B shows the crystal 
structure of the modified F190Dpc saNAL with the product (4S) 3-deoxy-2-heptulosonic acid 
(DOH) modelled into the active site, and the F190Dpc saNAL reversible aldol reaction of 
D-erythrose and pyruvate to form DOH. 
 
 
This work has shown that by using ncAAs it has been possible to alter the activity of saNAL. A 
modified ncAA-containing enzyme, F190Dpc saNAL, was found that had an increased activity 
with the shorter aldehyde substrate erythrose than the wild-type ManNAc aldehyde substrate. 
F190Dpc was shown to be a more efficient enzyme with erythrose and pyruvate as substrates 
than the wild-type enzyme, showing a 10-fold increase in kcatapp/Kmapp and a 15-fold increase in 
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kcatapp. F190Dpc was also shown to be a more efficient for the altered activity than the 
wild-type enzyme with the wild-type substrates, ManNAc and pyruvate, showing a ~10-fold 
increase in kcatapp. Production and kinetic characterisation of a saturation library at position 190 
also revealed that the non-canonical Dpc residue enhanced activity with erythrose by more 
than was achievable by any of the proteogenic amino acids, at that position.  
6.2 Future perspectives 
This work shows the use of ncAAs to alter enzyme substrate specificity; however it may be 
possible to further enhance these activities. Also the facile incorporation of ncAAs within an 
enzyme active site may provide a route to altering enzyme activities in other ways. For 
example by incorporating non-proteogenic side chains it may be possible to engineer and 
exploit interactions and chemistries not available in naturally produced proteins. 
6.2.1 Further alteration of substrate specificity 
The inclusion of the non-canonical Dpc side chain enhances activity with the substrates 
erythrose and pyruvate. However it may be possible to further enhance this activity by 
combining the chemical modification procedure with more traditional protein engineering 
approaches. For example by the addition of further proteogenic mutations at other sites within 
the enzyme the altered activity may be increased. Due to the necessity to retain the cysteine 
residue at position 190 and not to insert any other cysteine residues, which would prevent the 
modification procedure from being site-specific, it would be required to insert mutations in a 
targeted manner. Other residues within the active site could be targeted for saturation 
mutagenesis, due to the significant amount of structural data on both wild-type and F190Dpc 
saNAL, it may be possible to select mutations that would increase the binding efficiency with a 
smaller substrate. Also a CASTing (combinatorial active-site saturation test) approach could be 
used; sets of two or three residues, in close proximity to the active site, would be randomised 
and then screened for enhanced activity (Reetz et al., 2005, Reetz et al., 2006). Both of these 
approaches target specific residues and produce fairly small library sizes for screening, 
therefore would applicable to combining with the chemical modification procedure. The 
variants with the cysteine at position 190 would be grown in 96 deep-well plates and purified 
using HisGrab™ 96 well plates (Pierce, Rockford, USA). The proteins could be unfolded and the 
chemical modification procedure carried out in plate format, followed by screening for 
enhanced activity by the TBA assay. Combination of traditional protein engineering and 
170 
 
incorporation of ncAAs by nonsense suppression has been carried out previously and shown to 
be successful in enhancing functionality. A glycan-binding antibody, engineered to incorporate 
a p-boronophenyalanine in response to a TAG codon underwent evolution of the 
complementarity determining region (CDR) loops and was evolved to bind an acyclic amino 
sugar (Liu et al., 2009).  
The work presented in this thesis has focussed on the alteration of the aldehyde acceptor 
substrate of saNAL. This approach was taken as previous studies had shown the evolvability of 
the aldehyde binding pocket and that wild-type NAL had natural substrate promiscuity with 
regards to aldehyde acceptors (Williams et al., 2005, Williams et al., 2006, Campeotto et al., 
2010, Joerger et al., 2003, Chou et al., 2011, Hsu et al., 2005, Gijsen et al., 1996, Kim et al., 
1988). However it would also be interesting to attempt to alter the ketone donor substrate of 
NAL. The substrate scope of the ketone donor is far stricter than that of the aldehyde acceptor; 
3-fluoropyruvate has been shown to be a donor for some pyruvate-dependent aldolases 
including the E. coli NAL (Daniels et al., 2014, Chokhawala et al., 2007), however 
2-oxobutyrate, 3-bromo-pyruvate, 3-hydroxypyruvate are not accepted by NAL (Kim et al., 
1988). Therefore an approach using ncAAs could be taken to attempt to evolve activity with 
these donor substrates that would produce interesting biologically active compounds, for 




Figure 6.2 Potential ketone donor compounds for saNAL. Pyruvate is the wild-type saNAL 
ketone donor, 3-fluoropyruvate is reported to be accepted by E. coli NAL (Daniels et al., 
2014, Chokhawala et al., 2007), 3-bromopyruvate, 2-oxobutyrate and 3-hydroxypyruvate are 







6.2.2 Exploitation of interactions not found in the proteogenic amino acids 
Along with using ncAAs to alter substrate specificity, it may also be possible to utilise ncAAs to 
engineer novel binding motifs into proteins and enzymes. Carboxylate groups are a commonly 
found functional group in biological compounds. By use of ncAAs, it may be possible to 
incorporate a thiourea containing side chain which would interact with the carboxylate group 
(Fitzmaurice et al., 2007). By introducing interactions like the carboxylate-thiourea binding 
motifs it may be possible to alter substrate binding. 
 
    
Figure 6.3 Interaction of a thiourea containing ncAA with a carboxylic acid containing 
substrate.  
 
6.2.3 Alteration of catalysis 
By utilising non proteogenic side chains it may be possible to expand the catalysis of enzymes. 
This principle has been recently demonstrated by the production of an artificial 
metalloenzyme, which by incorporation of the metal-binding ncAA (2,2´-bipyridin-5yl)alanine 
(BpyAla) catalyses an asymmetric Friedal-Crafts reaction (Drienovska et al., 2015). This 
evolution of catalytic activity could be further extended to catalysis not generally found in 
enzymes.  
NAL catalyses reactions through a reactive enamine species; however by incorporation of 
methyl-lysine analogues it may also be possible to access iminium ion chemistry. Iminium ion 
catalysis is exploited by reactions such as Diels-Alder reactions and Michael additions. By 
reaction of a methyl-lysine analogue with a novel synthesised α,β-unsaturated carbonyl 
compound, an iminium ion would be produced which could then be reacted with a nucleophile 
or diene to undergo a Michael addition or Diels-Alder reaction respectively. saNAL would 
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provide an excellent scaffold for this work, as it has been optimised for the incorporation of 
the ncAAs that would be needed for the production of the iminium ion. Also saNAL has an 
(α/β)8-barrel fold, this fold is the most common throughout proteins and has been found in all 
except one of the enzyme classes; therefore it is highly versatile fold (Henn-Sax et al., 2001). 
This (α/β)8-barrel, fold found in many aldolases, has been shown to be highly malleable for 
catalysis. For example directed evolution studies of 2-keto-3-deoxy-6-phosphogluconate 
aldolase, repositioned the catalytic lysine within the active site of the  enzyme, which 
produced an active variant with an altered substrate specificity (Wymer et al., 2001).  This 
repositioning of the catalytic lysine has also been demonstrated in a computationally designed 
retro aldolase, where directed evolution studies on the designed enzyme relocated the 
catalytic lysine which resulted in a more active variant (Giger et al., 2013). These examples 
show the catalytic malleability of aldolases, and so an aldolase may provide an ideal scaffold 





Figure 6.4 Schematic of iminium ion catalysis. Panel A shows the enamine and imine formed 
during Schiff base formation between a lysine residue and pyruvate. Panel B shows potential 
iminium ion catalysis, reaction of the ncAA methyl-lysine analogue and an α,β-unsaturated 
carbonyl compound produces the iminium ion which can subsequently be reacted with 
nucleophiles or dienes. 
 
6.3 Concluding remarks 
Through this research it has been possible to use a chemical modification method to 
incorporate varied non-canonical side chain chemistries, individually throughout saNAL. It has 
also been possible to use this approach to alter the activity of the enzyme and produce an 
ncAA-containing enzyme with an increased activity towards a shortened substrate. The 
modified enzyme shows increased activity with the shortened substrate over that of the 
wild-type enzyme with the shortened substrate and also the wild-type substrate. The modified 
side chain outperforms any of the proteogenic amino acids for activity, with the shortened 
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substrate, when inserted at the same position within the protein. This work shows that by 
diversifying the side chains available to the protein engineer, it may be possible to develop 
activities above and beyond what would be achievable with the traditional proteogenic 
‘tool-kit’. This research provides an excellent platform, with the facile expansion of the amino 
acid alphabet, to extend the use of ncAAs to further alter enzyme activities and potentially 




Chapter 7 Appendix 
 
pH Wild-type saNAL K165-γ-thialysine saNAL 
kcat (min-1) Km (mM) kcat/ Km 
(min-1 mM-1) 
kcat (min-1) Km (mM) kcat/ Km 
(min-1 mM-1) 
5.0 80 ± 3 4.5 ± 0.4 18 ± 2 19 ± 1.6 4.5 ± 0.98 4.2 ± 0.99 
6.0 240 ± 9 4.0 ± 0.4 60 ± 6 31 ± 2.2 3.0 ± 0.61 10 ± 2.2 
6.2 250 ± 6 3.1 ± 0.2 81 ± 5 28 ± 0.96 2.3 ± 0.25 12 ± 1.4 
6.4 230 ± 7 2.3 ± 0.2 100 ± 8 28 ± 0.81 1.9 ± 0.19 15 ± 1.5 
6.6 250 ± 8 2.7 ± 0.3 93 ± 9 32 ± 0.86 1.4 ± 0.12 23 ± 2.1 
6.8 260 ± 6 2.4 ± 0.2 108 ± 7 29 ± 0.8 0.92 ± 0.09 32 ± 3.11 
7.0 240 ± 7 2.5 ± 0.2 96 ± 8 29 ± 0.55 0.99 ± 0.07 29 ± 2.0 
7.2 250 ± 5 2.4 ± 0.2 104 ± 7 26 ± 1.9 1.0 ± 0.30 26 ± 1.8 
7.4 250 ± 5 2.2 ± 0.1 114 ± 6 26 ± 0.85 1.4 ± 0.2 19 ± 2.3 
7.6 200 ± 7 1.9 ± 0.2 105 ± 12 25 ± 0.5 1.6 ± 0.1 16 ± 1.0 
7.8 230 ± 6 2.3 ± 0.2 100 ± 7 23 ± 0.4 1.4 ± 0.09 16 ± 1.1 
8.0 260 ± 13 2.6 ± 0.3 100 ± 10 25 ± 1.8 2.5 ± 0.4 10 ± 1.8 
9.0 57 ± 4 1.5 ± 0.3 38 ± 8 8.6 ± 0.79 3.2 ± 0.7 2.7 ± 0.61 





Figure 7.1 Raw data for the aldol condensation of erythrose and pyruvate to form 
deoxyheptulosonic acid determined by TBA assay (Section 2.4.16.3). Absorbance data at 
550 nm was collected and converted to specific activity using a standard curve of sialic acid 




Figure 7.2 Standard curve of Neu5Ac. A shows an image of samples of known concentration 
of Neu5Ac which have been assayed by TBA assay (Section 2.4.16.2). B shows the 
absorbance data at 550nm of the assayed samples 
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Oligonucleotide primers used in this work 
Oligonucleotide primer Sequence (5’-3’) 
saNAL-F190A-For -C CCA GAC AAA TTA ATC TTA TCT GGC GCT GAT GAA ATG TTA GTT CAA GCT ACG- 
saNAL-F190A-Rev -CGT AGC TTG AAC TAA CAT TTC ATC AGC GCC AGA TAA GAT TAA TTT GTC TGG G- 
saNAL-F190D-For -C CCA GAC AAA TTA ATC TTA TCT GGC GAT GAT GAA ATG TTA GTT CAA GCT ACG- 
saNAL-F190D-Rev -CGT AGC TTG AAC TAA CAT TTC ATC ATC GCC AGA TAA GAT TAA TTT GTC TGG G- 
saNAL-F190E-For -TTC CCA GAC AAA TTA ATC TTA TCT GGC GAG GAT GAA ATG TTA GTT CAA GCT ACG ATT- 
saNAL-F190E-Rev -AAT CGT AGC TTG AAC TAA CAT TTC ATC CTC GCC AGA TAA GAT TAA TTT GTC TGG GAA- 
saNAL-F190G-For -C CCA GAC AAA TTA ATC TTA TCT GGC GGT GAT GAA ATG TTA GTT CAA GCT ACG- 
saNAL-F190G-Rev -CGT AGC TTG AAC TAA CAT TTC ATC ACC GCC AGA TAA GAT TAA TTT GTC TGG G- 
saNAL-F190H-For -C CCA GAC AAA TTA ATC TTA TCT GGC CAT GAT GAA ATG TTA GTT CAA GCT ACG- 
saNAL-F190H-Rev -CGT AGC TTG AAC TAA CAT TTC ATC ATG GCC AGA TAA GAT TAA TTT GTC TGG G- 
saNAL-F190I-For -CA GAC AAA TTA ATC TTA TCT GGC ATT GAT GAA ATG TTA GTT CAA GCT- 
saNAL-F190I-Rev -AGC TTG AAC TAA CAT TTC ATC AAT GCC AGA TAA GAT TAA TTT GTC TG- 
saNAL-F190K-For -TTC CCA GAC AAA TTA ATC TTA TCT GGC AAG GAT GAA ATG TTA GTT CAA GCT ACG ATT- 
saNAL-F190K-Rev -AAT CGT AGC TTG AAC TAA CAT TTC ATC CTT GCC AGA TAA GAT TAA TTT GTC TGG GAA- 
saNAL-F190L-For -GAC AAA TTA ATC TTA TCT GGC TTA GAT GAA ATG TTA GTT CAA GCT AC- 
saNAL-F190L-Rev -GT AGC TTG AAC TAA CAT TTC ATC TAA GCC AGA TAA GAT TAA TTT GTC- 
saNAL-F190M-For -CCA GAC AAA TTA ATC TTA TCT GGC ATG GAT GAA ATG TTA GTT CAA GCT ACG- 
saNAL-F190M-Rev -CGT AGC TTG AAC TAA CAT TTC ATC CAT GCC AGA TAA GAT TAA TTT GTC TGG- 
saNAL-F190N-For -C CCA GAC AAA TTA ATC TTA TCT GGC AAT GAT GAA ATG TTA GTT CAA GCT ACG- 
saNAL-F190N-Rev -CGT AGC TTG AAC TAA CAT TTC ATC ATT GCC AGA TAA GAT TAA TTT GTC TGG G- 
saNAL-F190P-For -C CCA GAC AAA TTA ATC TTA TCT GGC CCT GAT GAA ATG TTA GTT CAA GCT ACG- 
saNAL-F190P-Rev -CGT AGC TTG AAC TAA CAT TTC ATC AGG GCC AGA TAA GAT TAA TTT GTC TGG G- 
saNAL-F190Q-For -TTC CCA GAC AAA TTA ATC TTA TCT GGC CAG GAT GAA ATG TTA GTT CAA GCT ACG ATT- 
saNAL-F190Q-Rev -AAT CGT AGC TTG AAC TAA CAT TTC ATC CTG GCC AGA TAA GAT TAA TTT GTC TGG GAA- 
saNAL-F190R-For -C CCA GAC AAA TTA ATC TTA TCT GGC CGT GAT GAA ATG TTA GTT CAA GCT ACG- 
saNAL-F190R-Rev -CGT AGC TTG AAC TAA CAT TTC ATC ACG GCC AGA TAA GAT TAA TTT GTC TGG G- 
saNAL-F190S-For -C CCA GAC AAA TTA ATC TTA TCT GGC AGT GAT GAA ATG TTA GTT CAA GCT ACG- 
saNAL-F190S-Rev -CGT AGC TTG AAC TAA CAT TTC ATC ACT GCC AGA TAA GAT TAA TTT GTC TGG G- 
saNAL-F190T-For -C CCA GAC AAA TTA ATC TTA TCT GGC ACT GAT GAA ATG TTA GTT CAA GCT ACG- 
saNAL-F190T-Rev -CGT AGC TTG AAC TAA CAT TTC ATC AGT GCC AGA TAA GAT TAA TTT GTC TGG G- 
saNAL-F190V-For -CA GAC AAA TTA ATC TTA TCT GGC GTT GAT GAA ATG TTA GTT CAA GCT- 
saNAL-F190V-Rev -AGC TTG AAC TAA CAT TTC ATC AAC GCC AGA TAA GAT TAA TTT GTC TG- 
saNAL-F190W-For -CCA GAC AAA TTA ATC TTA TCT GGC TGG GAT GAA ATG TTA GTT CAA GCT ACG A- 
saNAL-F190W-Rev -T CGT AGC TTG AAC TAA CAT TTC ATC CCA GCC AGA TAA GAT TAA TTT GTC TGG- 
saNAL-F190Y-For -CCA GAC AAA TTA ATC TTA TCT GGC TAT GAT GAA ATG TTA GTT CAA G- 
saNAL-F190Y-Rev -C TTG AAC TAA CAT TTC ATC ATA GCC AGA TAA GAT TAA TTT GTC TGG- 
saNAL-I251R-For -CAG TGT TAT CAA TGG GGA GGT ATC CAA CAT TGA AAG- 
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